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History of peripheral artery disease 
 Atherosclerotic plaque formation of the artery is a systematic disease also known as 
atherosclerosis. Atherosclerotic plaques are composed of an accumulation of connective 
tissue, central lipid cores, inflammatory cells and smooth muscle cells covered by a fibrous 
cap between the intimal and medial layer of the vessel.1,2 These plaques can cause two types of 
vascular disease: an occlusive arterial disease or an aneurysmal arterial disease. Aneurysms 
of the popliteal artery (PAA) constitute 70% of peripheral aneurysms.3 The pathogenesis of 
an aneurysm is still not completely clarified, however, atherosclerosis is considered to be the 
main driving factor. Nonetheless, other factors are also considered to play a role in etiology, 
such as collagen disorders, trauma and infection.4 Peripheral arteries are the arteries outside 
the thoracic and abdominal cavity. These peripheral arteries may develop an occlusive disease 
or an aneurysmal disease, both have a different history and each one has his own type of 
approach and treatment.
 Fascinatingly, observation of atherosclerotic plaques were already made in the calf vessels 
of Egyptian mummies.5 The collected papers of Ruffer (1921) describe calcification of the aorta, 
subclavian, carotid, iliac, posterior tibial and peroneal arteries in mummies of the 18th-20th dynasty 
(1189-1077 BC).5 The discovery of ischemic tissue damage by Harvey in the early 17th century 
stimulated further research on this matter which resulted in the first description of an association 
between an arterial obstruction and distal gangrene (1771).6 Further analysis of atherosclerosis 
and the symptoms that it could cause, led to the definition of intermittent claudication primarily 
described in a horse (1831) and later on in man by Brodie (1846) (figure 1).6,7  
Figure 1. Sir Benjamin Brodie (1783- 1862), who first described the syndrome of intermittent claudication 
in man in 1846. (Cheatle TR, Coleridge-Smith PD, Scurr JH. The investigation of peripheral vascular 
disease-a historical perspective. Vascular Medicine Review 1991)
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 Although from that moment on the relation between atherosclerosis and intermittent 
claudication was established, still the recognition of it with physical and diagnostic tests was 
a slow process. In addition, many attempts trying to treat intermittent claudication failed, 
until 1948 when there was a breakthrough in the treatment of peripheral artery occlusive 
disease (PAOD). The first femoral artery bypass was created with a venous conduit by Jean 
Kunlin. Hereafter the autologous venous bypass has been the gold standard for short and long 
occlusive lesions of the superficial femoral artery ever since. 
 Like occlusive arterial disease, the discovery of arterial aneurysms dates back 4000 years 
ago and was described in Ebers Papyrus (ca 2000 BC).8 Eventually, Galen introduced the first 
definition of an aneurysm: ‘a localized pulsatile swelling which disappeared on pressure’.9 As 
mentioned earlier an aneurysm of the popliteal artery is the most common aneurysm of the 
peripheral arteries. Therefore management of PAA has committed surgeons since 200 BC. 
Antyllus, a Greek surgeon, was the first to describe elective surgery of an aneurysm called 
the Antyllus technique. This technique consisted of applying ligatures to the entering and 
exiting arteries of the aneurysm and opening the sac and evacuate its contents.9,10 In 1744 
this technique was also applied to PAA with the use of a tourniquet.11 Subsequently, the 
lower legs were left unrevascularized. In the end of the 18th century several case reports 
were published all being modifications to Antyllus’ technique. Unfortunately they all ended 
up with an amputation.12 Eventually in 1785 the first successful surgical treatment of a PAA 
was reported by Sir John Hunter (The Hunterian Operation, 12th December 1785) by ligating 
the superficial femoral artery at the distal subarterial canal (Hunters canal) and leaving the 
aneurysm intact.10,13 The hypothesis of Hunter was that collateral arteries in their natural state 
would take over the blood supply of a major artery, after ligature of that artery. The discovery 
of Hunter and his hypothesis of collateral arteries was later confirmed by Astley Cooper. In 
1786 Sir Astley Cooper studied the effects of ligation of the femoral and brachial artery in dogs 
additionally the collateral system was injected and investigated.14 The invention of Hunter and 
Cooper had a major impact on the development of managing PAA and led to an increase in 
research. 
Treating PAOD
 Cardiovascular risk reduction is the primary treatment of atherosclerosis in general, 
and thus also of PAOD. Risk reduction measures include lifestyle changes (smoke cessation, 
weight loss and exercise) and pharmacotherapy (treat dyslipidemia, antiplatelet therapy, treat 
hypertension and optimize diabetes management).2,15,16 In addition to risk reduction, patients 
with intermittent claudication are primarily approached with supervised walking exercise.15,16 
However, in patients with symptoms, such as rest pain or limb threatening ischemia, 
revascularization of the lower extremity is usually needed on the shorter term. Revascularization 
may also be indicated when patients still have life-style limiting claudication after medical 
management and supervised exercise training. When opting for revascularization the Trans 
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Atlantic inter-Society Consensus II (TASC) guidelines reported which approach is the best 
treatment for several types of femoropopliteal lesions (figure 2). A great amount of research 
was done with TASC II as a guideline, however the results of studies were progressing, and 
therefore development of new guidelines were inevitable.17,18
Figure 2. TASC II femoropopliteal lesions(Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus 
for the management of peripheral arterial disease (TASC II). Journal of Vascular Surgery 2007)
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According to the TASC guidelines, surgical reconstruction with a venous conduit is the gold 
standard for lesions ≥15 cm in length in the SFA (Type C and D lesions).19 However, approximately 
one third of patients requiring a femoropopliteal bypass do not have a suitable vein and therefore 
managing these lesions without prosthetic graft material may not always be possible.20 In the 
past decades various types of prosthetic graft material were used for bypass surgery, including 
polyester (such as Dacron) and polytetrafluorethylene (PTFE) showing feasible patency rates. 
However, patency rates of a venous conduit remained significantly higher. With the introduction 
of the heparin-bonding technology as a coating inside these prosthetic grafts, patency rates 
seemed to further improve thereby approaching patency rates of autologous venous conduits.21 
Endovascular therapy
 The PAOD population is a frail group of patients as vascular disease can affect arteries 
throughout the whole body. In patients with PAOD 30-50% also have coronary artery disease 
and 15-25% have a significant stenosis of the carotid artery.16 Moreover this disease mostly 
affects the elderly with an associated high co-morbidity rate (figure 3). Surgery in this group of 
patients often results in a relatively high complication rate and a prolonged hospital stay.22 For 
these reasons there is a considerable need for a less invasive treatment modalities. 
former), hypertension (69%), hyperlipidemia (47%), and diabetes (38%) was elevated
in the PAD-only cohort.
Thus, current epidemiologic and community survey data demonstrate a high preva-
lence of PAD in individuals in the United States and Europe that increases with advanc-
ing age and with increasing exposure to atherosclerosis risk factors.
RELATIONSHIP OF PAD TO OTHER 
ATHEROSCLEROTIC SYNDROMES
Atherosclerosis is a systemic disease that may affect multiple arteries throughout the
body. The diagnosis of PAD should be considered a marker for increased risk of coex-
istent atherosclerosis involving other vascular territories regardless of whether the
patient is asymptomatic or suffers claudication symptoms. It has been shown that indi-
viduals diagnosed with PAD have a higher coprevalence of CAD and cerebrovascular
disease (29,32,49). Patients found to have lower extremity arterial occlusive disease
should undergo a focused physical examination to ascertain if there is coexistent coro-
nary or carotid disease, or an aortic aneurysm.
In a large study by Hertzer and colleagues, severe CAD was found angiographically
in 36% of patients with an abdominal aortic aneurysm and in 28% of patients with lower
extremity occlusive disease (50). In a separate report, carotid bruits were noted in 11%
of patients with abdominal aortic aneurysm and 25% of patients with PAD, while a sig-
nificant number of patients (44%) proved to have high-grade ( 75%) carotid stenoses
or occlusions (51).
In a study of coprevalence of atherosclerotic syndromes by Aronow and Ahn in a
long-term care facility, 25% of patients over 62 yr of age had at least two manifestations
of atherosclerosis (52). Of patients with CAD, 33% also had PAD and 32% had experi-
enced an ischemic stroke. Of patients with a history of ischemic stroke, 53% also had
CAD and 33% also had PAD. Conversely, of those patients with PAD, 58% had CAD
and 34% had suffered an ischemic stroke (52).
28 P ripheral Arterial Dis ase
Fig. 3. The increased prevalence of PAD in men and women with advancing age. (Modified from:
Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of
peripheral arterial disease in a defined population. Circulation. 1985;71:510-515.)
Figure 3. Prevalenc  of PAOD withi  advancing age.(Bordeaux LM, Reich LM, Hirsch AT. Th  Epidemiology 
and natural history of peripheral artery disease. Contemporary Cardiology: Peripheral arterial disease 
2003)
 The insight of endovascular therapy started with the discovery of x-ray in 1895 by Wilhelm 
Röntgen and when Lindentahl produced the first contrast enhanced radiograph of the veins of 
the hand. However, clinical application of contrast angiography took more than two decades. 
The first angioplasty was accomplished by Charles Dotter (1964) which was the start of a new 
era. In 1975 Grüntzig further developed the angioplasty technique by using an expandable 
balloon on a catheter shaft, which allowed smaller punctures for arterial access and larger 
vessels to be dilated.23 Later on, in 1985 Julio Palmaz invented the balloon-expandable 
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stent made of bare metal consisting of a mesh like tube of thin wire made of stainless steel, 
specifically meant for cases in which angioplasty alone would not suffice.
 Thus, according to the TASC II guidelines endovascular treatment is recommended in 
short lesions.19 However, the 1-year patency rates of percutaneous transluminal angioplasty 
(PTA) alone were low: 33%-35%.24,25 The low patency rate after 1-year follow up was due to 
restenosis. Nitinol stent placement was introduced to limit the occurrence of restenosis. 
Several randomized controlled trials, such as the VIENNA, FAST and RESILIENT trial, 
showed the superiority of stent placement in addition to PTA.26-28 However, the patency rates 
of nitinol stent placement were limited by the occurrence of (in-stent) restenosis (ISR) due 
to intimal neo-hyperplasia.24-26 Longer lesions are related to a poorer outcome as the risk 
on (in-stent) restenosis is likely to increase with lesion length.29-31 Due to this knowledge 
alternative strategies have been developed, including atherectomy, drug-based technologies 
mostly using paclitaxel, and PTFE- covered stents. Covered stents were developed with the 
hypothesis that the covering material would shield the stent from tissue in-growth and they 
therefore would reduce the incidence of ISR. Initial results of covered stents, used for treating 
PAOD, were variable and hard to compare due to several reasons, including patient and lesion 
characteristics, development in stent design, treatment protocols and variation in medical 
therapy. As a consequence, randomized trials were deemed fundamental to investigate the 
outcome of these covered stents. The VIASTAR trial showed 1-year primary patency rates of 
73.3% in patients treated with a covered stent and a patency of 33.3% in patients treated with 
a nitinol stent.32 Furthermore, the randomized trial of McQuade et al. showed similar patency 
rates of covered stents and prosthetic femoropopliteal bypasses at the above the knee level 
up to 4 years follow up.33 In addition secondary patency rates were also comparable as were 
limb salvage rates, indicating that covered stents could be an acceptable alternative to bypass 
surgery. However, covered stent failure mainly due to thrombosis remained an essential 
limitation. With this knowledge W.L. Gore & associates produced a new type of covered stent; 
the Viabahn endoprosthesis (W.L. Gore & associates, Flagstaff, AZ, USA). The Viabahn was 
created to prevent acute thrombosis and therefore the heparin-bonding technology was 
added to the ePTFE covered stent and the proximal edge was reshaped. This new technology 
is considered to bond the heparin-molecules to the inner surface of the graft and therefore 
preventing thrombosis and thereby increasing the performance of the covered stent. A recent 
randomized controlled trial compared these new covered stents with surgical bypass which 
shows comparable 1-year primary, primary assisted and secondary patency’s.34
 With the evolution of endovascular therapy for lesions of the SFA and the feasible outcomes 
of endovascular treatment with covered stents the interest of using this technology in PAA 
emerged. The gold standard in PAA repair is still surgery with venous bypass grafting.35-37 
Similar to bypass surgery for occlusive disease of the SFA a polyester of PTFE prosthetic graft 
can be used if no suitable vein conduit is available. Unfortunately using these prosthetics 
results in a decrease in patency of 30% at long-term follow up.38,39 Furthermore, surgical 
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treatment is associated with perioperative and postoperative morbidity and a prolonged 
hospital stay in cardiovascular vulnerable patients. Therefore a less invasive approach could 
be beneficial. The first endovascular PAA repair was reported in 1994.40 Since then stent graft 
technology has evolved and several types of covered stents have been used for PAA repair. 
Various studies showed early patency rates varying between 64-88%, which is comparable to 
prosthetic surgical bypass (69-88%).41-46 However, the long-term outcome and the effects of the 
heparin-bonding technology remain unclear so far. 
Aims and outline of this thesis
 In this thesis we analyze the performance of self-expanding covered stents in the 
femoropopliteal artery, used to treat occlusive (Chapters 2-7) and aneurysmal disease 
(Chapter 8). The following research questions were addressed (corresponding parts and 
chapters given between parentheses):
 -    How do covered stents fit in the current treatment algorithm of PAOD and what are the 
treatment modalities (Ch2)?
 -    What is the outcome in patency rates of heparin-bonded covered stents after a three-
year follow up (Ch3)?
 -    What is the efficacy of treating edge stenosis of covered stents (Ch4)?
 -    What is the outcome of thrombolysis and thrombectomy in thrombosed covered stents 
(Ch5)?
 -    What is the clinical outcome after covered stents failure (Ch5, Ch6)?
 -    What is the clinical outcome of endovascular treatment with heparin-bonded covered 
stents (Ch7)?
 -    What is the long-term outcome of PAA treated with covered stents (Ch8)?
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The role of superficial femoral 
artery endoluminal bypass 
in long de novo lesions 
and in-stent restenosis.
D.E. Doomernik, B. Golchehr, M.M.A. Lensvelt, M.M.P.J. Reijnen.
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Aim: Results of endovascular treatment for long de-novo lesions of the superficial femoral 
artery (SFA) are limited by in-stent restenosis (ISR). Polytetrafluoroethylene (PTFE) covered 
stents are developed to reduce the incidence of ISR. This study was conducted to summarize 
available data on the use of endoprosthesis in the treatment of SFA occlusive disease and to 
evaluate their use in the treatment of ISR. 
Methods: A systematic literature search was performed, using MEDLINE, EMBASE and 
Cochrane databases. Reports on the application of Hemobahn® and Viabahn® endoprosthesis 
in the treatment of long de-novo lesions and ISR of the SFA were included. 
Results: A total of 19 articles were included. Technical success rates varied between 95-
100%. Case series have shown 1-year primary patency rates varying between 44% and 86%, 
with secondary patency rates between 58% and 93%. Large differences in patient and lesion 
characteristics, medical therapy and developments in stentgraft design complicate comparisons 
between studies. Randomized studies have shown a superiority of the endoprosthesis above 
angioplasty only and similar patency rates with above-knee prosthetic femoro-popliteal bypass 
up to 48 months. Data on the use of endografts for ISR are scarce. 
Conclusion: The use of an endoprosthesis for SFA occlusive disease is an effective and safe 
treatment strategy for long de-novo lesions. Patient selection and adequate medical support 
appear to be important in achieving long term patency. Data focusing on the effectiveness of 
endoprosthesis for ISR are still limited.
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 Peripheral arterial disease (PAD) affects up to 14% of the general population1. The 
prevalence increases with age to 15-20% over the age of 70 years2-4. Facing an aging population 
with a prohibitively high perioperative cardiovascular risk, the search for minimal invasive 
treatment alternatives, especially in long-segment occlusions of the superficial femoral artery 
(SFA) seems valid5, 6. The primary treatment for short lesions (<15 cm) of the SFA in patients 
with limb threatening symptoms or disabling claudication is endovascular7. Angioplasty is 
related to high technical success rates up to 95% and a low complication rate. However, a 
40-60% incidence of restenosis at 1 year, increasing up to 70% for long de-novo lesions of the 
SFA (>10cm) have been reported8. Therefore, the TransAtlantic Inter-Society Consensus (TASC) 
recommends surgery for longer lesions of the SFA (>15cm, TASC-2 C and D) as the first choice 
of treatment in patients with Rutherford 3-67. 
 Endovascular treatment options for long de-novo lesions of the SFA are increasing 
continuously. Nitinol stents have improved outcome of endovascular treatment of SFA occlusive 
disease. Randomized trials have shown their superiority in lesions from 6.5 to 9.5 cm length9, 
10 while in shorter lesions there were no differences11. In longer lesions bare metal stents 
are likely to perform worse due to the occurrence of in-stent restenosis (ISR). Moreover, bare 
metal stents are related to stent fractures, due to biomechanical forces in the highly mobile 
SFA segment, which significantly influences outcome12, 13. Nitinol stents have lowered the stent 
fractures rate to 7.7% in long lesions (mean 20.7cm)14. 
 In order to reduce the incidence of ISR covered stents were introduced. The mechanical 
barrier around the nitinol stent could prevent ISR by acting as a physical barrier to neointimal 
proliferation. The endoprosthesis ideally should have a high flexibility, adequate radial strength 
and a low fracture rate (2%)15. The Hemobahn® endoprosthesis (W.L. Gore & associates, 
Flagstaff, AZ, USA) was first described by Virmani et al.16 in 18 adult greyhounds, undergoing 
a bilateral ileofemoral placement of the endoprothesis. Neointimal growth was present in all 
grafts but accounted for only a nominal 6% reduction in luminal area. Flow surfaces were 
endothelialized for more than 75% within 3 months and nearly complete at 6 months. The 
endoprosthesis remained patent up to 1 year after implantation and a healing process similar 
to conventional stents was observed. Various modifications in the endoprosthesis design and 
deployment system, improved the performance of the endoprosthesis which was renamed the 
Viabahn®. 
 In this review, we summarize all available clinical trials focusing on the use of the 
Hemobahn® or Viabahn® endoprosthesis for the treatment of SFA occlusive disease and their 
use for ISR. 
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 A systematic literature search was conducted to identify reports on the application of 
Hemobahn® and Viabahn® endoprosthesis in the treatment of long de-novo lesions in the 
SFA, published until May 1, 2012, using the MEDLINE, EMBASE and Cochrane databases. 
An additional search was performed to identify reports of the use of these endoprosthesis in 
the treatment of in-stent restenosis. The following MeSH search terms were used peripheral 
arterial disease, balloon angioplasty, endovascular procedures, blood vessel prosthesis, 
stents, femoral artery, polytetrafluoroethylene (PTFE), vascular graft occlusion. Other non-
MeSH terms such as Hemobahn®, Viabahn®, covered stent, heparin-bonded, extended PTFE 
(ePTFE), Viabahn®-Assisted Subintimal Revascularization (VASIR), restenosis and in-stent 
restenosis were also used. These terms were applied in various combinations in addition to 
the use of the ‘related articles’ and ‘citing articles’ function. Full-text articles were studied 
with restriction of language of publication (English or German) and manual cross-referencing 
was performed. Reports were classified by case series, comparative studies, and randomized 
controlled trials. Only reports in which the use of the Hemobahn® or Viabahn® endoprosthesis 
was specifically mentioned were included. Exclusion criteria were non peer-reviewed reports 
and series dealing with less than 20 cases. Articles of which no full text electronic version was 
available in two university libraries or after request from the author were also excluded.
RESULTS
De-novo lesions in the SFA 
Case series
 Thirty articles were found using the search strategy. After reading abstracts, 7 non peer-
reviewed articles were excluded and 23 articles were selected for full text reading. Further 
exclusion was carried out for articles presenting case series of less than 20 patients (n=4). 
When authors published several times over the same cohort (n=5), the most recent publication 
was used for evaluation. A total of 14 articles were selected for further assessment5, 6, 15, 17-27. 
A summary of the results is shown in table 1. In addition, 2 ongoing trials of which no peer-
reviewed reports are available to date will be described. 
 From January 2000 until January 2012 a total of 789 limbs of 747 patients were described 
that were treated with the Hemobahn®15, 17-24 or Viabahn®5, 6, 15, 17, 24-27 endoprosthesis for primary 
femoropopliteal occlusive disease (fig. 1 and 2). The treated length of the occluded or stenotic 
femoral segment varied from 1 to 40 cm, occasionally extending into the popliteal artery. 
There were 519 cases of intermittent claudication (IC) (Rutherford 0-3), 235 cases of critical 
limb ischemia (CLI) (Rutherford 4-6) and 24 patients with acute limb ischemia (ALI). None of 
the articles described the exact anatomic configuration of the lesions. The number of patent 
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distal run-off vessels differed between 0 to 3, with an average ≥ 2. The mean length that was 
covered varied between 2.5 and 47 cm and the device diameter between 5 and 8 mm, with 
a mean of 6 mm. Technical success was achieved in 95-100% of cases. Procedure related 
complications were seen in 17.9% (99/554 patients) varying from minor complications, such 
as groin hematoma to major complications such as acute thrombo-embolism or dissection. 
The distal embolization rate was low (3%). Four articles reported the mean hospital stay, that 
varied between 1 to 8 days (range 1-33 days)5, 22, 25, 27. Literature focusing on cost-effectiveness 
of endovascular procedures lack to date. 
 The one-year primary patency rate greatly varied between 44% and 86%, with a secondary 
patency rate between 58% and 93%. Long term follow-up of primary patency was reported in 
8 articles5, 15, 17, 20, 22-24, 27, being 74-85% after two years, 40-71% after three years, 55% after four 
years and 45% after five years. The secondary patency rates were 83-89% at two years, 66-82% 
at three years, 79% at four years and 69% at five years. The reported limb salvage rate was 
92-100%5, 21, 23, 25-27. For TASC-II C lesions three-year primary and secondary patency rates are 
in the range of the above knee venous (71 & 82%) and prosthetic (59 & 68%) femoropopliteal 
bypasses, respectively 5. Promising results have been shown for TASC D lesions6, 15, 25-27. 
1a 2a1b 2b
Figure 1a+b: Angiography of a 82-year old men suffering from Rutherford category 3 of the left leg, with 
an ankle brachial index of ABI 0.74, showing a 14 cm long occlusion of the left superficial femoral artery, 
ending 5cm above the upper margin of the patella.
Figure 2a+b. Post-procedural angiography of the SFA after insertion of two 7 mm Viabahn® endoprosthesis 
(10 and 15 cm, respectively) showing excellent patency of the SFA with good distal run-off and no residual 
stenosis. Afterwards, the patient received ascal 80mg/d for life and clopidogrel 75 mg/d for at least 3 
months. 
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Table 1. A summary of clinical trials focusing on endovascular endografting of long de novo lesions in the SFA.
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(range/SD)
Mean device 















Lammer18 2000 74 (NR) 65 (37-89) 80 Hemobahn IC (65)         
CLI (9)
NR NR >1 NR (3.0-20.0) 13.1 (5.0-40.0) 6 (6-7) 0.60
Bauermeister19 2001 26/9 65 (41-85) 35 Hemobahn IC (9)         
CLI (26)
NR 100% (35) NR (1.6) 22.0 (4.0-40.0) 15.0 (5.0-30.0) NR (6-7) 0.25
Jahnke20 2003 41/11 62 (45-81) 52 Hemobahn IC (50)        
CLI (2)
TASC B (31)        
TASC C (21)            
83% (43) ≥ 2  
(2.4 ± 0.7)
8.5 (± 4.3) 10.9 (± 5.1) 6 (6-7) 0.54
Bray21 2003 42/12 73 (55-91) 59 Hemobahn IC (49)            
CLI (10)
NR 53% (31) ≥ 0 (1.8) 18.9 (± 7.0) 22.3 (± 8.7) 6 (6-7) NR
Hartung22 2005 30/2 70 (52-89) 34 Hemobahn IC (16)           
CLI (14)             
ALI (4)
TASC B (13)          
TASC C (21)
47% (16 ) ≥ 0 10.8 (3.0-22.0) 14.1 (5.0-25.0) NR (6-7) NR
Daenens23 2005 29/9 66 (39-91) 40 Hemobahn IC (32)             
CLI (8)
NR 63% (25) ≥ 1 (2) 5.0 (1.0-20.0) 15.0 (5.0-35.0) NR (6-7) 0.5
Fischer24 2006 46/11 62 (44-82) 60 Hemobahn (56)    
Viabahn (4)
IC (55)          
CLI (5)
NR 87% (52) ≥ 0 (2.3) 10.7 (3.0-34.0) 15.9 (5.0-33.0) 6 (6-8) NR
Saxon15 2007 49/27 72 (45-88) 87 Hemobahn (15)    
Viabahn (72)
IC (22)             
CLI (65) 
TASC A (0)                    
TASC B (6)                
TASC C/D (81)
42% (37) ≥ 1 14.2 (2.8-40.0) NR 6 (5-8) 0.70
Alimi5 2008 66/29 72 (52-94) 102 Viabahn IC (50)       CLI 
(32)          ALI 
(20)
TASC A (9)                      
TASC B (42)          
TASC C (28)          
TASC D (23)
NR ≥ 0 CI: 11.6 (3.5-29.5)        
CLI: 12.4 (2.6-30.2)     
ALI: 10.8 (3.8-29.8)
14.3 (2.5-37.5) 6 (6-7) 0.52 
(CI)
Verta25 2008 15/13 71 (52-90) 28 VASIR with 
Viabahn
IC (14)            
CLI (14)
TASC B (2)            
TASC C (8)            
TASC D (18)
NR ≥ 0 (1.2) NR 26.2 (4.0-47.0) NR (5-6) 0.47
Farraj6 2009 18/12 58 (NR) 32 Viabahn IC (28)           
CLI (2)
TASC C/D (32) NR NR 15.4 (NR) 24.6 (NR) 6 (NR) 0.54
Fritchy17 2010 96 (NR) 64 ± 
9 (M)                  
66 ± 
9 (F)
96 Hemobahn         
Viabahn
IC (79)             
CLI (17)
TASC A (18)               
TASC B (30)              
TASC C (35)              
TASC D (13)
19% (18) NR NR NR 6,1(6-7) 0.70
Schneider26 2011 13/14 72 ± 11 28 VASIR with 
Viabahn
IC (14)        
CLI (14)
TASC C (8)                 
TASC D (20)
- (0) ≥ 0 (1.9) NR NR 6 (5-7) NR
Lensvelt27 2012 40/13 70 ± 9 56 Heparin-bon-
ded Viabahn
IC (36)          
CLI (17)
TASC B (9)                  
TASC C (14)              
TASC D (33)
NR ≥ 0 (2.6) 18.5 (± 7.7) NR 6 (5-8) 0.49
M:male, F:female; IC: intermittent claudication; CLI: critical limb ischemia; ALI: acute limb ischemia; VASIR: Viabahn Assisted 
Subintimal Recanalization; TASC: Transatlantic Inter-Society Consensus; Distal runoff: number of patent distal vessels; FU: 
follow-up; SD: standard deviation; N: number of cases; PP: postprocedure; NR: not reported; LMWH: low molecular weight 
heparin; Acc. Prescription: according to prescription; IU: International Units; IU/h: international units per hour; U/kg: units 
per kilogram; mg/d: milligram per day; mL/d: milliliter per day; LD: loading dose; OOTTT:one of the two thereafter; RO: 
reocclusion not specified; ISR: in-stent restenosis; ES: edge stenosis; SF: stent fracture; SK: stent kinking.
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RO, ISR, ES, 
SF or SK 
0.97 (1M) 0.92 
(3M) 0.96 (6M) 
0.94 (12M)
100% Heparin                                      
Acetylsalicylic acid
NR 48 hours                                              
NR
14/80 2/80 >12 (NR) 79% (± 5) 93% (± 3) NR NR 17/80 (ISR/ES)  
0.87 (PP) 100% Heparine                                        
LMWH                                                 
Aspirin                                   
Clopidogrel  
300 U/kg                            
2d1 
100 mg/d                       
75 mg/d




0/35 NR 7 (1-18) 73% 83% NR NR 10/35 (RO)
0.89 (NR) 100% Heparin                                          
Acetylsalicylic acid                       
Clopidogrel
1000 IU/h                    
100 mg/d                               
75 mg/d
24 hours                 
Lifetime                            
6 weeks




13/52 (RO)            
0/52 (ISR)               
3/52 (ES)
NR 95% Heparin                                           
Aspirin                                             
Ticlopidine or Clopidogrel 
1000-1500 IU/h                
NR                                       
250 mg/d                                           
75 mg/d  
24 hours                     
Lifetime                           
10 days (runoff <2)
10/59 0/59 NS 58,0% 73% NR NR 14/59 (RO)         
1/59 (SK)
NR 100% Nadroparin                                            
Aspirin                                
Clopidogrel 
2850-3500 IU 2d1            










1.00 (PP) 100% LMWH                                      
Ticlopidine                             
Acetylsalicylic acid
1d1                                     
250 mg 2d1                    
160 mg/d
NR                       
4 weeks                      
after 4 weeks





NR 98% Aspirin                                          
Clopidogrel
NR                                     
150 mg LD + 75mg/d
Lifetime          
3 months
33/60 NR 55 (36-75) 67% 81% 45% (5Y) 69% (5Y) 28/60 (ISR/ES)
0.90 (MR) 100% Ticlopidine or  
Clopidogrel Aspirin 
250 mg 2d1                




NR NR 29 
(6M-102M)
76% 93% 55% (4Y) 79% (4Y) 6/87 (RO)         
12/87 (ES)        
4/87 (ISR)          
0/32 (SF)          
1/87 (SK)
0.94 (IC,3Y) 100% Nadroparin 
Aspirin                                          
Clopidogrel 
2850/3500 IU 2d1         









19/102 (RO)         
8/102 (ES)
0.88 (PP) 100% Aspirin 
Clopidogrel
 Warfarin
25 mg/d                            
75 mg/d                                
Acc. prescription
>6 months                    
>6 months                           
on indication
0/28 NR 8 (1-13) 44% (±16) 57% (±17) NR NR 4/28 (RO)                
8/28 (ES)
0.76 (1Y) 100% Aspirin 
Clopidogrel 
NR                                            
NR
Lifetime            
Lifetime
0/32 NR 12 (NR) 86% NR NR NR 5/32 (RO)             
1/32 (ISR)
0.97 (6M) 0.91 
(3Y)
98,00% LMWHCarba-
salaatcalsium                                              
Clopidogrel 
0.6 ml/d                              
80 mg/d                           
75 mg/d             
Discharge             
3 months                      
3 months
3/96 2/96 26 (4-65) 82% 89% 70% (3Y) 82% (3Y) 18/96 (RO)      
0/96 (SF)         
0/96 (SK)
NR 100% Aspirin                                 
Warfarin                                     
Clopidogrel                          
81-325 mg/d                               
Acc. Prescription                        
75mg/d if not taking 
Warfarin
NR                              
on indication
NR




NR NR 10/28 (RO)
1.00 (PP) 95% Dipyridamol 
or Clopidogrel                                         
Aspirin  (alone/combi)                  
Statins (Coumarines)
400 mg/d                            
75 mg/d                               
80 mg/d                               
NR                                  
Acc. Precription
NR                            
NR                           
NR                                  
NR                             
on indication
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 Graft failure was mostly related to acute thrombosis due to progression of atherosclerotic 
disease proximal or distal to the endoprosthesis (edge-stenosis)5, 15, 17, 20, 25 or to stent kinking15, 21. 
No stent fractures were described. Five cases of primary in-stent restenosis are reported. No 
statistic significant difference in patency rates were observed with regard to age26, smoking26, 27, 
comorbidities17, 27 (hypertension, diabetes, coronary artery disease), presenting symptoms21 
(IC/CLI/ALI), lesion characteristic15, 20, 21, 25-27 (TASC classification), lesion length27, stent graft 
length15, 20, 21, 25, 27, endoprosthesis diameter26, 27, level of distal anastomosis27 and distal run-
off 21, 25-27. Saxon et al.15, however, showed significantly better patency rates for patients treated 
with devices with a diameter of 6 mm or larger. Primary patency at 4-years was 82% for devices 
of 7 mm or larger. Fischer et al.24 have excluded those factors that supposedly adversely affect 
patency rates and identified ideal circumstances for endovascular treatment, i.e. no total AFS 
occlusion, ≥ 1cm ‘healthy’ proximal and distal vascular segments, no popliteal obstruction, ≥ 1 
patent distal runoff vessel, no severe calcifications and adequate anti-platelet or anticoagulation 
therapy. Primary and secondary patency rates at 1-year in this ideal population were 80% and 
91%, respectively, compared to 67% and 81% for the entire cohort. 
 To date there is no standardized adjunctive antiplatelet or anticoagulation policy after 
endoprosthesis placement in SFA occlusive disease. In early studies heparin 300 UI/kg or 
1000-15000 UI/h was administered for 24-48 hours post procedure18-21. In more recent studies, 
heparin has been changed for low-molecular-weight-heparin (LMWH) daily (2850-3500 UI/12-
24 hours) for 1 week or until discharge5, 17, 22, 23, while others use heparin during the procedure 
only6, 15, 24-27. Most patients received aspirin (carbasalaatcalcium/acetylsalic acid) 80-325mg 
daily for 6 weeks until lifetime. In addition, some patients received additional ticlopidine 160-
250mg 1-2/d15, 21, 23, clopidogrel 75mg/d5, 6, 15, 17, 19-22, 24-27 or dipyramidol 400mg/d27 for 10 days up 
to lifetime. Anticoagulation therapy was only administered in patients with another medical 
indication. In two studies, the use of warfarin tended to protect stent graft failure25, 26. 
 The most recent development in the endoprosthesis was the integration of the heparin-
bonding technology with the ePTFE covered endoprothesis. Using this technique, results 
may further improve. We have recently published the first cohort of patients treated with this 
heparin-bonded endoprosthesis27. A total of 56 limbs were treated with the heparin-bonded 
endoprosthesis in 53 patients for chronic ischemia Rutherford category 3 (n = 36), 4 (n = 5), 
5 (n = 11), and 6 (n = 1). The mean treated lesion length was 18.5 ± 7.7 cm. At 1 year, the 
primary patency was 76%, the primary-assisted patency 82%, and the secondary patency 
89%. The limb salvage rate was 100%. It was concluded that heparin-bonded covered stents 
seemed to provide a valid alternative to surgical treatment of long occlusive lesions in the SFA. 
Randomized trials and long-term data, however, are required before considering the technique 
as a new standard of care. The data of this study are supported by results of the VIPER trial 
(Gore Viabahn® Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial 
Femoral Artery Obstructive Disease, NCT00541307). Preliminary results show a one-year 
primary patency of 74% with a secondary patency of 92%. Primary patency was similar for 
529929-L-bw-Golchehr
Processed on: 1-4-2019 PDF page: 29
ENDOLUMINAL BYPASS IN SUPERFICIAL FEMORAL ARTERY LESIONS
29
2
lesions > 20 cm (72%) and lesions ≤ 20 cm (75%)28. In addition, an ongoing trial, performed by 
Zeller et al. (NCT01263665), evaluates the safety and effectiveness of the 25 cm Viabahn® for 
the treatment of de-novo and restenotic lesions in the SFA in patients with lifestyle limiting IC 
or CLI. Patient enrollment is still going on. 
Randomized controlled trials
 Four reports were included; 3 randomized controlled trials29-31 and a comparative 
retrospective non-randomized trial32. The randomized controlled trials are summarized in 
table 2. In addition, two ongoing trials are discussed.
 In a premarket approval trial, performed by Saxon et al30, 197 patients with IC or CLI were 
randomized to angioplasty alone or angioplasty with endoprosthesis placement. The study was 
terminated early due to device-related technical difficulties and problems with the original 
study outcome definitions and hypothesis. Therefore the endpoints, specifically technical 
success and primary patency, were redefined. Statistically significant better technical success 
rates and improved target vessel patency was seen in the endoprosthesis group for lesions 
longer than 3 cm. Placement of an endoprosthesis was associated with a 9% improvement in 
clinical status and a 15% improvement in CLI score at one year. In contrast, Boufi et al.32, found 
no statistically difference in 1-year primary and secondary patency rates between subintimal 
angioplasty with or without endografting of the entire length of the recanalized AFS in a 
non-randomized retrospective analysis. Endoprosthesis addition depended on the surgeon’s 
preference and the extension of the femoropopliteal occlusion. Further, the study was limited 
by a small population and variations antiplatelet regimes. 
 In a prospective randomized trial McQuade et al.29 compared the efficacy of the Viabahn® 
endoprosthesis to that of an open surgical PTFE above-knee bypass in patients with IC or 
CLI. Postoperative complications were equal in both groups, but the mean hospital stay was 
significantly shorter for the stent graft group (0.9 versus 3.1 days, p<0.001). The number of 
re-interventions were comparable after 12 months and there were no significant differences 
in 1-year primary and secondary patency between the endoprosthesis and the surgical bypass 
group (p=0.895; p=0.861). In the Viabahn® group, 13 stents failed during the first year, while in 
the surgical group, 11 graft thrombosis occurred. At 48 months follow-up, there was still no 
significant difference in primary (p=0.807) or secondary patency (p=0.891) between the groups. 
Patency was slightly higher in the 6 and 7 mm stent graft group compared to surgical bypass. 
Despite the small cohort and low compliance to anti-platelet therapy, this study demonstrated 
a similar primary and secondary patency rate for all TASC-II (A-D) lesions in the SFA between 
the Viabahn® and the above-knee prosthetic femoro-popliteal bypass up to 48 months. 
Another randomized trial comparing the Viabahn® with surgery was performed by Lepäntalo 
et al31. In this study a PTFE-graft bypass was compared to the Viabahn® endoprosthesis for 
SFA occlusions in IC and CLI with healthy adjacent segments. The intention was to enroll 60 
patients eligible for both treatments in each group. However, only 44 patients in 41 months 
were randomized by the 8 participating centers. Therefore, an interim analysis was performed 
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Table 2. A summary of the randomized controlled trials focusing on long de-novo lesions of the SFA. 
Author Year Angioplasty Viabahn Surgical 
bypass
P-value
Saxon30 2008 Number of treated limbs 100 97
Occlusion length in cm (range) 7 (0.4-13) 7 (0.5-13) NS
Technical success % 66% 95% 0.0001
Clinical success % 69% 84% 0.025
Complications % 21% 21% NS
Rethrombosis >30 days 6% 8% 0.593
Primary patency 1-year 40% 65% 0.0003
Secondary patency 1-year NR NR NR
Limb salvage % NR NR NR
Lapäntalo31 2009 Number of treated limbs 23 21
Occlusion length in cm (range) 10 (5-25) 13 (5-25)
Technical success % 100% 91% NR
Clinical success % NR NR NR
Complications % 39% 38% NR
Rethrombosis >30 days NR NR NR
Primary patency 1-year 42% 84% 0.09
Secondary patency 1-year 58% 100% 0.02
Limb salvage % NR NR NR
Kedora/ 
McQuade29
2010 Number of treated limbs 50 50
Occlusion length in cm (range) 26 (11-41)* NR NR
Technical success % 100% 100% NR
Clinical success % NR NR NR
Complications % 8% 6% NR
Rethrombosis >30 days 26% 20% NR
Primary patency 1-year 72% 76% 0.807
Secondary patency 1-year 83% 86% 0.891
Limb salvage % 98% 84% 0.039
NR = Not Reported; NS = Not Significant; * total length of artery covered with stent
at the time 44 patients were recruited and showed significantly better primary patency rates in 
the surgical bypass group (48% vs. 95%, p=0.02). The trial was prematurely terminated based 
on the results of the interim analysis. The limited recruitment was probably a result of the 
critically defined inclusion criteria, specifically TASC II B and C lesions with minimal one patent 
runoff vessel and at least 1 cm healthy SFA below and above the lesion. The poor outcome 
results may well have been related to the learning curve, as only few patients were enrolled 
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in each center. Furthermore, the anticoagulation/anti-platelet therapy was not defined within 
the protocol. 
 There is a clear indication for further randomized trials, comparing the latest generation 
endoprosthesis with bare metal stents or with the venous femoropopliteal bypass. The 
VIBRANT trial (Viabahn® versus bare Nitinol stent, NCT00228384) is a prospective randomized 
multicenter trial randomizing patients with complex SFA lesions (≥ 8cm; TASC C and D) to either 
the Viabahn® endoprosthesis or a bare nitinol stent. The study enrolled 150 participants over 
the course of three years. The three-year results, as presented at the Vascular Interventional 
Advances (VIVA) meeting in 201133, showed no significant difference in primary patency between 
the two arms (p = 0.392; p = 0.486 respectively). There were significantly more stent fractures 
in the bare nitinol stent arm (58%) versus the Viabahn® endoprosthesis (4%; P < .001). Quality-
of-life and standardized claudication questionnaires have been examined, but results are not 
available yet. The surgical versus percutaneous bypass (SUPERB, NCT01220245) trial34 was 
designed to compare the heparin-bonded Viabahn® with the venous bypass for patients with IC 
and CLI with >15 cm lesions in the SFA and is currently enrolling patients. The primary endpoint 
is primary patency and quality of life evaluated by the RAND-36 questionnaire and the Walking 
Impairment Questionnaire. Secondary endpoints include secondary patency, freedom-from-
TLR (target lesion revascularization) and complications.
Treatment of in-stent restenosis
 One article was identified focusing on the subject of endovascular treatment with the 
Viabahn® endoprosthesis in femoropopliteal ISR35. To date, no randomized controlled trials 
have been published. One ongoing randomized controlled trial was found.
 The SALVAGE Trial35 (a prospective, multi-center, trial to evaluate the safety and 
performance of spectranics laser with Adjunct PTA and Gore Viabahn® endoprosthesis for the 
treatment of SFA ISR) aimed to evaluate the safety and effectiveness of treating femoropopliteal 
ISR with laser debulking followed by implantation of a Viabahn® endoprosthesis . The planned 
enrollment was 100 patients (age 18-90) with moderate to severe IC or CLI. Unfortunately, 
the trial was terminated early due to initial safety concerns of the laser. A total of 27 patients 
(17M/10F; age 70.0±10.5 years) with mainly TASC C and D lesions (81.4%) were enrolled. The 
mean target lesion length was 20.7±10.3 cm and the mean endoprosthesis length was 23.8±9.6 
cm. Technical success was achieved in all patients and distal embolization occurred in 3 cases. 
No stent fractures or ISR were reported during follow-up. Primary patency at one-year, defined 
as uninterrupted patency with no procedures on or at the margins of the treated segment and 
with no restenosis ≥50% as documented by peak systolic velocity ratio >2.0 assessed by duplex 
ultrasonography, was 48% due to the occurrence of edge-stenosis. Despite this, all subjects 
experienced significant clinical benefit, with improved ABI, walking distance, speed and ability 
to climb stairs, which was maintained up to 1 year. 
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 Currently, there are no randomized controlled trials that support the use of any specific 
treatment strategy for the management of femoropopliteal ISR. The POBA (Gore Viabahn® 
endoprosthesis with propaten bioactive surface versus plain old balloon angioplasty for the 
treatment of SFA ISR, NCT01108861) trial is an ongoing prospective, randomized, multi-center 
study recruiting patients with an ISR in the SFA. In 4 Belgian and 2 German centers a total 
of 80 patients will be enrolled to either Viabahn® stent grafting or angioplasty only. Primary 
endpoints are primary patency at 12 months, defined as the absence of restenosis or occlusion 
within the originally treated lesion based on duplex ultrasound without TLR within 12 months 
and device-related serious adverse events within 30 days. It is expected that the use of the 
Viabahn endoprosthesis will result in a higher 12 month primary patency of treated SFA ISR 
lesions.
DISCUSSION
 In this review we have provided an overview of the available literature focusing on the 
endovascular treatment of long de-novo lesions and ISR in the SFA using an ePTFE covered 
nitinol stent graft (Hemobahn®/Viabahn®). Available data suggest potential improvements in 
patency rates in the treatment of long segment SFA disease. Primary and secondary patency 
rates of covered stents correspond to those of above-knee prosthetic surgical bypasses and to 
bare nitinol stent grafting. Literature review reveals scarce data on ISR treatment in the SFA. 
 The Society for Vascular Surgery and The Society of Interventional Radiology have 
proposed reporting standards for clinical evaluation of new devices36. However, few clinical 
trials adhere to these guidelines. The review of literature showed a wide range of inclusion and 
exclusion criteria, treatment strategies and distal runoff, unclear definitions of primary and 
secondary endpoints, varying additional revascularization techniques and large differences 
in post interventional antiplatelet regimes. Often, no distinction was made between major 
and minor complications and graft failure due to in-stent or edge stenosis. In addition, all 
research populations consisted of mixed patients with IC and CLI and were evaluated as one 
similar group. Patients with CLI have often a more advanced disease, i.e. worse outflow, 
more occlusions and/or calcifications and longer lesions than patients with IC22. Other study 
limitations were the small sample sizes, the low statistical power and the lack of multiple 
randomized controlled trials. This great variety in characteristic renders comparisons between 
the various studies complicated and may explain the wide variety in described primary and 
secondary patency rates. 
 Another factor that affects the outcome of the various studies is the progress in stent 
design. Since the introduction in 1996, the Hemobahn®/Viabahn® endoprosthesis has been 
modified. During the years the deployment has changed for hub to tip toward into hub enabling 
a more precise positioning of the graft, possibly affecting outcome. Moreover the proximal edge 
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of the endograft has no longer a straight, but a contoured edge (fig. 3). This adaptation will 
reduce infolding in case of oversizing, thereby maintaining laminar blood flow and preventing 
intimal hyperplasia and thus edges stenosis. Another development was the introduction of the 
heparin bonding technology in the endoprosthesis37, 38. This technology has improved outcome 
of surgical vascular grafts39-41, but the efficacy in endografts remains to be proven, although 
the early results described by Lensvelt et al.27 are promising. While awaiting the results of the 
SUPERB trial34, further research is required to understand the mechanisms of the development 
of edge stenosis.
Figure 3. Heparin-Bonded Viabahn® endoprosthesis (W.L. Gore & associates, Flagstaff, AZ, USA) with the 
contoured edge, developed in order to reduce infolding in case of oversizing.
 Endograft failure has been an important issue in the femoropopliteal arterial segment 
since their introduction. Causes of graft failure include acute thrombosis, recoiling, stent 
fractures, intimal hyperplasia and edge stenosis37, 38, 42. Clinical experience has demonstrated 
that the Viabahn® is associated with low stent fracture rates (0-4%) and low incidence of 
intimal hyperplasia within the body of the stent15, 33. The reported ISR rates in this review are 
also very low. The preliminary data of the VIBRANT trial show a relation between graft failure 
and IRS for bare nitinol stents, but not for the Viabahn endograft33. Thus, the endoprosthesis 
might alleviate the problem of ISR. In addition, the SALVAGE trial showed one-year maintained 
clinical benefit in patients with IC with femoropopliteal ISR treated with laser debulking 
followed by endografting, while no recurrent ISR was reported35. Additional randomized trials 
are necessary to collect data that support the use of any specific treatment strategy for the 
management of femoropopliteal ISR. 
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 Another important point of discussion has always been the coverage of collateral arteries, 
that might reduce the limb salvage rate or may change the level of amputation after failure 
of the graft37, 42, 43. The reported limb salvage rate in the present study is high (92-100% >3 
years)5, 21, 23, 25-27. Moreover, in the randomized trial by McQuade et al.29, a failure of endografts 
did not increase the amputation rate compared to bypass surgery. These data suggest that the 
occlusion of these collaterals is clinically of low relevance. Further studies should confirm this 
hypothesis.  
 The use of covered stent is likely to increase procedural costs compared to bare nitinol 
stents and surgery. In addition, endovascular techniques are related to higher incidence of 
re-interventions in order to maintain patency. However, endovascular treatment is associated 
with shorter hospital stay and less complications because of the minimal invasive character. 
To date, no cost benefit analysis has been performed. Quality of life questionnaires have been 
collected in the VIBRANT33 and SUPERB34 trials. While awaiting the results on quality of life, 
further randomized controlled trials are required to compare the various treatment options for 
extensive SFA occlusive disease to determine which device will provide the most cost-effective 
and efficacious option. 
 In conclusion, covered stents improve results of endovascular treatment of extensive SFA 
occlusive lesions. The Viabahn® endoprosthesis may provide a valid alternative in patients 
with extensive SFA disease. Uniformity in study design and additional randomized controlled 
trials are necessary to compare long lesions of the SFA with the gold standard. Edge stenosis 
remains an important cause of graft failure. Results of new techniques and devices, including 
the heparin-bonded Viabahn® with the contoured edge for the treatment of long de-novo 
lesions in de SFA or ISR, should be awaited. 
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Objective: Self-expanding covered stents for superficial femoral artery occlusive disease have 
undergone an evolution during the years. Early results of the latest generation, the heparin-
bonded Viabahn with a contoured proximal edge, were promising with reported one-year 
primary patency rates of 73-78% in long lesions. The aim of the present study was to present 
the 3-year outcome of the heparin-bonded Viabahn for SFA occlusive disease. 
Methods: All patients treated with a heparin-bonded Viabahn in three centers between April 
2009 and December 2011 were included in the study and retrospectively analyzed. Clinical state 
in Rutherford category, ankle-brachial indices (ABI) and duplex ultrasound scans were the 
features of follow-up at 6 weeks, 6, 12, 24 and 36 months. Primary endpoints of the study were 
the 3-year primary, primary-assisted and secondary patency rates. 
Results: A total of 73 SFAs in 70 patients were treated with a heparin-bonded Viabahn and 
included in the study. Fifty-four patients were male (78%) and the mean age was 70.0 ± 9.1 
years. The mean lesion length was 17.4 ± 7.0 cm and 84% was classified as TASC-2 C and 
D. The median follow up was 25 months (range 2-55 months). The 3-year primary, primary-
assisted and secondary patency rates were 59%, 71% and 82%, respectively, with a 3-year 
freedom from amputation of 100%.
Conclusion: The use of a heparin-bonded Viabahn for SFA occlusive disease is related to 
patency rates within limits of surgical reconstruction. The procedure is related to low morbidity 
and amputation rates. 
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 Plain balloon angioplasty and bare metal stenting yield good results for short occlusive 
and stenotic lesions in the superficial femoral artery (SFA). Results however tend to decrease 
with lesion length. For that reason alternative strategies have been developed, including 
atherectomy, paclitaxel-based technologies and the use of covered stents. Initially the use 
of covered stents was related to mixed results, likely to be due to a variety in patient and 
lesion characteristics, treatment protocols and improvements of the covered stent.1,2 The 
latest generation Viabahn has incorporated the heparin-bonding technology and in addition 
the proximal edge has been reshaped towards a contoured edge in order to prevent infolding 
in case of oversizing. Moreover, longer stents are now available reducing the number of 
overlap zones. Initial one-year results, of three case series and one randomized trial, have 
demonstrated a primary patency rate of 67-78% .3-6 The randomized Viastar trial comparing the 
heparin-bonded Viabahn with bare metal stents (BMS) proved the superiority of the Viabahn 
over BMS at 24 months.7 There was, however, no significant impact on clinical outcome and 
target revascularization rate. Recently, the performance and safety of the 25-cm long heparin-
bonded Viabahn was assessed in TASC II C and D lesions showing 1-year primary and secondary 
patency rates of 67.0% and 96.9%, respectively.6
In the previously published one-year results of our two-center cohort3 of 56 limbs treated with 
the heparin-bonded Viabahn the primary patency at one year was 76%, with a primary-assisted 
and a secondary patency rate of 82% and 89%, respectively. As patency rates may decrease 
over time it is essential to assess a prolonged follow-up. The aim of the present study was to 
study the 3-year outcome of the heparin-bonded Viabahn in the treatment of SFA occlusive 
disease. In order to increase the sample size a third center was added to the cohort.
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PATIENT POPULATION AND METHODS
 All patients treated with a heparin-bonded Viabahn, between April 2009 and December 
2011 in one of the three participating hospitals (Rijnstate Hospital, Arnhem, Isala Clinics, 
Zwolle, and St. Antonius Hospital, Sneek, The Netherlands), were gathered in a database and 
retrospectively analyzed. The initiation time of the randomized SuperB trail, comparing the 
heparin-bonded Viabahn to the venous femoro-popliteal bypass, was the end date of inclusion 
in the present study.8 Patients of this cohort may also have been included in other sub-
analyses.3,9-12 Data were retrospectively collected and anonymously analyzed. Retrospective 
research of patient’s charts is not in scope of the Dutch Law on Human Bound Research and 
therefore neither formal approval of the Central Committee Human Research (CCMO) nor 
patient consent were required.
 Indication for intervention included disabling claudication and critical limb ischemia. In 
all patients secondary risk prevention was performed according to national guidelines and 
patients with disabling claudication were primarily treated with (supervised) walking exercise. 
The choice for endovascular treatment with a covered stent was based on anatomic suitability 
and preferences of the patient and interventionalist. Interventions were performed by vascular 
surgeons and interventional radiologists. 
 Patient characteristics, medical history, clinical state and demographics were retrieved. 
Clinical state was classified using Rutherford system13, cardiovascular risk factors according 
to the Society for Vascular Surgery (SVS) and American Association of Vascular Surgery (AAVS) 
medical co-morbidity grading system and lesion characteristics according to the TASC-II 
criteria.14 Procedural aspects and post-procedural data were retrieved from the case files. 
Standard follow-up consisted of clinical assessment, ankle-brachial index (ABI) measurements 
and duplex ultrasound examination at 6 weeks, 6 months, 12 months, and annually afterwards. 
Treatment protocol
 The treatment protocol has been described before.3 In summary, the common femoral 
artery was approached either percutaneous or by surgical cut down. In case of a concomitant 
lesion in the common or deep femoral artery, an endarterectomy was performed. The stenotic 
section was passed using a Terumo® wire (Terumo Medical Corporation, Elkton, MD, USA) 
and a catheter and a distal re-entry was made. The diseased segment was dilated and 
endografts (Viabahn Endoprosthesis, W.L. Gore & Associates, Flagstaff, AZ, USA) were placed 
from distal to proximal with minimal oversizing. The entire diseased segment was covered 
with endografts, which were post-dilated with an angioplasty balloon of the same size as the 
endograft. Control angiography of the endograft and outflow vessels was routinely performed. 
All patients received statin treatment and dual anti-platelet inhibitors for at least 6 months, 
unless oral anticoagulation was indicated for other reasons. 
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 Primary patency was defined as the absence of re-stenosis or occlusion in the treated 
segment. Primary-assisted patency was defined as patency achieved by secondary endovascular 
interventions to treat re-stenosis of the target vessel. Secondary patency was defined as 
patency achieved by all procedures aimed at recanalizing an occluded endograft preserving 
the endograft. Re-stenosis was defined as a peak systolic velocity (PSV) ratio >2.5, as measured 
on duplex ultrasound.15An occlusion was defined as absence of flow in the treated segment. 
A failure of the endoluminal graft was defined as occlusion of the endograft, with or without 
clinical symptoms, not responding to therapy. Limb salvage was defined as the absence of an 
above-ankle amputation.
Endpoints
 The primary endpoints of this study were the 3-year primary, primary-assisted and 
secondary patency rates of the endograft. Secondary endpoints included adverse outcomes 
defined as secondary interventions and amputation rate.
Statistical analysis
 Normality was tested using the Shapiro-Wilk test. Categorical variables are presented as 
numbers followed by percentages; continuous variables are presented as mean ± standard 
deviation or as median with range when appropriate. Patency rates were determined using 
the Kaplan-Meier life-table method. Cox-regression analyses were generated to analyze 
possible risk factors. P-values <0.05 were considered statistically significant. All analyses were 
performed with SPSS 22.0 (SPSS Inc., Chicago, IL, USA). 
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 A total of 73 SFA’s in 70 patients were treated with a heparin-bonded Viabahn during the 
study period and were included in the study group. Fifty-four patients were male (77%) and the 
mean age was 70.0 ± 9.1 years. Patient characteristics are shown in Table 1. Fourteen patients 
(20%) had previously undergone treatment of the ipsilateral leg and consisted of angioplasty 
of the SFA (n=7), angioplasty of the iliac artery (n=1), angioplasty of the iliac artery and stent 
placement of the iliac artery (n=2), aortoiliac bypass surgery (n=1), and endarterectomy 
of the common femoral artery (n=1). Two patients had already undergone an ipsilateral toe 
amputation. Lesion characteristics are shown in Table 2. 
Table 1. Baseline characteristics including cardiovascular risk factors, Rutherford classification and 
ankle-brachial index
Tobacco use     39 (56%)
Hyperlipidemia  54 (77%)
Diabetes mellitus 30 (43%)
Hypertension 59 (84%)
Renal failure 15 (21%)
Pulmonary disease 16 (23%)
Coronary artery disease 26 (37%)
Cerebrovascular disease   8 (11%)
Rutherford Classification 
             3
             4
             5
             6
51 (73%)
  7 (10%)
11 (16%)
  1 (1%)
Ankle brachial index (ABI)  0.59 ± 0.17
ABI exercise n=15 0.39 ± 0.23
ASA
             1
             2
             3
             4
  1 (1%)
32 (46%)
34 (49%)
  3 (4%)
.
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Table 2. Lesion characteristics including the lesion length, popliteal level and the outflow vessels.
Left leg/right leg 34 (47%) /39 (53%)
Lesion length (cm) 17.4 ± 7.0
Flush occlusion 21 (28%)
TASC-II
            A
            B
            C
            D
  1 (1%)




             P1
             P2
             P3
50 (69%)
20 (27%)
  3 (4%)
Outflow vessels
            0
            1
            2
            3
  1 (1%)




 Twenty-two subjects (30%) were treated under local, 26 (36%) under spinal and 25 cases 
(34%) under general anesthesia. During all procedures heparin i.v. was administered. Twenty-
four lesions (34%) were treated with one endograft, 23 (31%) with two endografts, 25 (34%) with 
three endografts and 1 (1%) with four endografts. In total 149 endografts were used of which 9 
(6%) had a diameter of 5 mm, 116 endografts (78%) with a diameter of 6 mm, 22 (15%) with 7 mm 
and 2 (1%) with a diameter of 8 mm. Concomitant treatment was performed in 29 procedures 
(39%) consisting of endarterectomy of the common femoral artery (n=13), angioplasty of the 
iliac arteries (n=7), angioplasty of the popliteal artery (n=3), endovascular abdominal aneurysm 
repairs (EVAR, n=2), surgical debridement of an ulcer (n=2), toe amputation (n=1) and one 
subject was treated with thrombolytic therapy due to preprocedural crural thrombosis. There 
were 2 procedural complications, one due to a perioperative thrombosis which was treated 
with thrombolysis and one due to a dissection of the popliteal artery which was treated with an 
additional endograft.
Postoperative period
 Postoperatively complications occurred in 10 cases (14%). In 2 cases a re-bleed in the 
groin required surgery, one patient had atrial fibrillation which was treated with medication, 
another patient had a hematoma of the groin and one patient had a wound infection, both 
treated conservatively. One patient underwent a non-scheduled forefoot amputation due 
to progression of necrosis. One patient had hypopotassemia which was treated with oral 
medication, another had a dislocation of the hip which was treated with a closed reduction, 
a patient had urine retention which was treated with an urinary catheter, and a last patient 
developed a pneumonia which was treated with antibiotics. 
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The median hospital stay was 2 days (range 1-12 days). The majority of patients were 
postoperatively treated with acetylsalicylic acid 80 mg in combination with clopidogrel 75 mg 
daily (n=57). The remaining patients were treated with a daily dose of acetylsalicylic acid 80 
mg and dipyridamol 400 mg (n=9), Coumarin derivates alone (n=1) or in combination with 
clopidogrel 75 mg (n=3) or acetylsalicylic acid 80 mg (n=3).
Follow up
 The median follow up was 25 months (range 2-55 months). Seventeen patients (24%) died 
during the study period unrelated to the treatment. During follow-up 14 patients (20%) were 
lost to follow up due to moving from the hospital area, patient preference, and terminal illness. 
The majority of patients (92%) had an improved Rutherford category after endograft placement. 
The mean postprocedural ABI was 0.95 ± 0.19 (N=55). In 5 cases early occlusion occurred 
of which 4 were successfully treated with thrombolytic therapy and one received a surgical 
bypass. These early occlusions were considered as primary failures. The 1, 2 and 3 year 
primary patency rates were 73%, 64% and 58%, respectively (Fig. 1). The primary-assisted 
patency rates were 78%, 71% and 71% and the  secondary patency rates were 91%, 82%, 82% 
at 1, 2 and 3 years, respectively. The use of multiple stents showed a difference in the 3-year 
primary patency 73%, 56% and 45% with 1, 2 and 3 stents, respectively (p=0.77).  Analysis of 
factors which could influence the patency did not show any significance.
Occlusions
 Out of the 73 SFA’s treated with a heparin-bonded endograft 14 (19%) presented with an 
occlusion (including the 5 early occlusions mentioned above) during follow up and all were 
treated with thrombolytic therapy of which 9 successfully. In total 9 endografts had a permanent 
failure. Six patients with a permanent failure were eventually treated with a surgical bypass of 
which one above the knee and 5 below the knee bypass. The remaining 3 permanent failures 
were treated conservatively because of lack of clinical symptoms. During follow up no major 
amputations were performed. 
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Figure 1. Primary, primary assisted and secondary patency rates from 0-36 months.
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 In the present study we have shown that the heparin-bonded Viabahn inserted for SFA 
occlusive disease is related to a good midterm outcome. This is the first study describing a 
3-year follow-up with the newest generation Viabahn. In a recent meta-analysis, Rychlick et 
al. have shown that 3-year the primary patency rate for prosthetic above the knee bypasses 
is 46-70%, which is in line with the results of our study.16 Obviously, patient groups might not 
be comparable as they have not been matched. Nevertheless, 84% our patients were treated 
for TASC-C and D lesions with a mean lesion length of 17.8 ± 7.2 cm. In a randomized trial 
McQuade et al. have already shown that the regular Viabahn was related to similar patency 
rates as above the knee prosthetic bypass up to 4 years.17 The 3-year primary patency of 
McQuade et al. was 63% for both the endograft and surgical bypass groups, which is close 
to the 59% described in our study. Whether the heparin-bonding technology indeed improves 
patency rates of the Viabahn remains therefore to be shown. The heparin-bonding technology 
lowers platelet deposition and reduces thrombogenicity18. Moreover, the laser-cut contoured 
proximal edge may improve apposition of the device to the vessel wall, possibly improving 
endograft performance.
 The role of endografts in the treatment of SFA occlusive disease will remain under debate. 
Several studies have shown a satisfying outcome after treatment of extensive SFA occlusive 
disease using paclitaxel-based stents of balloons.19-21 The advantage of the use of drug-coated 
balloons could be that no foreign materials are implanted and that collaterals are preserved. 
Direct comparative studies are clearly needed to assess the position of both techniques in 
the treatment algorithm. Previously, we have shown that overstenting of collaterals does 
not deteriorate clinical outcome in case of failure, suggesting that the clinical relevance of 
overstenting collaterals in the SFA is low.10 In our study only 9 treated SFAs had a permanent 
failure of which 6 were eventually treated with a surgical bypass, while the amputation rate 
was zero percent, confirming the safety of the technique. To date, surgery is still considered 
the gold standard for extensive SFA occlusive disease in various guidelines, that could be 
considered outdated. Minimally invasive techniques may yield less complications in this often 
frail patient group. Nevertheless, studies like the SuperB trial, comparing the heparin-bonded 
Viabahn with the venous bypass, are essential to provide further support for an endovascular 
first strategy, also in extensive SFA occlusive disease.8
 The minimal invasive character of the endovascular treatment may be reflected in the 
low morbidity rate. Surgical bypass of the femoropopliteal region is known for a relatively high 
morbidity, including wound healing problems, graft infection and edema. The incidence of 
these complications vary between 5-60%.22-25 Our study showed an overall complication rate of 
16%. Due to its minimal invasive character, a low complication and amputation rate, treatment 
with a heparin-bonded endograft could also be considered as a supplementary treatment 
option thus postponing surgical reconstructions.     
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 Limitations of our study were the retrospective design of the study and small sample size, 
rendering any subanalysis unreliable. The small sample size is also related to the limited use 
of the covered endograft for this indication in our country. We could not exclude a selection 
bias as patients were treated according to the institutional standards and at the discretion 
of the surgeon/interventional radiologist. Additionally the entire cohort did not complete the 
36-months of follow up. Furthermore, we did not analyze risk factors as potential confounders 
influencing endograft patency due to low sample size. Moreover further research is necessary 
to compare the covered endograft with other therapies, such as angioplasty, bare metal stents 
and surgical bypass. 
 In conclusion, using heparin-bonded endografts for SFA occlusive disease is a safe and 
good treatment option with low morbidity and amputation rates. The 3-year patency rates are 
promising, but need to be established in comparative studies with both other endovascular 
options and surgery. 
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Objective: The role of endografts in the treatment of extensive superficial femoral artery (SFA) 
occlusive disease is enlarging. Results are limited by the occurrence of edge stenosis. The 
aim of the study was to retrospectively evaluate the efficacy of treatment of edge stenosis of 
endografts inserted for SFA occlusive disease.
Methods: All patients, treated between November 2001 and December 2011, with a self-
expandable polytetrafluoroethylene-endograft were gathered in a prospective database in 
three hospitals. The incidence of primary edge stenosis and the incidence of re-edge stenosis 
after treatment were retrospectively noted and a comparison was made between the results of 
percutaneous transluminal angioplasty (PTA) and extension of the endograft.
Results: A total of 88 patients presented with 115 edge stenoses, of which the majority 
presented within 1 year after insertion of the endograft (mean time to edge stenosis 10.768.2 
months). Seventy-three stenoses (63%) manifested at the proximal and 42 at the distal edge 
(37%). The 1-year incidence of restenosis and/or occlusion was 45% after PTA and 43% after 
endograft extension, with 1-year patency rates of 81% and 92%, respectively. The incidence 
of restenosis/occlusion after treatment with PTA was 12% higher at two years compared to 
extension of the endograft (55% vs. 43%, respectively). 
Conclusion: Edge stenosis may well be treated with either PTA or extension of the endograft. 
The incidence of restenosis and/or occlusion after both PTA and extension is high, but patency 
rates are acceptable. Aggressive surveillance is needed during the first year after insertion.
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 Peripheral arterial occlusive disease (PAOD) is commonly caused by occlusive lesions in 
the superficial femoral artery (SFA). To date, surgical reconstruction by means of a venous 
femoro-popliteal bypass is still considered the standard treatment for extensive lesions.1 
Bypass surgery, however, is associated with a prolonged recovery and complications such as 
wound infections, edema and graft failure. Self-expanding endografts have shown to have a 
similar patency as above the knee prosthetic bypasses.2 Short-term patency of heparinbonded 
endografts have been related to patency rates in the SFA that approach the surgical results, 
although comparative data are still lacking.3-5 The ongoing SuperB Trial will hopefully 
give a definitive answer if these endografts are a valid alternative for the venous surgical 
femoropopliteal bypass.6 Patency rates of percutaneous transluminal angioplasty (PTA) and 
bare metal stenting are limited by the occurrence of (in-stent) restenosis (ISR). Longer lesions 
are related to a poorer outcome as the risk of (in-stent) restenosis is likely to increase with 
lesion length.7,16,22 Endografts were introduced with the hypothesis that the covering material 
may shield the stent from tissue ingrowth and that they therefore could reduce the incidence 
of ISR. Initial results were very inconsistent, due to several reasons, including varying patient 
and lesion characteristics, development in stent design and variation in medical therapy.8 
The integration of the heparin-bonding technology with endografts has resulted in consistent 
good patency rates. In 247 patients, published in three studies, the cumulative primary and 
secondary patency rates were 75% and 91%, respectively, with a mean lesion length of 19 
cm.3-5 Edge stenoses, either at the proximal or distal edge, are a possible, but certainly not 
the only reason for failure of primary patency of endografts. If untreated, these edge stenoses 
may cause acute thrombosis due to reduced flow. A recent study showed that three out of 
four of patients that presented with an acute endograft thrombosis had an underlying edge 
stenosis.9 The optimal treatment modality of edge stenosis of endografts in the SFA has not 
been identified so far. The aim of this study was to evaluate the outcome after treatment of 
a primary edge stenosis of endografts inserted in the SFA for occlusive disease (PTA versus 
extension of the endograft).
MATERIALS EN METHODS
 Between November 2001 and December 2011 a total of 341 patients were treated with an 
endograft for SFA occlusive disease. We retrospectively gathered follow-up data of all patients 
that presented with an edge stenosis from date of endograft insertion until February 2013. 
These data were available for 88 patients who were included in the current study. There were 
three participating hospitals (Rijnstate Hospital Arnhem, Isala Clinics Zwolle, and Antonius 
Hospital Sneek, The Netherlands). Routine follow-up after placement of endografts consisted 
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of clinical assessment, anklebrachial index (ABI) measurements and duplex ultrasound scans 
at 6 weeks, 6 months, and 12 months, and yearly thereafter. We included patients with PAOD 
with an endograft who presented with an edge stenosis, as determined by a peak systolic 
velocity (PSV) ratio of >2.5, during routine surveillance or determined after treatment for an 
acute occlusion. Patients in whom the endograft had been inserted for aneurysmal disease 
were excluded. Baseline patient and lesion characteristics, scored according to the TASC-
2 criteria10, procedural aspects of endograft placement and treatment of edge stenosis, as 
well as the follow-up after the latter procedure were evaluated. Cardiovascular risk factors 
were scored according to the Society for Vascular Surgery (SVS) and American Association of 
Vascular Surgery (AAVS) medical comorbidity grading system. The Rutherford classifications 
for acute and chronic limb ischemia were used to categorize the clinical symptoms.11 For this 
type of retrospective study formal consent approval was not required. 
Treatment Protocol 
 The protocol of endograft placement has been described in detail previously.3 In brief, 
the common femoral artery was approached either percutaneous or surgically, the diseased 
segment was passed with a hydrofil guide wire, and a distal re-entry was created. Then the 
segment was pre-dilated and endografts (Viabahn Endoprosthesis, W.L. Gore & associates, 
Flagstaff, AZ) were positioned from distal to proximal with minimal oversizing, followed by 
post-dilation with an angioplasty balloon with the same diameter as the endograft. Control 
angiography of the bypass and outflow vessels was performed routinely. The treatment 
of edge stenosis was not protocolized during the study period in the three participating 
hospitals. Typically, the common femoral artery was entered percutaneous and, after heparin 
administration, the edge stenosis was dilated using regular angioplasty balloons. It was the 
choice of the interventionalist whether or not to insert an additional endograft to treat the 
lesion.
End Points
 The primary end point of the study was the composite end point of the incidence of a 
re-edge stenosis and/or occlusion. In addition, an analysis was performed to gain insight in 
possible predictors of failure of treatment, including cardiovascular risk factors, clinical state, 
lesion, and endograft characteristics. 
Definitions
 An edge stenosis was defined as a PSV ratio >2.5, as measured on duplex ultrasound 
scanning. Primary patency after treatment of an edge stenosis was defined as the absence 
of a restenosis at the treated edge. Secondary patency after treatment of an edge stenosis 
was defined as patency of the endograft after (re) occlusion. Secondary failure was defined 
as the occurrence of a re-edge stenosis or thrombosis of the endograft after treatment of a 
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primary edge stenosis. Reintervention was defined as treatment necessary for the endograft 
to maintain or restore patency.
Statistical Analysis
 Categorical variables are presented as numbers followed by percentages; continuous 
variables are presented as mean ± standard deviation or as median with range when 
appropriate. Distribution of normality was tested using the Shapiro-Wilk test. Chi-square tests 
were performed to compare incidence of re-edge stenosis and thrombosis after treatment of 
the primary edge stenosis with PTA and extension of the endograft with another endograft. 
Kaplan-Meier survival analysis and log-rank testing were performed to assess primary and 
secondary patencies after treatment of primary edge stenosis. Pearson correlation tests were 
performed to analyze the significance of various variables on outcome after treatment and put 
in a binary logistic regression analysis. P-values <0.05 were considered statistically significant. 
All analyses were performed with SPSS 22.0 (SPSS, Chicago, IL).
RESULTS
 During the study period 88 patients developed 115 primary edge stenoses and were 
included in the study group. Patients had a mean age of 66.9±9.2 years and the majority were 
male (72%). Baseline characteristics are depicted in Table I. All included patients were initially 
treated with a self-expandable endograft (Viabahn®, Endoprothesis, W. L. Gore & Associates 
Flagstaff, AZ). Median follow-up time was 22 months (range 3-68 months). Fifty-one patients 
(58%) were treated with the heparin-bonded endograft with the proximal contoured edge and 
the others with the old generation non-heparin bonded endograft with a straight proximal 
edge. Thirty patients were also reported in another recent study.8 One patient with a proximal 
edge stenosis was treated with a drug-eluting balloon and another proximal edge stenosis was 
treated with a self-expandable nitinol stent (Absolute Pro®, Abbott Laboratories, Chicago, IL). 
In one patient a proximal edge stenosis was resolved by venous patching. These three patients 
were excluded from further analyses. Thus, in total 85 patients were included in the further 
analyses. 
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Table 1. Baseline Characteristics Including Cardiovascular Risk Factors, Rutherford Classification, Lesion 
Characteristics and the Number of Inserted Endografts.
 PBA Extension No treatment All
No of patients 58 11 17 88
Clinical characteristics     
Age (years) 66.3 ± 9.7 64.1 ± 9.0 66.6 ± 9.9 66.2 ± 9.6
Men 44    (76%) 8     (73%) 11  (65%) 64     (73%)
Current smoking 27    (47%) 5     (45%) 11  (65%) 43    (49%)
Hyperlipidemia  40    (69%) 9     (82%) 11  (65%) 62    (70%)
Diabetes mellitus 29    (50%) 1     (9%) 3    (18%) 34    (39%)
Hypertension 45    (78%) 10   (91%) 13  (76%) 70    (80%)
Renal Failure 8      (14%) 1     (9%) 4    (24%) 13    (15%)
Pulmonary disease 12    (21%) 2     (18%) 2    (12%) 17    (19%)
Coronary artery disease 25    (43%) 4     (36%) 6    (35%) 37    (42%)
Cerebrovascular disease 4      (7%) 3     (27%) 1    (6%) 9    (10%)
ASA     
1 3       (5%) 0 1  (6%) 4      (5%)
2 37    (64%) 6     (55%) 7  (41%) 50    (57%)
3 16    (28%) 5     (46%) 9  (53%) 32    (36%)
4 2      (3%) 0 0 2      (2%)
Rutherford     
3 38    (66%) 7     (64%) 12  (71%) 58    (66%)
4 10    (17%) 2     (18%) 2    (12%) 14    (16%)
5 8      (14%) 1     (9%) 1    (6%) 11    (13%)
6 2      (3%) 1     (9%) 2    (12%) 5      (6%)
Ankle Brachial index (ABI) 0.63 ± 0.15 0.62 ± 0.09 0.71 ± 0.19 0.64 ± 0,16
Lesion characteristics prior to insertion of the endograft 
Lesion length 13.0 ± 8.2 18.9 ± 14.6 17.2 ± 6.7 14.6 ± 9.0
TASC-II     
A 7      (12%) 2    (18%) 2  (12%) 11    (13%)
B 16    (28%) 2    (18%) 1  (6%) 19    (22%)
C 20    (35%) 4    (36%) 7  (41%) 32    (36%)
D 15    (26%) 3    (27%) 7  (41%) 26    (30%)
No of edge stenosis 76 14 22 115
Number of stents     
1 34    (59%) 5    (64%) 8   (47%) 48    (47%)
2 11    (19%) 3    (27%) 7   (41%) 22    (25%)
3 11    (19%) 1    (9%) 2   (12%) 14    (16%)
4 2      (3%) 2    (18%) 0 4      (5%)
(Numbers are presented followed by percentage; TASC-II=Trans Atlantic Intersociety Consensus second 
version; ASA=American Society of Anesthesiologists)
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Presentation of Primary Edge Stenosis 
 The mean time from insertion of the endograft to diagnosis of a primary edge stenosis 
was 10.7±8.2 months. Sixty-seven percent of edge stenoses (n=77) occurred within the first 12 
months after insertion, and 23% already within the first three months (n=27). The remaining edge 
stenoses developed in the second (n=35) or third (n=3) postoperative year. Seventythree edge 
stenosis (63%) of the 115 edge stenosis were located at the proximal and 42 (37%) at the distal 
edge. No in-stent stenosis were found in the study group. Forty-one percent of the edge stenoses 
(n=47) presented with acute thrombosis of the endograft and the other edge stenoses (59%) 
were diagnosed during routine surveillance. The clinical state of patients that presented with 
an occluded endograft and with an underlying edge stenosis was category I in 14 patients (30%), 
category IIa in 26 patients (55%) and category IIb in 7 patients (15%), according to the Rutherford 
classification for acute limb ischemia. All included patients who presented with an occluded 
endograft were successfully treated with thrombolysis (Abbokinase®, Abbott Laboratories, 
Chicago, IL). The ABI at the time of an acute occlusion was missing in the majority of cases. 
In approximately half of the edge stenoses that were detected during routine surveillance the 
patient was asymptomatic (Rutherford 1 in 31 patients (46%). Patients presenting with symptoms 
were classified as Rutherford 2 in 26 patients (38%), Rutherford 3 in10 patients (15%) and 1 
patient was classified as Rutherford 4 (1%). The mean ABI at time of presentation with a primary 
edge stenosis was 0.75±0.18 (n=30). Treatment of Primary Edge Stenosis Seventy-six edge 
stenoses (proximal=45; distal=31) (66%) were treated with PTA only. Thirty-seven (49%) of them 
presented as an acute occlusion which were all successfully treated with thrombolysis and the 
others were detected during surveillance. In 14 cases (proximal=7; distal=7) (13%) the endograft 
was extended by an additional self-expandable endograft (Viabahn®). Ten of these patients (71%) 
presented with an acute occlusion and the remaining four were detected during surveillance.
Outcome of Treatment by PTA of the Primary Edge Stenosis
 The median follow-up after PTA of the primary edge stenosis was 8 months (range 0-50 
months). The primary and secondary patency rates of PTA of edge stenosis are depicted in 
Fig. 1. The incidence of restenosis/occlusion after PTA was 45% at 12 months (n=34) with 
19 re-edge stenoses (25%) and 15 occlusions (20%). Fourteen re-edge stenoses (18%) and 
9 occlusions (12%) developed already within the first 6 months after PTA. During the second 
year after PTA 6 additional re-edge stenoses and another 3 occlusions occurred, rendering 
the incidence of restenosis/occlusion at 2 years 55%. The other 2 re-occlusions both 
manifested at 29 months. At 12 months 81% of the endografts, in which an edge stenosis 
was treated with PTA, were still patent (Fig. 1) and no amputations were performed. After 
treatment with PTA, the incidence of restenosis/occlusion of primary edge stenoses that 
were detected during surveillance were comparable with those that presented as an acute 
occlusion (46% vs. 43% at 1-year for surveillance vs. thrombolysis, respectively). However,
the incidence of re-edge stenosis after PTA was higher in patients in whom the primary edge 
stenosis was detected during routine surveillance compared to patients who presented with an 
529929-L-bw-Golchehr
Processed on: 1-4-2019 PDF page: 60
CHAPTER 4
60
acute occlusion (38% vs.14% at 1-year for surveillance vs. thrombolysis, respectively, P=0.009). 
The opposite was true for the incidence of rethrombosis (10% vs. 30% for surveillance vs. 
thrombolysis, respectively at 1-year, respectively, P=0.0016). Patients that presented with a 
secondary occlusion were treated with thrombolysis (n=9) or femoropopliteal bypass (n=9). Two 
patients were treated conservatively and no amputations were performed.
Figure 1. Kaplan Meier curve showing the primary and secondary patency of treatment of primary edge 
stenosis with PTA and extension of the endograft during 24 months after treatment of the edge stenosis.
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Outcome of Treatment of the Primary Edge Stenosis by Endograft Extension with Another
Endograft
 The median follow-up after extension of the endograft was 6 months (range, 0–34 months). 
Patency rates of treatment of the primary edge stenosis by endograft extension with another 
endograft are shown in Figure1. The 1-year incidence of restenosis/occlusion was 43% due to 
2 re-edge stenoses (14%) and 4 occlusions (29%). All 4 occlusions and one re-edge stenosis 
were already observed within 6 months after placement of the endograft extension. During 
follow-up up to 34 months no additional edge stenosis or occlusions were detected. Three 
secondary occlusions (75%) were successfully treated with chemical thrombolysis. A re-edge 
stenosis was detected as the underlying causal lesion in all three cases. The remaining patient 
was treated with a surgical bypass. At 12 months, 13 of 14 endografts that were treated with an 
extension for an edge stenosis, were still patent (92%) (Fig.1). After treatment with an extension 
of the endograft, incidence of restenosis/occlusion was lower in patients in whom re-stenosis 
was detected during routine surveillance compared to patients who presented with an acute 
occlusion (20% vs. 56% for surveillance vs. thrombolysis at one year). Moreover, the incidence 
of re-edge stenosis after extension of the endograft was higher in patients who presented 
with a primary edge stenosis during routine surveillance compared to those who primarily 
presented with an acute occlusion (20% vs. 11% for surveillance vs. thrombolysis at one-year, 
respectively, P=0.106). In contrast, the incidence of re-thrombosis after extension was higher 
after those who primarily underwent thrombolysis compared to those who did not (30% vs. 0%, 
respectively, P=0.0004). The incidence of restenosis/occlusion after treatment with PTA was 
12% higher at two years compared to extension of the endograft, (55% vs. 43%, respectively, 
P=0.226). Within the PTA and extension groups none of the patients needed minor or major 
amputation during follow-up, neither were they lost to follow up. During our study none of the 
patients died. The Pearson correlation test and the binary logistic regression analysis did not 
show any significant predictor of failure after treatment of the edge stenosis with either PTA or 
extension of the endograft. 
Outcome of Patients in Whom the Primary Edge Stenosis Was Not Treated
 Twenty-two patients in whom a primary edge stenosis was detected (proximal=18; distal=4) 
(19%) were not treated for various reasons, including renal dysfunction, or the wish of the 
patient, due to lack of symptoms or terminal illness. The median follow up was 7 months 
(range 1-24 months). One patient had an acute thrombosis after 4 months of follow up that was 
successfully treated with thrombolysis. After one year, 12 patients (55%) of this subgroup were 
lost to followup. The remaining 10 patients (45%) still had a patent endograft.
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 In this study we showed that both PTA and extension of the endograft with another 
endograft are feasible treatment modalities for edge stenosis of endografts inserted in the SFA 
for occlusive disease, but that recurrence rates are high. Nevertheless, patency rates are in 
line with previous research, but rather disappointing, especially when considering that 35% of 
patients were initially treated for TASC-2 A and B lesions. An extension of the endograft seems 
to yield somewhat better results. We could not detect any predictor of failure in our series, but 
due to the small number of patients this has to be regarded with care. An important finding 
of this study is that most primary and re-edge stenoses develop during the first year after 
treatment. In our study 41 patients (54%) with an edge stenosis who were primarily treated with 
PTA and 9 patients (64%) that were treated with an extension of the endograft did not develop 
any re-edge stenosis during follow-up. The 1-year incidence of re-edge stenosis was 25% 
after PTA and 14% after endograft extension, which is in accord with data from other studies 
focusing on the SFA, that described a restenosis rate of 18-50% after PTA of the native SFA.12-15 
The primary and secondary patency rates are also comparable with other studies.7,12-19 These 
studies have described 1-year primary patency rates that vary from 40 to 81% and secondary 
patency rates from 63 to 86%. The large variation in these results may well be explained by 
differences in patient and lesion characteristics and an inconsistent medical treatment. In 
this study we observed more re-edge stenosis after PTA compared to after an extension of 
the endograft (32% versus 14%). However, more occlusions occurred after extension of the 
endograft when compared to PTA (21% versus 14%). The majority of re-edge stenosis were 
diagnosed during the first 6 months after treatment of the primary edge-stenosis, both after 
treatment with PTA and following extension. This observation emphasizes that patients should 
be under intensive routine surveillance during the first year after treatment. Results, however, 
should be considered with care as the treatment of edge stenoses was not protocolized during 
the study period. The extension of the endograft may have therefore have been reserved for the 
more severe lesions by the interventionalist, thereby introducing a selection bias. In addition, 
although no technical failures were noted, the use of an endograft for failed PTA could not always 
be excluded from the case files. No re-edge stenosis were detected after the first 6 months up 
to 34 months follow-up in patients treated with an extension of the endograft. The incidence 
of restenosis/occlusion at 1 and 2 years were lower after an extension of the endograft when 
compared to treatment with PTA only. These results suggest that extension of the endograft 
might lead to better patency rates than treatment of an edge stenosis with PTA, as we observed 
at 12 months with a 9% difference in favor of the extension group. Whether treatment with drug 
coated balloons (DCB) will improve results of the treatment of edge stenosis remains to be 
investigated. DCBs are related to a good outcome after treatment of in-stent restenosis after 
bare metal stenting. Stabile et al. have described a 92% 1-year patency rate when using a DCB 
for in-stent restenosis and in another study Liistro et al. described that the use of a DCB for 
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this indication led to a significant reduction in recurrent restenosis and repeat angioplasty at 
1-year follow-up as compared to historical controls.20,21 There are more limitations in this study 
than the ones already mentioned. First of all, this study is retrospective in nature. We cannot 
exclude a selection bias as patients were treated according to the institutional standards and 
at the discretion of the surgeon/intervention radiologist in three different hospitals. There was 
no uniform treatment protocol of edge stenosis. Furthermore, due to the small sample size 
of our cohort results have to be regarded with care. Due to these two limitations we could not 
draw any robust conclusions on the optimal treatment modality of edge stenosis. Comparative 
studies are indicated to confirm our data and to analyze possible risk factors concerning 
the cause of edge stenosis and to point out potential factors of influence such as the site of 
proximal and distal ending of the endograft, the used generation of the endograft (i.e., with 
or without heparin-bonding technology and contoured proximal edge), antiplatelet therapy, 
shear stress, and comorbidity. Additionally, more research on this matter could result in a 
uniform protocol to treat edge stenosis and the effect of drug eluting techniques remain to 
be elucidated. Indications for initial treatment might also have affected the outcome of the 
present study as primary stenting was performed in 30 patients with TASC-A and TASC-B 
lesions. Usually a PTA only would be sufficient for these patients. In summary, although 
the incidence of restenosis/occlusion rates are high, our study shows that edge stenoses of 
endografts, inserted in the SFA for PAOD, can be treated safely with both PTA and endograft 
extension and may therefore exclude and in some cases postpone bypass surgery. Conservative 
treatment is also an option if symptoms are acceptable for patients. The 1-year patency rates 
are acceptable and an extension of the endograft seems to yield better results. Nevertheless 
this is based on low statistical power due to small number of patients. In our opinion, it is 
essential to detect an edge stenosis before it causes an occlusion and we therefore suggest 
intensive surveillance, i.e., duplex ultrasound at each 3 months, during the first year after both 
insertion of an endograft and after treatment of an edge stenosis. Nevertheless, conservative 
treatment seems to be an acceptable treatment option in patients with severe comorbidities 
and a poor conditional state if frequent outpatient clinic is provided.
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Purpose: To evaluate the efficacy and outcome of thrombolysis and thrombectomy for 
thrombosed polytetrafluoroethylene stent-grafts inserted in the superficial femoral artery 
(SFA) for occlusive disease.
Methods: A retrospective review was conducted of 79 consecutive patients with a thrombosed 
SFA endograft between November 2001 and December 2011. Of these, 46 (58%) were treated 
with thrombolysis (n=40, 87%) or thrombectomy (n=6, 13%) and form the study group (33 men; 
median age 66.8 years, range 30–80). Median time from stentgraft insertion to thrombosis was 
3 months (range 0–53).
Results: Thrombolysis was successful in 38 (95%) patients over a mean 24 hours (range 
3–48); one patient had failed lysis and another died during lytic treatment. Thrombectomy 
was successful in all 6 patients. Thrombosis without a causal lesion was significantly more 
common in occlusions that presented ,30 days after insertion (p=0.01). Over a median follow-up 
of 14 months (range 1–69), reinterventions were performed for restenosis in 12 patients and 
reocclusion in 14 patients, all within 18 months after thrombolytic treatment. More than a third 
of patients (16/45) had definitive failures (2/6 from the thrombectomy group); 4 were treated 
conservatively (no/minor symptoms) and 12 had bypass grafts. Three (7%) patients eventually 
required a major amputation. The primary, assisted primary, and secondary patency rates of 
thrombolysis at 6 months were 56%, 56%, and 68%, respectively. Secondary patency for the 
entire cohort was 58% at 1 year. 
Conclusion: Thrombolysis and thrombectomy of thrombosed endografts in the SFA is effective 
and safe. Patency rates after treatment are moderate, but prolonged secondary patency can 
be achieved.
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 The role of endografts in the treatment of superficial femoral artery (SFA) occlusive 
disease is still under debate. According to the TransAtlantic Inter-Society Consensus II (TASC) 
guidelines,1 surgical reconstruction is the gold standard for lesions ≥15 cm in length. Surgery, 
however, is associated with more complications and a prolonged hospital stay.2 A randomized 
trial has shown that the implantation of endografts can achieve patency rates similar to above-
knee femoropopliteal bypasses up to 4 years.3 Further, the introduction of heparin bonding 
technology to flexible stent-grafts has improved these results. Recently, we reported 1-year 
patency rates of 76% (primary), 82% (assisted primary), and 89% (secondary) in a series of 
long occlusive SFA lesions treated with heparin-bonded endografts.4 Acute thrombosis, often 
caused by an edge stenosis, is the most common cause of failure of an endograft and may be 
limb-threatening. While thrombectomy is an effective treatment for acutely thrombosed native 
arteries and bypass grafts, thrombolysis has developed into an accepted treatment alternative. 
A recent Cochrane review was not able to recommend either of these modalities as an initial 
treatment because there was no overall difference in limb salvage or death rates at 1 year 
between surgery and thrombolysis.5 In another recent review,6 the authors concluded that 
catheter-directed thrombolysis, with an acceptable low complication rate, should be considered 
a complementary therapy and not a technology competing with surgical revascularization. To 
date, no studies of which we are aware have focused on the optimal treatment modality for 
thrombosed SFA endografts inserted for occlusive disease, so we undertook the present study 




 A prospectively maintained database containing 341 consecutive patients implanted with 
Viabahn Endoprostheses (W.L. Gore & Associates, Flagstaff, AZ, USA) for SFA occlusive disease 
at 3 Dutch hospitals between November 2001 and December 2011 was interrogated to identify 
patients who presented with a thrombosed endograft during admission or routine surveillance. 
The treatment protocol for SFA endograft placement has been previously described.4 For 
acute stent-graft thrombosis, the presence of muscle weakness or profound sensory loss 
at presentation was typically the indication for surgery; patients with contraindications for 
thrombolysis also underwent thrombectomy. Patient demographics, clinical status, medical 
history, procedure details, complications, and follow-up data were extracted for analysis. 
The Rutherford classification was used to categorize clinical symptoms.7 This database was 
529929-L-bw-Golchehr
Processed on: 1-4-2019 PDF page: 70
CHAPTER 5
70
previously used for another analysis focusing on the clinical outcome of patients who presented 
with definitive failure of the SFA endograft.8
Patient Cohort
 Interrogation of the database identified 79 (23%) patients with SFA endograft occlusion 
among the 341 patients treated in the 10-year period. Of these, 46 (58%) patients underwent 
either thrombolysis (n=40, 87%) or thrombectomy (n=6, 13%) and form the study group (33 
men; median age 66.8 years, range 30–80). Of the remaining 33 patients, 23 (70%) had a 
surgical bypass and 10 (30%) were treated conservatively. Baseline risk factors of the study 
group are given in Table 1. The median time from insertion of the SFA endograft to primary 
thrombosis was 3 months (range 0–53). Details of the indications for stent-graft insertion and 
the devices implanted are given in Table 2. The vast majority (89%) of thromboses occurred 
within the first year after insertion of the endograft(s), 17 (37%) within the first 30 days. At the 
time of thrombosis, the clinical state was classified as category I in 15 (33%) patients, category 
IIa in 20 (43%), and category IIb in 11 according to the Rutherford classification for acute limb 
ischemia.7 The mean ankle-brachial index (ABI) at the time of occlusion was 0.54±0.23.
Table 1. Demographics and Risk Factors in 46 Patients Presenting With a Thrombosed SFA Endograft 
Treated With Thrombolysis or Thrombectomy. 
Age,y    66.8 (30-80)
Men    33    (72%)
Tobacco use    27    (59%)
Hyperlipidemia    40    (87%)
Diabetes Mellitus    18    (39%)
Hypertension    37    (80%)
Renal failure      4    (9%)
Pulmonary disease      4    (9%)
Coronary artery disease    20    (43%)





     2    (4%)
   29    (63%)
   15    (33%)
(Continuous data are presented as the median (range); categorical data are given as the counts (percentage). 
ASA: American Society of Anesthesiologists).
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Table 2. Indications for SFA Stent-Graft Implantation in the 46 Patients Who Subsequently Presented With 
a Thrombosed Stent-Graft.






6    (13%)
5    (11%)
1    (2%)






2    (4%)
8    (17%)
12  (26%)
23  (50%)
Length of diseased segment, cm 17.2±10.9
Proximal SFA diameter, mm 4.5±1.2
Flush SFA occlusion 11  (23%)
Popliteal artery diameter, mm 3.9±1.2



















(Continuous data are presented as the means±standard deviation; categorical data are given as the counts 
(percentage). TASC: TransAtlantic Inter-Society Consensus, SFA: superficial femoral artery, P1: Popliteal 
artery cranial to the upper border of the patella, P2: popliteal artery between the tibial plateau and upper 
border of the patella).
Thrombolysis
 Patients underwent a retrograde puncture of the common femoral artery using the 
Seldinger technique under local anesthesia. Through a 6-F sheath, a thrombolysis catheter 
(Uni-Fuse; Angiodynamics, Latham, NY, USA) was inserted into the thrombosed endograft. 
Then, a bolus of 100,000 IU urokinase (Abbokinase; Abbott Laboratories, Chicago, IL, USA) was 
infused into the thrombus, followed by a continuous infusion of 250,000 IU per 24 hours until 
complete lysis was achieved. During treatment, patients received 25,000 units of heparin per 
24 hours, controlled with repeated activated partial thromboplastin time measurements and 
adapted if necessary. In some cases, additional mechanical thrombolysis was performed using 
a Hydrolyser (Cordis, Waterloo, Belgium). Follow-up angiograms were repetitively performed 
to evaluate the progression of thrombolysis. Any detected cause of the thrombosis was treated 
immediately, according to the local protocols. 
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 Surgical thrombectomy was performed under either regional or general anesthesia by 
exposure of either the common femoral artery or the popliteal artery. After administration of 
5000 units of heparin, an arteriotomy was performed, and balloon catheters (LeMaitre Vascular, 
Burlington, MA, USA) were used repeatedly to extract the clot from the occluded endograft 
until no more thrombus was retrieved. The distal and proximal segments were then flushed 
with heparin saline, and the arteriotomy was closed using a 6-0 Prolene suture. Imaging of the 
endograft was always performed during and after the procedure, and any detected cause of the 
thrombosis was treated according to the local protocols.
Definitions and Outcome Measures
 Successful lysis was defined as >95% clot lysis within the endograft as determined by digital 
subtraction angiography. Restenosis was diagnosed based on a peak systolic velocity ratio 
(PSVR)>2.5 as measured on duplex ultrasound. Primary patency after thrombolytic treatment 
was defined as sustained blood flow without treatment for restenosis or occlusion. Assisted 
primary patency referred to patency restored by secondary endovascular intervention(s) 
after stent-graft restenosis. Secondary patency referred to patency restored by secondary 
thrombolytic or surgical treatment after endograft occlusion. A definitive failure was defined 
as occlusion of the endograft, with or without clinical symptoms, not responding to therapy 
or not treated due to the absence of clinical symptoms. Major amputation was defined as an 
amputation above the ankle. The primary outcomes of the study were the efficacy of treatment 
for endograft occlusion and the patency rates after treatment. Secondary endpoints included 
complications, secondary interventions, and amputation rate.
Statistical Analysis
 Categorical variables are presented as counts and percentages; continuous variables are 
presented as mean ± standard deviation or as median with range (depending on Gaussian 
distribution). Kaplan-Meier survival analysis and the log-rank test were performed to assess 
primary, assisted primary, and secondary patency rates after thrombolytic therapy. A 2-sided 
p<0.05 was considered statistically significant. All analyses were performed with SPSS software 
(version 18.0; (IBM Corporation, Somers, NY, USA).
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 There was no significant difference in the incidence of cardiovascular risk factors between 
patients undergoing thrombolysis and those who were operated upon. In the thrombolysis 
group, 12 presented with an acute Rutherford category I, 19 with category IIa, and 9 with 
category IIb. In the thrombectomy group, 4 of 6 patients had an acute Rutherford I category 
and 2 an acute Rutherford IIb (p.0.05). The median time from the start of clinical symptoms 
until therapy was 0 days (range 0–6) in the thrombolysis group and 0 days (range 0–15) in the 
thrombectomy group.
Thrombolysis
 Complete lysis was achieved in 38 (95%) of 40 patients during a median 24 hours (range 
3–48). Two patients had additional mechanical thrombolysis performed using the Hydrolyser. 
One patient failed thrombolysis and another died during the procedure due to an unknown 
cause; unfortunately, no autopsy was performed. After lysis, a significant lesion was found at 
the proximal edge in 16 patients; these lesions were treated by angioplasty (n=13), angioplasty 
with stenting (n=2), or extension of the endograft (n=1). A distal edge stenosis was found in 12 
patients; they were treated with angioplasty (n=10) or endograft extension (n=2). In 2 patients, 
in-stent stenosis was found and treated with angioplasty. No causal stenosis of the endograft 
or the in- or outflow vessels was found in 9 patients, including the failed patient. Twenty-three 
(58%) patients had a 3-vessel runoff after thrombolysis, 10 (30%) had 2- vessel outflow, 5 (13%) 
had 1 patent outflow vessel, and 1 (3%) patient had no outflow vessels. The latter patient had 
the unsuccessful thrombolysis and developed an infected hematoma in the calf; he eventually 
required an above-knee amputation. Comparing these data to the outflow status after endograft 
insertion, 21 (53%) patients had 3-vessel, 11 (28%) patients had 2-vessel, and 5 (13%) patients 
had 1-vessel runoff before thrombosis [data unavailable in 3 (8%) patients]. Complications 
occurred in 6 (16%) patients, including 2 conservatively treated groin hematomas, pneumonia, 
wound infection at the puncture site, and temporary paresis of the peroneal nerve as part of a 
reperfusion syndrome in 2 patients. No compartment syndromes were identified. The median 
length of stay in the medium care unit was 1 day (range 0–2) and the median length of hospital 
stay was 5 days (range 2–19).
 Postprocedurally, 30 patients were treated with acetylsalicylic acid (80 mg/d); of these 4 
(10%) also received dipyridamole (75 mg/d), 16 (40%) were prescribed clopidogrel (75 mg/d), 
and 6 (15%) received warfarin derivates. Six (15%) patients were treated with the combination 
of clopidogrel (75 mg/d) and warfarin derivates, and 2 (8%) took warfarin derivates only. Thirty-
eight (95%) patients were on statin treatment.
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 Thrombectomy required a median 90 minutes (range 55–136) and was successful in all 
6 patients. One patient underwent an additional angioplasty of the anterior tibial artery and 
2 had concomitant endarterectomy of the common femoral artery. In 2 patients, no culprit 
stenosis of the endograft was found. Three patients had complications: 2 groin hematomas 
(conservatively treated) and a rebleeding requiring surgery. After thrombectomy, 3 patients had 
3-vessel outflow, 1 had 2-vessel, and 2 had 1-vessel. The only difference in runoff compared to 
after endograft insertion was 2-vessel in 2 patients and 1-vessel in one. The median length of 
stay of the thrombectomy group was 7 days (range 4–18). Postoperatively, 4 patients received 
acetylsalicylic acid (80 mg/d), 2 combined with dipyridamole (75 mg/d) and 1 with clopidogrel 
(75 mg/d). One patient was treated with the combination of warfarin derivates and clopidogrel 
(75 mg/d), and 1 patient was treated with warfarin derivates only. All 6 patients were on statin 
treatment. In the 45 surviving thrombosis patients, a significantly greater proportion of the 
patients with thrombosis, 30 days old (7/16, 47%) had no causal stenosis compared with 
patients who presented at a later stage (4/29, 14%, p=0.01).
Follow-up After Intervention for Stent-Graft Thrombosis
 The median follow-up after primary treatment for stent-graft thrombosis was 14 months 
(range 1–69). The median ABI (measured in 17 patients) after thrombolytic treatment was 0.96 
(range 0.28–1.18). All patients showed clinical improvement during the first month except the 
patient with an unsuccessful primary thrombolysis, who developed an infected calf hematoma 
and required aboveknee amputation, as mentioned above. The Rutherford categories pre and 
post endograft insertion, at endograft thrombosis, and after therapy for the entire cohort are 
shown in Figure 1. At 1-month post lysis, 25 patients were categorized as Rutherford 1, 8 as 
Rutherford 2, 2 as Rutherford 3, 2 as Rutherford 4, 3 as Rutherford 5, and 1 as Rutherford 6. 
Comparing this status in the lytic group to the Rutherford category after endograft insertion, 
13 had the same category, 13 had an improved category, and 6 had a deteriorated category 
(data incomplete in 7 patients and 1 deceased). In the thrombectomy group, 3 had the same 
Rutherford category, 1 with an improved category, and 1 with a deteriorated category (data 
incomplete in 1 patient). Reinterventions were performed for restenosis in 12 patients: 
balloon angioplasty of the SFA (n=4), the proximal edge (n=3), the distal edge (n=2), and the 
popliteal artery (n=1). The other 2 patients had stent placement in the SFA and popliteal artery, 
respectively. Reocclusion prompted secondary thrombolysis in 10 patients and thrombectomy 
in 4 patients. All reinterventions were performed within the first 18 months in patients who had 
thrombolytic treatment initially. During follow-up, 16 (36%) definitive failures occurred (2 in the 
thrombectomy group). Four patients were treated conservatively because they had no or only 
minor clinical symptoms. Of the remaining 12 patients, 4 had an above-knee femoropopliteal 
bypass (2 vein and 2 prosthetic) and 8 had a below-knee femoropopliteal bypass (5 vein, 3 
prosthetic). The primary, assisted primary, and secondary patency rates of thrombolysis 
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at 6 months (Fig. 2) were 56%, 56%, and 68%, respectively, vs. 67%, 67%, and 67% for the 
thrombectomy patients. Secondary patency for the entire cohort was 58% at 1 year. Finally, 
3 (7%) of the 45 surviving patients eventually underwent a major amputation at 1, 9, and 39 
months after primary thrombosis, respectively. The first patient was mentioned earlier. The 
second was a thrombectomy patient who developed acute limb ischemia 3 months after 
secondary thrombolysis. In the third patient, an above-knee prosthetic bypass failed. He was 






















  Rutherford 1 Ruhterford 2 Rutherford 3 Rutherford 4 Ruhterford 5 Rutherford 6
Pre-endograft 1 0 33 6 5 1
Post-endograft 21 6 5 4 3 2
Occlusion 0 5 18 16 3 2
Postthrombolytic treatment 25 8 2 2 3 1
Figure 1. Rutherford categories for patients with thrombosed endografts treated with thrombolysis or 
thrombectomy.
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Figure 2. Primary (PP), assisted primary (AP), and secondary patency (SP) rates after recanalization of 
thrombosed SFA stent-grafts inserted for occlusive disease.
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 Thrombolysis and thrombectomy are both safe modalities for the treatment of thrombosed 
endografts inserted in the SFA for occlusive disease. In our experience reported here, technical 
success rates were high and major complication (2%) and amputation (7%) rates during follow-
up were low. Patency rates after successful restoration of flow in thrombosed endografts seem 
to be lower than those described after initial placement,4,9 though they are within the published 
range of 38% to 90%.6 Yet, in 60% of our patients, prolonged secondary patency was achieved 
and bypass surgery avoided or at least postponed. In our study, half of the patients required 
angioplasty with/without stenting or stentgrafting after thrombolysis. In two thirds of the cases, 
an edge stenosis was the underlying cause of occlusion, emphasizing the need for strict follow-
up and early treatment of edge stenosis. Sizing is likely to be among the most important factors 
that could influence the incidence of edge stenosis and subsequent thrombosis. Additional 
studies on this subject are warranted. Most of the edge stenoses were treated with balloon 
dilation, even though the paradigm of covering the entire diseased segment would seem to call 
for an extension of the endograft. However, in proximity to collaterals, balloon dilation alone 
may be a valid option. The effects of drug-eluting balloons remain to be explored. Further 
studies should focus on the optimal treatment modality of edge stenosis. Overall, no causal 
lesion could be identified in a quarter of the patients, significantly more often in the case of 
patients presenting with occlusion <30 days after insertion of the endograft(s). In these patients, 
no causal lesion could be identified in half of the cases. Sometimes an occlusion without 
an anatomical cause can be due to prolonged flexion of the knee during sleep or activities. 
This appeared to be the case in some of our patients, but these associations are difficult to 
prove. Analysis of possible risk factors of failure did not show any significant associations, 
especially not for antiplatelet/anticoagulant therapy or the occurrence of complications. 
Obviously, the groups in the present analysis may well have been too small to identify such 
a relationship. Several studies found confounding factors that influence the success rate of 
thrombolysis, such as diabetes, a history of lower limb ischemia, an occluded bypass graft, 
and poor runoff.10-13 In our study, the vast majority of patients were treated with thrombolysis. 
We could not identify a difference in outcome between patients treated with thrombolysis and 
those with thrombectomy, but again, sample size was a significant limitation. After successful 
thrombolysis, a completion angiogram outlines the vascular tree and discloses possible 
underlying causes of endograft failure. Additionally, it has been reported that thrombolysis 
results in more patent outflow vessels compared with thrombectomy.14 Therefore, thrombolysis 
could be the preferred treatment modality, especially in the often frail group of patients with 
multiple comorbidities.15,16 Importantly, the clinical state of the patients who needed secondary 
thrombolytic therapy did not worsen in comparison with their status after the primary 
thrombolysis. In two thirds of patients, the Rutherford category was equal to the score after 
initial recanalization; 2 patients even had an improved clinical status. These observations 
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support the hypothesis that thrombolytic therapy should always be considered, as secondary 
failure does not worsen clinical status of the patient. Although the overall complication rate of 
our series seems high, most were minor and self-limiting. In contrast to other studies where 
they reported major hemorrhagic complication rates varying from 4% to 13%,11,17 only 1 (2%) of 
our patients had significant bleeding that required surgery. Whether the death of one patient 
during thrombolysis was caused by bleeding cannot be concluded, as no postmortem study 
was performed. Various studies have reported amputation rates after thrombolysis of 18% 
to 25%.16,18 In our study, the amputation rate was only 7%. Two amputations occurred after 
failure of a secondary thrombolysis and a secondary bypass, respectively. The low amputation 
rate might be partially explained by the relatively low percentage of patients treated for critical 
limb ischemia. Still, other studies of SFA endografting have reported similar low amputation 
rates.3,8,9 In our recent study of 49 patients presenting with a definitive failure of an endograft,8 
we documented an amputation rate of only 4% and showed that definitive failure was not 
associated with a deterioration in clinical state. Data from the present study further proves 
the safety of the technique. These data provide circumstantial evidence that the overstenting 
of collaterals in the SFA does not inevitably lead to an endangered limb in case of stent-graft 
occlusion.
Limitations
 The present study was limited by its retrospective design and small sample size. Therefore 
additional comparative studies are indicated to confirm our data. Discrepancies were seen 
between the hospital centers in the post-thrombolytic anticoagulation strategy. To date, clear 
evidence-based guidelines on the anticoagulant therapy after thrombolytic treatment are 
lacking, and future research on this topic is necessary.
Conclusion
 Our study has shown that an occlusion of an endograft inserted in the SFA for occlusive 
disease may be successfully treated with thrombolytic therapy with low rates of major 
hemorrhagic events and amputation. Patency rates are in line with those reported after 
thrombolysis of surgical bypasses.
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Outcome of failed endografts 
inserted for superficial 
femoral artery occlusive disease.
M.M. A. Lensvelt, B. Golchehr, R.R. Kruse,S. Holewijn, 
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Objective: Endografts represent a relatively new treatment modality for occlusive disease 
of the superficial femoral artery, with promising results. However, endografts may occlude 
collateral arteries, which may affect outcome in case of failure. The purpose of this study was 
to analyze the clinical outcome of failed endografts in patients with superficial femoral
artery occlusive disease.
Methods: All patients treated with one or more polytetrafluorethylene-covered stents between 
November 2001 and December 2011 were prospectively included in a database. Patients with a 
failure of the endograft were retrospectively analyzed. Clinical and hemodynamic parameters 
were assessed before the initial procedure and at the time of failure. Outcome of secondary 
procedures was analyzed.
Results: Among the 341 patients who were treated during the study period, 49 (14.4%) failed 
during follow-up. Mean (standard deviation) Rutherford category at failure did not differ from 
the category as scored before the initial procedure (3.1 [1.3] vs 3.3 [0.6]; P =.33). Forty-three 
percent of patients (n=21) presented with the same Rutherford category as before the initial 
procedure, 37% (n=18) with an improved category, and 20% (n=10) with a deteriorated category. 
The ankle-brachial index was significantly lower at the time of failure (0.66 [0.19] vs 0.45 [0.19]; 
P <.002). Seventy-six percent of patients with a failure needed secondary surgery, of which 
25% were below knee. The 1-year primary, primaryassisted, and secondary patency rates of 
secondary bypasses were 55.1%, 62.3%, and 77.7%, respectively. The amputation rate was 
4.1% (n=2).
Conclusions: Failure of endografts is not associated with a deterioration in clinical state and 
is related to a low amputation rate. The hypothesis that covered stents do not affect options for 
secondary reconstructions could not be confirmed, as 25% of patients with a failure underwent 
a below-knee bypass. Secondary surgical bypasses are correlated with poor patency. The 
amputation rate after failure is low.
529929-L-bw-Golchehr
Processed on: 1-4-2019 PDF page: 83




 Nitinol stents have improved the outcome of endovascular treatment of occlusive disease 
of the superficial femoral artery (SFA). Randomized trials have shown their superiority in 
lesions from 6.5 to 9.5 cm long,1,2 whereas no differences have been reported for shorter lesions 
compared to angioplasty only.3 In more extensive lesions, bare metal stents are likely to perform 
worse due to the occurrence of in-stent restenosis. Therefore, surgical reconstruction is still 
the gold standard for lesions longer than 15 cm.4 However, bypass surgery is associated with 
complications and prolonged hospital stay. The use of covered stents may improve the results of 
endovascular treatment of more extensive disease in the SFA. Various case series have reported 
mixed results, most likely due to large variances in both lesion and patient characteristics. In a 
multicenter randomized trial, McQuade et al.5 reported that, using endografts, similar patency 
rates were achieved compared to above-knee (AK) femoropopliteal bypasses after 4 years of 
follow-up, without differences in complication rates. With the development of heparin-bonding 
technology, the results of endografts may improve further. In a recent study, 1-year primary 
patency of 75%, primary-assisted patency of 81.7%, and secondary patency of 89% were 
reported from a series of mostly TransAtlantic InterSociety Consensus (TASC-II) D lesions.6 
A possible shortcoming of covered stents might be the coverage of collateral arteries. Such 
coverage is believed to reduce the limb salvage rate or possibly change the level of amputation 
after graft failure. However, in the above mentioned randomized trial,5 failure of endografts did 
not increase the amputation rate. The aim of the present study was twofold: first, to study the 
clinical state of patients who presented with a failure of covered stents used for SFA occlusive 
disease that possibly had covered collateral arteries, and, second, to assess the outcome of 
eventual secondary reconstructions in case of failure.
METHODS
 Information on all patients treated with a polytetrafluorethylene-covered endograft 
between November 2001 and December 2011 in the Rijnstate Hospital Arnhem, the Isala 
Clinics Zwolle, and the Antonius Hospital Sneek, The Netherlands, were prospectively gathered 
in a database. The indication for endovascular treatment was based on anatomic suitability 
and the preference of both the patient and the surgeon. All patients had an indication for 
surgery, and treatment with an endograft was offered as a minimally invasive alternative. 
Routine follow-up consisted of clinical assessment, ankle-brachial index (ABI) measurements, 
and ultrasound studies at 1, 3, 6, and 12 months and yearly thereafter. Complications and 
additional treatments were registered in the hospital files. All patients who presented with 
a failed endograft, either clinically or during routine surveillance, were included in the study 
and retrospectively analyzed. Demographics, clinical status, and medical history were noted. 
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Procedural aspects of the initial procedure and follow-up data were retrieved, as was follow-up 
of a secondary procedure if applicable. Cardiovascular risk factors were scored according to 
the Society for Vascular Surgery medical comorbidity grading system. Clinical symptoms at the 
time of the initial procedure and symptoms at the time of failure were categorized according 
to the Rutherford classification. ABI measurements at the time of failure were compared with 
ABI measurements before insertion of the endografts. Lesions were reviewed at the time of 
the initial procedure and at the time of failure, and scored according to the TASC-II criteria by 
two authors (M.L., B.G).4 The number and patency of the runoff vessels were scored at both 
time points. Patency of runoff vessels was classified as open, open with stenosis (peak systolic 
velocity ratio >2.5), or occlusion. The outcome of all secondary procedures was assessed, as 
was the limb salvage rate. 
Treatment protocol
 The treatment protocol has been previously described.6 Briefly, the common femoral 
artery was approached either percutaneously or surgically. When there was a concomitant 
lesion in the common or profunda femoral artery, an endarterectomy was performed. Heparin 
and antibiotic prophylaxis were administered. The diseased segment was passed, either 
endoluminally or subintimally, using a 0.035-inch Terumo Glidewire (Radiofocus Guidewire 
M; Terumo Medical Corp, Elkton, Md) and a catheter, and a subsequent reentry was created 
distally. The segment was predilated, and endografts (Viabahn Endoprosthesis; W. L. Gore 
& Associates, Flagstaff, Ariz) were positioned from distal to proximal with minimal or no 
oversizing. Sizing was performed using a computed tomographic or magnetic resonance scan. 
The entire diseased segment was covered with endografts, which were postdilated with an 
angioplasty balloon of the same size as the endograft. Control angiography of the endograft and 
outflow vessels was performed routinely. Postprocedurally, patients received statin treatment 
and dual antiplatelet inhibitors, unless oral anticoagulation was indicated for other reasons. 
Definitions
 Failure of the endograft was defined as occlusion of the endograft, with or without clinical 
symptoms, not responding to fibrinolytic or surgical therapy or not eligible for therapy. An 
occlusion was defined as the absence of flow in the treated segment of the SFA. Primary patency 
was defined as the absence of restenosis or occlusion in the target vessel. Restenosis was 
defined as a peak systolic velocity ratio >2.5 as measured on ultrasound scanning. Primary-
assisted patency was defined as patency achieved by secondary endovascular interventions 
to treat restenosis of the target vessel. Secondary patency was defined as patency after 
thrombolytic or surgical treatment performed for bypass occlusion. Limb salvage was defined 
as the absence of an above-ankle amputation. End points. The primary endpoints of the study 
were comparison of the initial and postfailure Rutherford categories and the clinical outcome 
of failures, including amputation rate, and patency rates of eventual secondary interventions. 
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Secondary end points were the differences between initial and postfailure ABI, and the 
differences between the quality of outflow vessels at the initial procedure and postfailure.
Statistical analysis 
 Continuous variables are presented as mean (standard deviation) or median with range; 
nonparametric values as median (standard deviation) and range; and categorical variables 
as count and percentage. Univariate analyses were performed to identify a possible influence 
of various confounding factors acting on the Rutherford classification at the time of failure. 
Kaplan-Meier survival analysis was performed to assess primary patency after secondary 
surgical intervention. P<.05 was considered statistically significant. Data were analyzed using 
IBM SPSS Statistics (version 19; IBM, Armonk, NY).
RESULTS
 During the study period, a total of 341 patients were treated with an endograft for occlusive 
SFA disease. Median follow-up was 24 months (range, 0-72 months). During follow-up, 49 
patients presented with an occluded endograft. The majority of these patients were male 
(67.3%), and the mean age was 66 (9) years. The incidence of cardiovascular risk factors is 
given in Table 1. Before the initial procedure, three patients (6.1%) had already undergone 
balloon angioplasty of the SFA without stent placement, and five (10.2%) had undergone 
angioplasty of the iliac artery with (n=3) or without (n= 2) bare metal stent placement. Two 
patients were treated for an abdominal aneurysm with an endograft, and one had undergone an 
endarterectomy of the ipsilateral proximal SFA. Initial procedure. Before the initial procedure, 
the Rutherford classification was category 3 in 38 patients (77.6%), category 4 in nine patients 
(18.4%), category 5 in one patient (2%), and category 6 in one patient (2%).
 Mean maximum walking distance for patients with disabling claudication was 143 ± 91 
meters. Before treatment, mean ABI at rest was 0.66±0.19 and after exercise was 0.39±0.15. 
Two lesions (4.1%) were classified as TASC-II A lesions, 14 (28.6%) as TASC-II B lesions, 14 
(28.6%) as TASC-II C lesions, and 19 (38.7%) as TASC-II D lesions. Mean lesion length of the 
SFA was 13.4 (10.0) cm, and five patients (10.2%) had a flush occlusion of the SFA. Other lesion 
characteristics are listed in Table 2.
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Table 1. Incidence of cardiovascular risk factors of patients presenting with an occluded endograft. 
Hyperlipidemia 
             Normal cholesterol
             Mildly elevated, dietary
             Type II,III, IV, dietary
             Treated with drugs            
11        22.4%
1          2%
0          0%
36        73.5%
Diabetes Mellitus
             No
             Adult, dietary
             Adult, insulin dependent
             Juvenile diabetes
36        73.5%
5          10.2%
8          16.3%
0          0%
Hypertension
             No
             Treated with one drug
             Treated with two drugs
             Treated with three drugs
11        22.4%
11        22.4%
10        20.4%
17        34.7%
Renal Failure 
                No
                Creatinin 1.5-3.0; GFS 30-50
                Creatinin 3.0-6.0; GFS 15-30
                Creatinin >6.0; GFS <15, renal transplant
47        95.9%
1          2%
1          2%
0          0%
Pulmonary disease
                 Asymptomatic
                 Mild dyspnoe
                 Moderate dyspnoe
                 O2-needed, pulmonary hypertension
42        85.7%
5         10.2%
2          4.1%
0          0%
Cardiac status
                 Asymptomatic
                  Non recent MI (>6m), or asymptomatic MI on EKG
                 Stable AP, arrtimias, treatable heartfailure
                 Instable AP, recent MI (<6m)
31        63.3%
11        22.4%
7          14.3%
0          0%
Carotic status
                 No disease
                 Asymptomatic, signs of disease
                 TIA/CVA w/o restsymptoms
                 CVA w restsymptoms
43        87.8%
2          4.1%
3          6.1%
1          2%
Pre-operative medication
                Acenocoumarol
                Acetylsalicylic acid
                Fenprocoumon
                Clopidogrel
                Dipyridamol
                Statin
4          8.2%
38        77.6%
0          0%
1          2%
4          8.2%
37        75.5%
ASA
             1
             2
             3      
2          4.1%
32        65.3%
15        30.6%
(AP, Angina pectoris; CVA, cerebrovascular accident; GFR, glomerular filtration rate; MI, myocardial 
infarction; TIA, transient ischemic attack.).
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Table 2. Clinical outcome of patients presenting with an occluded endograft before endograft placement 
vs postfailure.






















9    (18.4%)
1    (2%)
1    (2%)
N=49
3     (6.1%)
14   (28.6%)
18   (36.7%)
7     (14.3%)
4     (8.2%)
3     (6.1%) .328
N=0







9    (18.4%)
1    (2%)
0
N=45
26    (53.1%)
8      (16.3%)
2      (4.1%)








31    (63.3%)
7      (14.3%)
10    (20.4%)
N=42
22    (44.9%)
6      (12.2%)









5    (10.2%)
6    (12.2%)
N=42
27  (55.1%)
4    (8.2%)








34    (69.4%)
5      (10.2%)
8      (16.3%)
N=42
30    (61.2%)
3      (6.1%)
9      (18.4%) .57
N=2;
N=7
 (SD, Standard deviation.Values are given as number (%) unless otherwise indicated)
During the initial procedure, a concomitant endarterectomy of the common femoral artery was 
performed in three patients (6.1%), of the external iliac artery in two (4.1%), of the proximal 
SFA in one (2.0%), and of the deep femoral artery in one (2.0%). Angioplasty of the popliteal 
artery was performed in four patients (8.2%). Twentyfive patients (51%) were treated with 
only one endograft, 15 (30.6%) with two endografts, six (12.3%) with three endografts, and 
three (6.1%) with four endografts. In the vast majority (93.9%) a 6-mm endograft was used. 
One patient was treated with a 5-mm endograft, and the remaining two patients were treated 
with a 7-mm endograft. Thirty-seven patients (75.5%) were treated with a regular endograft, 
and the remaining 12 patients (24.5%) were treated with a heparin-bonded endograft. After 
the procedure, 30 patients (61.2%) were treated with dual antiplatelet therapy, eight (16.3%) 
received acetylsalicylic acid 80 mg, and one (2%) was treated with clopidogrel 75 mg only. Six 
patients (12.2%) were treated with coumarin derivates because of other indications; two of 
these patients also received acetylsalicylic acid (80 mg). Of the remaining four patients (8.2%), 
data on postoperative medication could not be retrieved. Seventy-four percent of patients (n= 
36) were treated with statins. After the initial procedure, clinical improvement was observed 
in all but one patient. This patient had an early occlusion and was treated with chemical 
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thrombolysis. The ABI was significantly increased to 0.95±0.26 (P < .001). The 30-day morbidity 
was 8.2% (n= 4) and included wound infection (n=1), hematoma (n=1), decubitus (n=1), and a 
deep vein thrombosis (n=1). During the first year after the initial procedure, 15 of 49 patients 
(30.6%) who finally failed already had an occlusion of the endograft that was successfully treated 
by surgical thrombectomy (n=1) or chemical thrombolysis (n= 14). Eleven patients underwent 
an additional angioplasty of the SFA or popliteal artery with (n=4) or without (n= 7) additional 
stent placement, and two patients underwent a toe amputation. Outcome of failures. Median 
time from initial surgery to failure was 7.3 months (range, 0.4-74.4 months). Six endografts 
failed within the first 30 days, 23 within the first 6 months, and seven within the first year after 
treatment. The remaining endografts failed at 18 months (n=4), 28 months (n= 4), 32 months 
(n= 2), 43 months (n= 2), and 74 months (n=1). The Rutherford categories of these patients after 
failure are listed in Table II. The overall clinical state after endograft failure did not significantly 
differ from the clinical state before the initial procedure (3.1±1.3 vs 3.3±0.6, respectively; P = 
.33). Of the 49 patients, 21 (42.9%) presented within the same Rutherford category, 18 (36.7%) 
with an improved category, and 10 (20.4%) with a deteriorated category. Maximum walking 
distance after failure was recorded in 22 patients (44.9%). Nineteen patients (38.8%) had a 
mean maximum walking distance of 158±127 meters, which was not significantly different from 
their maximum walking distance before the initial procedure (P = .69). Three other patients 
(6.1%) had an unlimited walking distance. Univariate analysis of cardiovascular risk factors 
did not demonstrate any significant correlation with clinical state after failure. Mean ABI after 
failure was significantly lower than the ABI before the initial procedure (P < .01). However, the 
postfailure ABI was often missing. When comparing the index ABI with the postfailure ABI in 
the 18 patients with a known postfailure ABI, the difference was still significant (0.64±1.4 vs 
0.48±0.16, respectively; P <.01). At the time of failure, the level at which the popliteal artery 
was patent was located significantly more distally compared to that before baseline (P < .001). 
Twelve patients (24.5%) with a failed endograft were treated conservatively, and 37 patients 
(75.5%) underwent a secondary reconstruction . Median follow-up of the conservatively treated 
group was 9.9 months (range, 0.4-36.4 months). Maximum walking distance in this subgroup 
varied from 1000 meters to an unrestricted walking distance. All patients in the conservative 
group were discharged from further follow-up and were categorized as Rutherford category 
1. Median follow-up after secondary surgery was 7.5 months (range, 0.7-100.2 months). In 
34 patients (69.4%), a secondary bypass was constructed. In 22 of these patients (44.9%), 
an AK femoropopliteal bypass was constructed with either vein (n=9) or prosthetic material 
(n=13). Twelve patients (24.5%) were treated with a below-knee (BK) bypass with either vein 
(n=9) or prosthetic material (n=3). At 1 year, the primary patency was 55.1%, the primary-
assisted patency was 62.3%, and the secondary patency was 77.7% (Fig). Reinterventions of 
the secondary bypass were performed in eight patients (36.4%) with an AK bypass and in five 
patients (41.7%) with a BK bypass, including angioplasty (n=5), chemical thrombolysis (n=1), 
and surgical thrombectomy (n= 2). In three patients a third bypass was constructed, all BK. 
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In total, 2 of 49 patients (4.1%) underwent a BK amputation, one after unsuccessful chemical 
thrombolysis due to endograft failure and one after failure of the secondary procedure. The 
patient with an unsuccessful chemical thrombolysis had an infected hematoma in the lower leg, 
possibly due to thrombolytic treatment, and underwent a BK amputation 7 days after bypass 
surgery. The other patient had a wound infection of the foot after receiving an AK prosthetic 
bypass and underwent a BK amputation 3 months after secondary surgery. Both patients were 
diabetic and initially presented with Rutherford category 3 and returned with category 3 and 6, 
respectively, at the time of endograft failure. Amputations were performed 0.2 and 39 months 
after failure of the endograft, respectively.
Figure 1. Kaplan-Meier curve showing primary, primary-assisted, and secondary patency after secondary 
surgery.(SE, Standard error).
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 The major drawback of using endografts for occlusive arterial disease is potential 
occlusion of collateral arteries, which may worsen clinical outcome in case of failure. In the 
present study we found that failure of endografts inserted for occlusive disease of the SFA does 
not deteriorate the clinical state of patients compared with the baseline situation. Therefore, 
the data do not support the hypothesis that endograft placement, possibly covering collateral
circulation, worsens patient clinical outcome after failure. Seventy-six percent of patients with 
a failure needed secondary surgery. The theory that use of covered stents does not affect the 
options for secondary reconstructions in case of failure could not be confirmed, as 25% of 
patients with a failure underwent a BK bypass. Data from the present study may contribute to 
the discussion on the role of endografts in the treatment algorithm of SFA occlusive disease. It 
has been thought that endografts may postpone surgery in this category of often frail patients 
and may be a “bridge to surgery.” In the present study we found that after mean follow-up of 2 
years, no secondary surgery was indicated in 89% of patients because of patency of the bypass 
or no indication after failure. Almost 25% of our population had no remaining symptoms after 
occlusion of the endograft. The observation that 80% of patients did not show deteriorated 
clinical outcome after failure and even may have improved suggests that the covering of 
collaterals may not be clinically relevant in this group of patients. However, this finding may 
not be extrapolated to the popliteal artery, which is regularly involved in TASC-II D lesions. 
It seems reasonable to assume that preservation of collaterals in this area may contribute 
to clinical outcome after failure. The use of reentry devices or the combined anterograde-
retrograde approach may contribute to sparing as many collaterals as possible at the popliteal 
level.7 Surprisingly, although endograft thrombosis was related to a decreased ABI, the clinical 
state was often similar or even improved compared with the baseline situation. The reason 
for this finding is unknown but may be hypothesized to be the result of a phenomenon similar 
to that occurring during walking-exercise training, where increased clinical performance is 
not related to increased ABI.8 This emphasizes the discrepancy between clinical state and 
ABI that might occur due to unknown reasons. It is possible that treatment of the occlusion 
with an endograft allowed the patient a rapid return to daily activities and provided the patient 
with sufficient time to develop new collaterals. In the present study, 33% of patients showed a 
progression of disease in the popliteal artery distal from the bypass after failure. This finding 
was reflected by a decreased ABI; however, the quality and quantity of crural outflow vessels 
were not affected, except for the posterior tibial artery. The increased incidence of an occluded 
posterior tibial and popliteal artery may be considered as an ongoing disease. Obviously, this 
may have contributed to the occurrence of failure. Due to this progression, a BK bypass was 
indicated in one of three patients, possibly affecting the outcome of the secondary procedure. 
Prosthetic material was used in half of these patients, mostly because the saphenous vein 
was unsuitable. This is in line with the observation that only 45% of patients have a suitable 
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saphenous vein available reported by Gisbertz et al.9 in a randomized trial comparing surgery 
to remote endarterectomy. The outcome of secondary surgery was rather disappointing in the 
present study. Although the group was a mix of AK and BK bypasses, primary 1-year patency was 
as low as 55.1%. Nolan et al.10 recently came to the same conclusion in a retrospective analysis 
of 1880 lower-limb bypasses. They found that prior ipsilateral endovascular revascularization 
or bypass surgery, but also dialysis dependence, use of a prosthetic conduit, and distal bypass 
target, were independent predictors of higher 1-year amputation and graft occlusion rates. 
The high failure rate of secondary procedures might be due to progression of disease, the 
vulnerability of this specific patient group, or other risk factors such as comorbidity, poor 
runoff, and type of graft material. In this study cohort, no composite or arm vein conduits were 
used. The sample size of our cohort does not allow further analysis and conclusions on this 
point. Although secondary surgery is related to a relatively high failure rate, the amputation 
rate was low in our study. The amputation rate was 4% in the group of patients with a failed 
bypass, but only after failure of a secondary procedure. The amputation rate after failure of 
the secondary procedure was only 6%, which is much lower than the 31% reported by Nolan 
et al.10 Our data are in line with previous reports on the outcome of endografts for occlusive 
SFA disease, which also described low overall amputation rates (range, 0%-4%).5,11,12 Defining 
the role of endografts for treatment of occlusive SFA disease remains a challenge because 
it depends on many variables, including the outcome of failures described here. In addition 
to patency rates, issues such as quality of life and cost-benefit analysis are important in the 
discussion. Hopefully, randomized trials such as the Surgical versus Percutaneous Bypass 
(SUPERB) trial will provide answers to settle this debate.13 Limitations of the present study 
are mainly related to the retrospective analysis of the prospective database. Data were not 
always complete, which may have affected outcome. Moreover, although this is the largest 
group of failed endografts described to date, the sample size was still relatively small. This 
renders a subanalysis of various factors affecting the outcome of failure unreliable. Additional 
comparative studies are indicated to confirm our data. During the study period, the design of 
the endograft was changed because heparin-bonding technology and the contoured edge were 
introduced. The present study design does not allow a comparison between both endografts 
because sample sizes were too low.
Conclusions
 Failure of endografts is not related to deterioration of the clinical state in the majority 
of patients, thereby rejecting the hypothesis that coverage of collateral arteries reduces the 
limb salvage rate after surgery. Secondary procedures are related to low patency rates, but 
amputation rates are low.
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Objective: The use of self-expanding stent grafts for treatment of popliteal artery aneurysms 
(PAA) is a matter of debate although several studies showed similar results as compared to 
open surgery. In the past years, a new generation stent graft, with heparin-bonding technology, 
became available. The aim of this study is to present the results of endovascular PAA repair 
with heparin-bonded stent grafts.
Methods: All patients with PAA treated with a heparin-bonded polytetrafluoroethylene (ePTFE) 
stent graft between April 2009 and March 2014 were gathered in a database and retrospectively 
analyzed. Data were collected in four participating hospitals. Standard follow-up consisted 
of clinical assessment, duplex ultrasound at 6 weeks, 6 months, 12 months, and annually 
thereafter. Primary endpoint of the study was primary patency. Secondary endpoints were 
primary-assisted and secondary patency and limb salvage rate. 
Results: A total of 72 PAA were treated in 70 patients. Mean age was 71.2 ± 8.5 years and 93% 
was male (n=65). The majority of PAA were asymptomatic (78%). Sixteen cases (22%) had a 
symptomatic PAA of which seven (44%) presented with acute ischemia. Early postoperative 
complications occurred in two patients (3%). Median follow-up was 13 months (range 0-63 
months). Primary patency rate at 1 year was 83% and after 3 years 69%; primary assisted 
patency rate was 87% at 1 year and 74% after 3 years. Secondary patency rate was 88% and 
76% at 1 and 3 years, respectively. There were no amputations during follow up. 
Conclusion: Endovascular treatment of PAA with heparin bonded stent grafts is a safe 
treatment option with good early and mid-term patency rates comparable to open repair using 
the great saphenous vein. 
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 Popliteal artery aneurysms (PAA) account for 70-80% of all peripheral artery aneurysms.1-3 
PAA occur more frequently in men than in women and the incidence increases with age. The 
popliteal artery is considered aneurismal when the diameter reaches 1.5 cm or exceeds 50% 
of the size of the normal artery defined by the diameter of the contralateral popliteal artery. 
PAA occur bilaterally in 45% of the patients.4 Approximately 40% of PAA are symptomatic and 
associated with a risk of amputation of 30-40%.1,5,6 The reported incidence of thromboembolic 
events in asymptomatic untreated PAA is 14% per year.7-10 The gold standard for PAA 
repair is still surgical treatment with venous bypass grafting in combination with either 
ligation or resection of the aneurysm.11-13 If no suitable vein conduit is available, expanded 
polytetrafluoroethylene (ePTFE) or polyester grafts can be used, although with a 30% lower 
patency compared to the venous conduit at long-term follow-up.14,15 Another treatment option 
for PAA is endovascular repair which provides shorter operation time, hospital stay, and less 
perioperative and postoperative morbidity and therefore a faster patient recovery. Most studies 
have shown patency rates at four years varying between 64 and 88% which is comparable with 
the four-year patency rate of a surgical bypass (69-88%).16-21 
Heparin-bonding technology has increased patency rates of surgical grafts in general and 
results with heparin-bonded stent grafts for occlusive disease are promising.22 Early results in 
a small series of 10 patients showed good results up to 1-year. 23 The purpose of the present 
study was to evaluate patency of PAA treated with heparin-bonded stent grafts in a larger 
cohort of patients. 
MATERIALS AND METHODS
 All patients with a PAA treated between April 2009 and March 2014 with a 
polytetrafluoroethylene (ePTFE) heparin-bonded stent graft (Viabahn endoprosthesis, W. 
L. Gore & Associates, Flagstaff, AZ, USA) were gathered in a database and retrospectively 
analyzed. Patient data were retrieved from four hospitals (Klinikum Nuremberg Süd, Paracelsus 
Medical University, Nuremberg, Germany; University Hospital, Padua, Italy; University Medical 
Center Groningen, Groningen; and Rijnstate Hospital, Arnhem, the Netherlands). Indication 
for intervention included asymptomatic isolated PAA with a diameter of more than 20 mm.24 
Endovascular PAA treatment was chosen if the lesion was anatomically suitable with at least 
one patent outflow artery to the foot. Medical history, patient demographics and clinical state 
were noted. Patients with an untreated inflow stenosis (>50% diameter reduction) of the iliac 
or common femoral artery and patients with untreated atherosclerotic disease with a stenosis 
of the superficial femoral artery (> 50 %) were excluded from endovascular treatment. Other 
exclusion criteria were compression syndrome of the popliteal artery (lumen < 4.0 mm), 
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degenerative connective tissue disease, contraindications to anticoagulation or antiplatelet 
therapy, hypersensitivity to heparin, septicaemia, thrombophylic disease and severe untreated 
medical comorbidities (such as coronary artery disease, congestive heart failure, chronic 
obstructive pulmonary disease, metastatic malignancy, and dementia).
 Cardiovascular risk factors were scored according to the Society for Vascular Surgery 
(SVS) and American Association for Vascular Surgery (AAVS) medical co-morbidity grading 
systems. Procedural aspects and post-procedural data were retrieved from the patients’ case 
files. Standard follow-up consisted of clinical assessment, duplex ultrasound examination at 6 
weeks, 6 months, 12 months, and annually thereafter and yearly biplane x-rays of the knee in 
two directions. 
 Retrospective “patient’s files” research is not subject to the German, Italian and Dutch 
law for human bound research and therefore Investigational Review Board approval was not 
required. As a consequence, patient informed consent was not obtained. Patients’ data were 
analyzed anonymously.
Treatment protocol
 In all patients a pre-operative CT-angiography (1 mm cut) was performed to accurately 
plan the procedure. A proximal and distal landing zone of ±1.5 cm in length was required; the 
endograft oversizing never exceeded 15%. A below the knee popliteal artery of less than 4.5 
mm in diameter was not considered for treatment. 
 Before operation, antibiotic prophylaxis was administered. Access to the common femoral 
artery was performed either percutaneously or surgically, as preferred by the treating surgeon. 
After introduction of the sheath and administration of 5000 IU heparin intravenously, the PAA 
was passed with a Terumo® wire (Terumo Medical Corporation, Elkton, MD, USA). A calibrated 
straight angiocatheter was positioned just proximal to the trifurcation of the popliteal artery. 
Angiography was performed to determine the proximal and distal landing zones. An Amplatz 
wire (Amplatz Super Stiff guide wire, Boston Scientific Corporation, Marlborough, MA, USA) 
was used for insertion and deployment of the stent graft. All PAA were excluded with one 
or multiple Viabahn endoprostheses. The stent grafts were post-dilated with an angioplasty 
balloon with the same size as the stent graft. Completion angiography of the stent graft and 
outflow vessels was performed routinely including a lateral projection with forced leg flexion 
to identify any bending between the artery end the endograft. All patients received dual anti-
platelet inhibitors for at least 6 months, unless oral anticoagulation was indicated for other 
reasons. After 6 months patients received single antiplatelet inhibitors, usually acetylsalicylic 
acid, unless oral coagulation was indicated otherwise. 
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 Patency definitions as recommended in the guidelines of Rutherford et al. were applied.25 
Primary patency was defined as blood flow maintained through the device after implant without 
an intervention. Primary-assisted patency was defined as blood flow maintained through the 
device after implant regardless of re-interventions performed. Secondary patency was defined 
as blood flow through the device regardless of re-interventions performed following total 
occlusion. An occlusion was defined as absence of flow in the treated segment. A failure of the 
stent graft was defined as an occlusion, with or without clinical symptoms, not responding to 
therapy. Limb salvage was defined as the absence of major amputation. Exclusion of the PAA 
from the blood circulation was defined as the absence of flow in the PAA and without any PAA 
sac enlargement.
Endpoints
 The primary endpoint of this study was the primary patency rate of the stent graft. 
Secondary endpoints included primary-assisted and secondary patency rates as well as the 
limb salvage rate.
Statistical analysis
 Distribution was tested using the Shapiro-Wilk test. Categorical variables are presented 
as numbers followed by percentages; continuous variables are presented as mean ± standard 
deviation or as median with range when appropriate. Patency rates were determined using 
the Kaplan-Meier life-table method. Cox-regression analyses were generated to analyze 
possible risk factors. P-values <0.05 were considered statistically significant. All analyses were 
performed with SPSS 22.0 (Statistical Package for the Social Sciences Inc., Chicago, IL, USA).
RESULTS
 A total of 72 PAA were treated with a heparin-bonded stent graft in 70 patients. During the 
study period 97 other PAA were treated with open surgery. Sixty-five patients were male (93%) 
and mean age was 71.2 ± 8.5 years. The majority of PAA were asymptomatic (78%). Sixteen 
PAA (22%) were symptomatic of which seven (44%) presented with acute limb ischemia. 
Patient characteristics are shown in Table 1. Forty-six patients (66%) had a unilateral PAA and 
24 patients (34%) bilateral PAA. Only two patients were treated bilaterally. In the remaining 
patients the PAA had not reached the cut-off diameter for treatment. Thirty-two patients (44%) 
had a concomitant aneurysm (abdominal, n=24 (75%), iliac, n=6 (19%), femoral, n=2 (6%)). 
Mean preoperative ankle brachial index (ABI) was 0.89 ± 0.20. Lesion characteristics are shown 
in Table 2. The majority of PAA had a diameter >25 mm (83%), while 12 PAA had a diameter 
between 21 mm and 25 mm (16.7%). 
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Table 1. Patients’ baseline characteristics.
N=70
Tobacco use     28  (40%)
Hyperlipidemia  55  (79%)
Diabetes mellitus 3    (4%)
Hypertension 51  (73%)
Renal failure 26  (37%)
Coronary artery disease 24  (34%)
Table 2. Lesion characteristics.
N=72
Right/left leg 40/ 32    (56%/44%)
Median diameter PAA 31 mm   (21-86 mm)
Median distal neck length 54 mm   (20-133 mm)
Median PAA length 78 mm   (23-200 mm)
Number of distal run off vessels
        1 vessel
        2 vessels





 Twenty-three procedures (32%) were accomplished with local anesthesia for the 
intervention, 12 patients (17%) with spinal anesthesia and the remaining 37 procedures (51%) 
with general anesthesia. Heparin was administered during all procedures. Four cases (6%) 
underwent thrombolysis before stent graft placement. In 33 procedures (46%) one stent graft 
was used, 31 procedures (43%) two stent grafts, seven procedures (10%) were accomplished 
using three stent grafts, and in one procedure four stent grafts were used (1%). The median 
length of the covered segment of the femoropopliteal artery was 17 cm (range 10-36 cm) with 
a median overlap zone of 3 cm (range 3-10 cm). Median contrast volume administered was 45 
mL (range 25-135 mL). The median duration of only the stent graft placement was 45 minutes 
(range 23-120 minutes). A concomitant procedure was performed in 13 patients (19%). Two 
patients (3%) underwent endovascular repair of an abdominal aortic aneurysm, two patients 
(3%) had an interposition graft to treat a common femoral artery aneurysm, three patients 
(4%) had an angioplasty of the superficial femoral artery in order to treat a <50% stenosis 
and prohibit inflow problems, one patient underwent an embolization of a popliteal artery side 
branch, and the remaining five patients (8%) underwent angioplasty of crural vessels. The 
technical success rate was 100%.
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 The median length of hospital stay was four days (range 1-12 days). In the early postoperative 
period, two complications occurred (3%). One patient had a groin hematoma which was treated 
conservatively. The other patient developed a pseudoaneurysm of the common femoral artery 
which was successfully treated with thrombin injection. The mean postoperative ABI was 
0.98±0.20 (p=0.03 versus preoperative). Sixty-three cases (88%) were prescribed acetylsalicylic 
acid 80 mg in combination with clopidogrel 75 mg daily. Two cases (3%) were treated with 
coumarin derivates only, three cases (4%) with acetylsalicylic acid 80 mg in combination with 
coumarin derivates, and the remaining four cases (6%) with a combination of clopidogrel 75 mg 
and coumarin derivates. 
Follow up
 The median follow up was 13 months (range 0-63 months). During follow up, seven 
patients (10%) died. In all cases the cause of death was unrelated to the aneurysm or its 
treatment. Three patients (4%) were lost to follow up. One patient had an edge stenosis of the 
distal edge which was treated with balloon angioplasty. During follow up, four endoleaks (6%) 
were detected, including one type 1 endoleak, and three type 2 endoleaks. Duplex ultrasound 
examination in all four patients showed a decrease of the aneurysm size and therefore all were 
treated conservatively. Primary patency rates at 1, 2 and 3 years were 83%, 69%, and 69%, 
respectively (Fig. 1). Primary-assisted patency rates were 87%, 79% and 74%, and secondary 
patency rates were 88%, 81% and 76% at 1, 2, and 3 years, respectively. No stent fractures were 
reported during follow up. Analysis of possible risk factors, including number of stent grafts (p 
0.94), number of run-off vessels (p=0.95), sex (p=0.51), age (p=0.13), use of clopidogrel (p=0.73) 
and asymptomatic versus symptomatic (p=0.06) did not show any significant predictor for loss 
of patency.
Occlusions
 During follow up, 13 stent grafts (18%) occluded. Four cases (31%) presented with acute 
lower limb ischemia and were treated with a surgical bypass (n=3) or thrombolysis (n=1). Six 
cases (46%) presented with Rutherford 4 lower limb ischemia and were treated with a surgical 
bypass (n=4) or conservative therapy (walking exercise) (n= 2). Three cases (23%) presented with 
Rutherford 3 symptoms and were treated with thrombolysis (n=1) or conservative therapy (n=2). 
Both thrombolysis procedures were successful and uncomplicated. No major amputations 
were performed during follow-up.
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Figure 1. Patency rates at 1, 2, and 3 years follow-up.
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 In this study we have shown that treating PAA with heparin-bonded stent grafts has similar 
results compared to surgery and is associated with a low complication rate, a short hospital 
stay and without amputations during follow up. The 1-year primary patency of 84% is in range 
with published results of open surgery (76-90%).12,13,26. 
 Eslami et al. have compared endovascular repair of PAA with open surgery and stated that 
surgery is associated with lower major adverse limb events and a better primary patency.27 
Nonetheless, that study was retrospective, the two groups were not equally divided as the 
surgery group was larger, and the endovascular group had a higher rate of congestive heart 
failure and chronic obstructive pulmonary disease. Analysis of primary-assisted and secondary 
patency rates between surgery and endovascular therapy shows that they are in the same 
range. At 1 year, Cervin et al. found a secondary patency rate after endovascular treatment of 
86%, and Hernando et al. of 89%, while earlier studies have also shown similar outcomes after 
endovascular treatment of a PAA.13,28-33 In a recent meta-analysis, von Stumm et al. described 
comparable mid-term results of open versus endovascular repair of PAA.28 The complication 
rate in our study population was low (3%) compared to the reported complication rate of 
surgical therapy (11-25%).34,35 
 Previous studies have described that stent fracture is one of the main limits of endovascular 
treatment of the PAA.36 In our study population no stent fractures occurred during follow up 
although follow-up may have been too short for fractures to occur. The stent graft used in 
our study has a heparin-bonded ePTFE surface which lowers platelet deposition and reduces 
thrombogenicity. In addition, the stent graft has a laser-cut contoured proximal edge which 
may improve apposition of the device to the vessel wall. This contoured proximal edge and 
the addition of heparin could explain the better results compared with studies where older 
generation stent grafts were used. In a previous study of Tielliu et al. with only non-heparin-
bonded stent grafts, stent fractures frequently occurred at the borders of the overlap zone.36 
With the availability of longer stent grafts the number of required stent grafts is likely to 
decrease. In the present study 46% of patients were treated with a single stent grafts. In the 
study of Tielliu et al. a single stent graft was used in only 27% of cases and the remaining 
patients (73%) were treated with multiple stent grafts.36 
 There are certain assets of stent grafts in the treatment of PAA. Endovascular treatment 
has a minimal invasive character and is associated with a shorter operating time, a shorter 
length of hospital stay, lower morbidity, complication and amputation rates.37 Therefore, 
treatment of PAA with a stent graft should be considered as an alternative treatment option. 
However, long term results of endovascular therapy are still scarce. As also stated in a recent 
Cochrane review by Joshi et al., future research such as randomized controlled trials with large 
groups comparing endovascular approach with heparin-bonded stent grafts versus surgical 
approach are necessary to define the best treatment option.37 
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 Our study has limitations. First, this study has a retrospective design. We cannot exclude 
a selection bias as patients were treated according to the institutional standards and at the 
discretion of the surgeon. Patient selection, obviously, may explain the satisfying success rate 
in the present series as selection is likely to be a key factor for loss of patency. The diameter 
of which an PAA requires treatment is still matter of debate. 23 In the current study only a 
minority was treated with a smaller diameter between 21-25 mm. These smaller PAA’s seem 
to be easier to treat and could positively affect the results. The large variation in follow-up 
between the subjects prohibits analysis of long term results. In an earlier study of Tielliu et 
al. the use of clopidogrel significantly determined the patency of the stent graft.29 In this study 
the majority of patients received clopidogrel postoperatively. We did not find any possible risk 
factors which could influence the patency of the stent graft although sample sizes are small. 
Due to the limitations of our study the lack of significant risk factors should be handled with 
care. Therefore future research is essential to analyze possible risk factors concerning patency 
of the stent graft placed for PAA. 
 In conclusion, treating PAA with heparin-bonded stent grafts is a safe and feasible 
treatment option with low morbidity and amputation rates. The patency rates show promising 
results and no stent fractures at short-term follow-up. Nonetheless, long term outcomes 
and randomized controlled trials are necessary to determine the position of the endovascular 
treatment option in the treatment algorithm of the PAA. 
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Objective: The position of endovascular treatment in the algorithm of popliteal artery aneurysm 
(PAA) repair is still a matter of debate. Although several studies have described results similar 
to open surgery, follow up of the endovascular group has been relatively short so far. The 
aim of this study was to describe the long term outcome of endovascular repair of PAA with 
endografts. 
Methods: All patients with a PAA treated with a polytetrafluoroethylene (ePTFE) stent graft 
between June 1998 and November 2014 in a tertiary referral center were prospectively 
gathered in a database and retrospectively analyzed. The primary endpoint of this study was 
primary patency. Secondary endpoints included primary-assisted and secondary patency, 
patient survival, stent fractures, secondary interventions and limb loss.
Results: A total of 75 PAA were treated in 64 patients with a mean age of 68.1 ± 9.4 years. 
Unilateral PAA was present in 39 patients (61%) and bilateral PAA in 25 patients (39%) of which 
11 (17%) were treated bilaterally. Median follow up was 68 months (range, 2-187 months). 
Primary patency at 1, 5, and 10 years was 84%, 60%, and 51%, primary-assisted patency 
84%, 65%, and 57% and secondary patency 89%, 71%, and 60%, respectively. Stent fractures 
occurred in 28% of the cases (n=21) in a median follow up time of 47 months (range, 14-187 
months). One third of the fractures were associated with an occlusion which mainly presented 
with claudication and only one with acute ischemia. Reinterventions were performed in 12 
cases (16%) during a median follow up of 14 months (range, 1-47 months). The reintervention 
free survival after 1, 5 and 10 years was 93%, 79% and 79%, respectively. No major amputations 
were performed. The overall survival rate after 5 and 10 years was 78% and 46%, respectively.
Conclusion: Endovascular repair has established a definitive role in the treatment protocol 
for popliteal artery aneurysms. It is associated with acceptable long term patency rates. Stent 
fractures occurred in almost one third of cases, but never lead to limb loss. Future developments 
should focus on the design of more dedicated and durable stents for this specific indication.
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 In the late 1940s it was recognized that the natural history of popliteal artery aneurysms 
(PAA) is associated with a high complication rate.1,2 A conservative strategy is associated with a 
risk on ischemic complications of 30-40 percent, as shown in a systematic review published by 
Dawson et al.3 PAA are frequently diagnosed with symptoms such as intermittent claudication 
and acute limb ischemia due to thromboembolism or thrombosis, potentially leading to major 
amputation , while a rupture of a PAA is rare.4 Therefore the primary aim in the management 
of PAA is to prevent thromboembolism and subsequent amputation3,5-7. The gold standard for 
treatment of PAA is a venous bypass graft.8-10 The quality of the outflow arteries, whether the 
reconstruction is performed for acute ischemia or in an elective setting, and the type of bypass 
material (venous versus prosthetic graft material) are factors known to influence patency 
rates of surgical repair.3,5,11,12 The first endovascular repair of a PAA was reported in 1994.13 It 
was accomplished with a standard polytetrafluoroethylene (PTFE) graft which was introduced 
through the common femoral artery and fixed with stents at both ends. Since then endograft 
technology has evolved and several types of endografts have been used for PAA repair. Required 
specifications for an endograft crossing the hinge point of the popliteal artery are flexibility, 
kink and fracture resistance, as well as the availability of appropriate diameters and lengths to 
accommodate the sealing zones cranial and caudal to the aneurysm. The Viabahn (W. L. Gore 
& Associates, Flagstaff, AZ, USA) has been used in most reported patients for this purpose. The 
Viabahn has evolved from the Hemobahn and also advanced over time with a contoured instead 
of a straight proximal edge to prevent infolding in case of oversizing, longer available lengths 
(now up to 25 cm) reducing the number of overlap zones, and heparin-bonding features. Early 
and midterm results of endovascular treatment of PAA are promising but little is known about 
long term outcome. The purpose of this study is to evaluate the long term outcome of PAA 
treated with endografts. 
MATERIALS AND METHODS
 Data of patients with a PAA treated with an ePTFE covered endograft (Hemobahn/Viabahn 
endoprosthesis, W. L. Gore & Associates, Flagstaff, AZ, USA) between June 1998 and November 
2014 in one tertiary referral center were prospectively gathered in a database and analyzed 
retrospectively. Medical history, patient demographics, clinical state, procedural aspects and 
post-procedural data were retrieved from the case files. Retrospective patients’ files research 
was not in scope of the Dutch law for human bound research. The Investigational Review Board 
approval was therefore not required. As a consequence, patient informed consent was not 
obtained. Patients’ data were analyzed anonymously.
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 Primary endpoint of this study was stent graft primary patency. Secondary outcome 
measures included primary-assisted patency, secondary patency, occurrence of stent fractures, 
patient survival, any secondary intervention, and limb loss. Patients with a symptomatic PAA 
or an asymptomatic PAA with a diameter of more than 20 mm were considered to have an 
indication for intervention.14-16 The possibility for endovascular PAA repair was considered 
and discussed with the patient if the lesion was anatomically suitable with at least one patent 
outflow vessel without signs of stenosis. The absence of a landing zone in the proximal and/or 
distal popliteal artery of at least 2-3 cm length and a diameter mismatch between proximal and 
distal landing zone of >3 mm were considered exclusion criterion for endovascular treatment. 
 Cardiovascular risk factors were scored according to the Society for Vascular Surgery (SVS) 
and American Association of Vascular Surgery (AAVS) medical co-morbidity grading systems.17 
Standard follow-up consisted of clinical assessment, duplex ultrasound scanning (DUS), and 
biplane X-rays (antero-posterior and lateral views) of the knee in both flexion and extension to 
demonstrate fracturing or kinking of the stent, at 1 month, 6 months, 12 months, and annually 
thereafter.
Treatment protocol
 The preoperative evaluation and endovascular procedure have been described previously.18 
In summary, antibiotic prophylaxis was administered and access to the common femoral 
artery was obtained either percutaneously or surgically, according to the preference of the 
treating surgeon. An antegrade sheath was introduced, intravenous heparin (5,000 IU) was 
administered and the diseased segment was passed with a Terumo® guide wire (Terumo 
Medical Corporation, Elkton, MD, USA). A calibrated straight angiocatheter was positioned 
with its tip in the tibiofibular trunc. Angiography was performed to assess outflow vessels 
and to confirm proximal and distal landing zones. Determination of the landing zones was 
aided by either marks that have been placed at the level of the edges of the PAA at the time of 
the preoperative DUS or by extrapolating lengths from the multiple plane CTA reconstruction 
images using bony markers. An Amplatz wire (Amplatz Super Stiff guide wire (Boston Scientific 
Corporation, MA, USA)) was introduced and thereafter the aneurysmal segment was excluded 
with endograft(s) (Hemobahn (mainly until 2004) or Viabahn (after 2004)) starting at the most 
distal point. The endografts were post dilated with an angioplasty balloon with the same size 
as the endograft. Completion angiography was performed routinely to assess patency of both 
stent grafts and outflow vessels. Primarily all patients received statin treatment and single 
anti-platelet inhibitors. During the study period research had shown that dual anti-platelet 
therapy in a period of six months after the operation had yielded better results.18 After April 
2003 patients received dual anti-platelet inhibitors for the first six months postoperatively. 
Single antiplatelet therapy with acetylsalicylic acid (ASA) was administered thereafter, unless 
oral anticoagulation was indicated for other reasons.
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 Patency definitions were used according to the guidelines of Stoner et al.19 In summary, 
primary patency was defined as blood flow maintained through the device after implant without 
an intervention. Primary-assisted patency was defined as blood flow maintained through the 
device after implant regardless of re-interventions performed. Secondary patency was defined 
as blood flow through the device regardless of re-interventions performed following occlusion. 
Occlusion was defined as absence of flow in the treated segment. Failure of the endoluminal 
graft was defined as occlusion of the endograft, with or without clinical symptoms, not 
responding to therapy or without need for therapy because of lack of symptoms. Stent fracture 
was defined as any disruption of the normal structure of the stent as diagnosed on X-rays. 
Fractures were subdivided into circumferential disruptions and strut fractures, as described 
previously.18 (Fig.1) The overlap zone was defined as the zone where one endograft was inserted 
into the other. Limb loss was defined as any amputation above the metatarsal line. Exclusion 
of the PAA from the blood circulation was defined as the absence of ongoing aneurysm sac 
enlargement.
Figure 1. Lateral-view radiograph showing two circumferential stent graft fractures.
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 Distribution was tested using the Shapiro-Wilk test. Categorical variables are presented 
as numbers followed by percentages; continuous variables are presented as mean ± standard 
deviation or as median with range when appropriate. Patency rates were determined using the 
Kaplan-Meier life-table method. Cox-regression analyses were generated to analyze possible 
risk factors. Long rank tests were performed to compare the incidence of fracture, occlusion 
and patency between the Hemobahn and Viabahn endograft. P-values <.05 were considered 
statistically significant. All analyses were performed with SPSS 22.0 (Statistical Package for 
the Social Sciences Inc., Chicago, IL, USA).
RESULTS
Patients and procedures
 A total of 75 PAA were treated in 64 patients with a mean age of 68.1 ± 9.4 years and 62 were 
male (97%). Patient characteristics are depicted in Table 1. A unilateral PAA was present in 39 
patients (61%) and a bilateral PAA in 25 patients (39%) of which 11 (17%) were treated bilaterally. 
Seven bilateral PAA were treated simultaneously (11%) and the remaining four were treated in 
a separate procedure. Thirty-six patients (56%) had a concomitant aneurysm of the abdominal 
aorta (n=27, 42%), iliac (n=3, 5%) and common femoral artery (n=5, 8%) alongside the PAA. One 
other patient had both an abdominal aortic and an iliac artery aneurysm (2%). Sixty-four of the 
treated PAA were asymptomatic (85%) and 11 were symptomatic (15%). Symptoms included 
venous compression (n=4), claudication (n=1), necrosis due to thromboembolism (n=1), blue 
toe syndrome (n=1), pain in the popliteal fossa (n=1), acute ischemia (n=2), and rupture (n=1). 
The last four cases were treated in an acute setting. Procedural details are summarized in 
table 2.
Table 1. Baseline patient characteristics.
N=64
Tobacco use   40   (63%)
Hyperlipidemia  38   (59%)
Diabetes mellitus 9     (14%)
Hypertension 48   (75%)
Renal failure 9     (14%)
Coronary artery disease 22   (34%)
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Table 2. Procedural details.




















9    (12%)
3    (4%)
Number of outflow vessels
1
>1
3   (4%)
72 (96%)
Mean duration of the procedure 70 min (50-150)
Mean contrast volume used 50 mL (14-200)













(AAA, Abdominal aortic aneurysm; CFV, common femoral vein; CIA, common iliac artery; PAA, popliteal 
artery aneurysm; PTA, percutaneous transluminal angioplasty. 
Categorical variables are presented as number (%). Continuous variables are presented as mean (range)).
Early postoperative period
 The median length of hospital stay was two days (range, 2-10 days). Postoperatively 18 
cases (24%) received single antiplatelet therapy with ASA 80 mg daily; 42 cases (56%) were 
treated with dual antiplatelet therapy consisting of ASA 80 mg and clopidogrel 75 mg; three 
cases (4%) received ASA 80 mg and dipyridamol 100 mg; nine cases (12%) were treated with 
coumarin derivates and three cases (4%) received a combination of coumarin derivates and 
clopidogrel 75 mg. During hospital stay seven complications (9%) occurred including a groin 
hematoma (n=4), acute stent graft occlusion (n=2), and pneumonia (n=1). One case with an 
acute occlusion was successfully treated with thrombolysis and the other case was treated 
with a surgical bypass. The other complications were successfully treated conservatively.   
Follow up
 The median follow up time was 58 months (range, 1-187 months). In total 27 patients (42%) 
died after a median of 53 months (range, 1-150 months). After 5 and 10 years of follow up, 19% 
(n=12) and 39% (n=25) of patients had died. Total overall survival rate after 5 and 10 years of 
follow up was 78% and 46%, respectively (Fig.2). Patients died as a result of heart failure (22%; 
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n=6), cancer (19%, n=5), ruptured aneurysm of the thoracic aorta (7%, n=2), pneumonia (7%, 
n=2), and due to an unknown cause (44%, n=12). Two patients (3%) were lost to follow up after 
17 and 56 months, respectively. They had been diagnosed with an occlusion of the endograft 
and thereafter had further follow up in another hospital.
 Primary patency at 1, 5, and 10 years was 84%, 60%, and 51%, primary-assisted patency 
84%, 65%, and 57%, and secondary patency 89%, 71%, and 60%, respectively (Fig.3). The 
variation in patency between Hemobahn and Viabahn is shown in figure 4 without significant 
differences. 
Figure 2. Survival of the study cohort up to 12 years of followup.SE, Standard error.
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Figure 3. Patency rates of the study cohort up to 12 years of follow-up. prim, Primary patency; prim ass, 
primary assisted patency; sec, secondary patency; SE, standard error.
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Figure 4. Variation in patency rates of Hemobahn vs Viabahn up to 12 years of follow-up. 
prim, Primary patency; prim ass, primary assisted patency; sec, secondary patency; SE, standard error.
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 Stent graft occlusions occurred in 27 cases (36%) (Hemobahn n=14; 52% and Viabahn 
n=13; 48%) .Two (7%) occlusions occurred within one month; six (22%) between one month 
and one year; nine (33%) between one year and three years. Finally, 10 additional occlusions 
(37%) were diagnosed after a follow up of at least three years. The occlusion-free survival 
rate within 12 years of follow up is shown in figure 5. Fourteen cases with an occlusion (52%) 
presented with only mild claudication and were treated conservatively. The other 13 cases 
(48%) presented with acute ischemia: seven (54%) were successfully treated with thrombolysis; 
four (31%) were treated with a surgical bypass; the remaining two cases (15%) were treated 
by surgical thrombectomy. Analysis of risk factors which could influence the occurrence of 
occlusion such as age of the patient, diameter of the aneurysm, diameter of the endograft, 
number of endografts used, number of outflow vessels, comorbidity, type of endograft, and 
stent fracture showed no significance. No amputations had to be performed during follow up. 
Figure 5. Occurrence of stent occlusions up to 12 years of follow-up. 
SE, Standard error.
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 Stent fractures occurred in 28% of the cases (n=21) with a median time to detection 
on X-ray of 47 months (range, 14-187 months) (Fig.6). The 5 year and 10 year fracture free 
survival rate was 78% and 54%, respectively. Fourteen fractures occurred (67%) in cases 
that were treated with a Hemobahn in a median follow up period of 66 months (range, 
6-169 months) and the remaining seven stent fractures (33%) occurred in cases that were 
treated with a Viabahn in a median follow up period of 40 months (range, 20-72 months). 
Thirteen cases with a stent fracture had no symptoms (62%), 7 had claudication symptoms 
(33%) and one case had acute ischaemia (5%). Fractures were circumferential in 16 cases 
(76%), the remaining five had strut fractures only. Multiple stent fractures in one treated 
leg were diagnosed in nine cases (43%): two circumferential fractures (n=7, 78%), three 
circumferential fractures (n=1), and a circumferential fracture and a strut fracture (n=1).
Figure 6. Occurrence of stent fractures up to 12 years of follow-up. 
SE, Standard error.
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Stent fractures occurred in cases treated with one stent graft (n=2; 10%), with two stent grafts 
(n=14; 67%) and with three stent grafts (n=5; 23%). Thirteen fractures (62%) occurred at the 
level of the overlap zone of different endografts. Four occurred at the proximal end of the 
overlap zone, one in the middle of the overlap zone, five at the distal end, and three at both 
proximal and distal ends of an overlap zone. 
 Analysis of risk factors that could influence the occurrence of stent fractures such as age 
of the patient, diameter of the aneurysm, diameter of the endograft, number of endografts 
used, type of endograft, and comorbidity showed no statistically significant predictor for the 
occurrence of a stent fracture. The occurrence of stent fractures in cases with a Hemobahn was 
36% (n=14/39) and in cases that were treated with a Viabahn 19% (n=7/36) (p 0.30). Occlusion 
of the stent graft occurred in 33% of cases that had a fracture of the stent (n=7/21) and 37% 
of the cases that did not show a fracture of the stent (n=20/54) (p 0.92). Of the 7 cases with 




 Re-interventions were performed in 12 cases (16%) in a median time of 14 months (range, 
1-47 months). The reintervention free survival after 1, 5 and 10 years was 93%, 79% and 79%, 
respectively and included thrombolysis procedures (n=7, 58%) and surgical thrombectomies 
(n=2, 17%) for occlusions, stent extensions (n=2, 17%) due to sac expansion with an endoleak, 
and PTA (n=1, 8%) to treat endograft edge stenosis (Table 3). During follow up another 3 
endoleaks were diagnosed which did not need treatment. Four out of seven initially successful 
thrombolysis procedures (57%) eventually developed a definitive occlusion during median 
follow up of eight months (range, 1-65 months). Three of these four re-occlusions were treated 
conservatively and one case was treated with a surgical bypass. In total three out of 75 cases
(4%) eventually were treated with a surgical bypass due to occlusion of the stent graft after a 
median time of 3.5 months (range, 1-9 months).
Table 3. Details of reinterventions. 
Total number of cases 75     (100%)
Thrombolysis
Re-occlusion
7           (9%)
4           (5%)
Surgical thrombectomy 2           (3%)
Stent graft extension 2           (3%)
PTA 1           (1%)
Surgical bypass 3           (4%)
(PTA, Percutaneous transluminal angioplasty. Values are presented as number (%)).
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 This study describes the long term outcome of endovascular repair of PAA with a 
median follow up of more than 5 years and with patency rates up to 12 years. It is therefore 
unprecedented in terms of longer term outcome after endovascular PAA repair. 
 The study period covers the whole time line of changes to the original concept of the 
Hemobahn/Viabahn stent graft that was used. Therefore, the study covers a heterogeneous 
group of devices with numbers too small to statistically compare these different features of the 
device. The study also covers the timely change in diagnostic modalities over the years. As a 
result of improving CT technology and easier availability of center lumen line reconstructions 
with CTA, we now advise CTA as the preferred preoperative diagnostic tool for popliteal artery 
aneurysms. Length measurements can be done accurately and bony markers can be used as 
a reference for peroperative assessment of sealing zones. Diameter measurements with CTA 
are in our center however always checked with the duplex diameter measurements, which are 
performed on the preoperative day in presence of the operating surgeon and measured from 
intima to intima, which is a well recognised entity on the duplex ultrasound.
 Primary patency rates were estimated at 84%, 60%, and 51% at 1, 5, and 10 years of follow 
up. Patency rates at 5 years are similar with results shown in the recent meta-analysis of Patel 
et al.21 The authors described a 5-year primary patency rate of 69% of the Hemobahn/Viabahn 
endograft and acknowledged a considerable heterogeneity in reporting methodology among 
the studies. Similar studies also have shown promising patency rates of the endovascular 
treatment of PAA.10,18, 22-25 However, the follow up period varies between the studies and the 
follow up period is relatively short to determine if the long term outcomes are comparable with 
long term outcomes of open surgical repair. Nevertheless Wooster et al described a 4-year 
primary patency rate of open surgery of 66% and Dorigo et al. a primary patency rate of 55% 
after 13 years of follow up after open surgery.26,27
 The 30-day postoperative complication rate was relatively low (9%) compared to the 
reported complication rate of surgical therapy that lies between 11 and 25%.23, 28, 29 Complications 
after open surgery include major amputation, significant bleeding requiring re-intervention, 
infection of the wound, nerve damage, and deep vein thrombosis.10,20, 23,30 In our cohort the 
majority had minor complications, mostly groin hematoma while only two patients had a major 
adverse event, namely an acute occlusion. 
 The reintervention free survival after endovascular PAA repair, mainly consisting of 
thrombolysis procedures, was 79% after 5 years and 79% after 10 years of follow up in this 
study. Sixteen percent of cases needed a re-intervention in a median time of 14 months, which 
consisted of thrombolysis in most cases, and this is comparable to re-intervention rates 
described in other studies on endovascular repair.31-34 
 Fractures of the stent component of the endograft occurred in 28% of the cases. The 5 
year and 10 year fracture free survival rate was 78% and 54%, respectively. Occlusion of the 
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stent graft occurred in one third of the cases with a fractured stent although a causal relation 
was not established. No single risk factor for the occurrence of a stent fracture could be 
identified, potentially related to the low sample size in the current study. However, previous 
research described that both younger age and use of multiple stent grafts could lead to stent 
fractures.20Younger age may be a factor due to a higher physical activity level of the patient, 
although this has never been proven. The decision to intervene in case of a stent fracture is 
dependent on the severity of the fracture. A strut fracture is left alone and followed up with 
regular X-rays as per protocol for all patients with a popliteal stent graft. For a circumferential 
stent fracture an individual per patient decision is made, ranging from follow up without 
intervention for the asymptomatic cases to relining with a stent graft in the fractured stent 
graft for the cases with endoleak due to rupture of the graft material as well. In cases where 
relining would be deemed a risk for secondary occlusion due to the small diameters, an open 
reconstruction with removal of the stent graft and regular interposition graft could be opted for.
 The overall mortality rate after 5 years was 22%. Unfortunately in twelve patients the cause 
of death could not be revealed retrospectively. Of the retractable causes of death heart failure 
and cancer were the most common causes. A likely explanation for the high mortality rate could 
be that patients with peripheral artery disease have systemic arteriosclerosis and therefore 
underdiagnosed cardiac or cerebrovascular disease. Furthermore 56% of the patients had a 
concomitant aneurysm of the abdominal aorta, iliac artery and/or the common femoral artery. 
 One major complication of an occlusion of a PAA is a major amputation. Theoretically 
one would think that there would be a high amputation rate with occlusion of the stent graft. 
Nonetheless the amputation rate was 0% in this cohort. The majority of patients had mild 
symptoms during an endograft occlusion. This could suggest that collateral arteries provide 
adequate blood flow to the lower extremity even though in cases where the collateral arteries 
are overstented by the endograft. Previous research already reported that collateral geniculate 
arteries exist and can cause sac growth in excluded PAA but also prevent lower limb ischemia 
in case of an occlusion.35,36
 There are a number of limitations to this study, including the retrospective design and the 
relatively small sample size. Only patients both treated and followed in our vascular center 
were included in this study. This explains why the number of patients is almost equivalent to the 
study that was published by our group in 2010.20 Also, there was a wide variety in postoperative 
anticoagulation schedules that precludes any conclusion or recommendation. Furthermore, no 
data were collected on activity level of the patient, which in theory could be a factor influencing 
the incidence of stent fractures and occlusions. Finally, the study includes the learning curve 
of the procedure and evolvement of the endograft design. No possible risk factors that could 
influence patency, occlusion, or stent fracture of the endograft could be identified. Additionally, 
follow up of the patients treated with a Hemobahn was longer compared to the patients treated 
with a Viabahn. Finally, selection bias cannot be excluded as patients were treated according 
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to the institutional standards and at the discretion of the surgeon, which could possibly lead to 
treatment of the anatomically best suitable arteries.
 In summary, endovascular repair has gained an established role in the treatment protocol 
for popliteal artery aneurysms. It is associated with a 5 and 10-year primary patency rate of 
60 and 51%. Reinterventions are mainly performed for occlusions, which occurred in a third 
of cases. The conversion rate to open surgical repair was 4%. Stent fractures did occur in a 
quarter of cases but were not associated with a higher occlusion rate and with no limb loss. 
Future developments will have to be focused on the design of more dedicated and durable 
stents for this specific indication.
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SUMMARY AND GENERAL DISCUSSION
Peripheral arterial disease (PAD) is a global problem with a prevalence between 3 and 12%.1-3 It 
is estimated that > 200 million people worldwide are living with PAD.4 The prevalence increases 
up to 15-20% over the age of 70 years.5,6 In patients with symptomatic PAD, the femoral and 
popliteal arteries are affected in 80-90%, the tibial and peroneal arteries in 40-50%, and the 
aortoiliac arteries up to 30%.7 
 The treatment of PAD primarily consists of cardiovascular risk reduction, consisting 
of lifestyle management and pharmacotherapy. Furthermore, there is an important role of 
supervised walking exercise training in patients with intermittent claudication. Endovascular 
and/or surgical therapy may become an option if life style limiting claudication exists after a 
supervised exercise program and in patients with critical limb ischemia.
 Although the use of an autologous venous conduit in the treatment of extensive chronic 
occlusive disease of the superficial femoral artery (SFA) is still considered to be the gold 
standard treatment for complex lesions, according to the TASC II guidelines1, there has been 
a change in treatment modalities and guidelines in the last decades.8 Unfortunately, about 
one third of patients requiring bypass surgery due to femoropopliteal lesions do not have a 
suitable vein. Managing these lesions without the use of a prosthetic graft is therefore not 
always possible.9 Surgical treatment with prosthetic grafts such as polyester (Dacron) and 
polytetrafluorethylene (PTFE) showed 3-year primary patency rates of 61-64%, however 
patency rates with a venous conduit remained significantly higher.10-12 Still, bypass surgery is 
indissolubly associated with a prolonged hospital stay and a high complication rate, compared 
to endovascular treatment.13-16 Therefore, endovascular therapy, due to its minimal invasive 
character in a frail vascular patient group, has conquered a position in treating PAD. In the 
previous chapters we aimed to investigate and analyze the role of PTFE covered stents as 
treatment option in long chronic occlusive lesions of the SFA and popliteal artery aneurysms 
(PAA).
 For short lesions in the SFA percutaneous transluminal angioplasty (PTA) already was 
the primary treatment option.1 However, patency rates decreased with increasing lesion 
lengths. By combining PTA with the placement of nitinol stents in longer lesions, the patency 
significantly increased.17,18 The major limitation in treating long lesions with nitinol stents was 
the occurrence of in-stent re-stenosis (ISR) due to intimal neo-hyperplasia.17 To reduce the 
occurrence of ISR, covered stent grafts, drug-coated balloons and drug-eluting stents had been 
introduced. The Hemobahn was the most commonly used covered stent in the femoropopliteal 
tract, later developed into the Viabahn (W.L. Gore & associates, Flagstaff, AZ, USA). These 
covered stents are constructed with a PTFE lining which is attached to an external nitinol 
stent structure. Initially, the use of covered stents were related to mixed results, likely due to 
a variety of patient and lesion characteristics, treatment protocols, and improvements of the 
covered stent during the study periods.19 (Chapter 2) Hereafter, a randomized controlled trial of 
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McQuade et al. showed that the use of covered stents achieved patency rates similar to above 
the knee prosthetic femoropopliteal bypasses up to 4 years follow-up.20 To investigate the effect 
of covered versus non-covered stents, the Viabahn was compared with nitinol stents in the 
VIASTAR trial, which showed the superiority of the Viabahn over nitinol stents at 24 months, 
particularly in extensive disease.21 The design of covered stents kept on evolving, and the heparin-
bonding technology was added to the PTFE of the Viabahn endoprosthesis. Additionally, the 
proximal edge was reshaped towards a contoured edge in order to prevent infolding in case of 
oversizing. Furthermore, longer stent lengths became available, thereby reducing the number 
of overlap zones. Initial results of several studies showed promising results with 1-year primary 
patency rates of 67-78%.22-25 Lensvelt et al. described 1-year primary and secondary patency 
rates of 67% and 97%, respectively, with the heparin-bonded Viabahn used in TASC II C and 
D femoropopliteal lesions.22 Additionally, the 3-year results showed primary, primary assisted 
and secondary patency rates of 59%, 71% and 82%, respectively, and a 3-year freedom from 
amputation of 100%. (Chapter 3) The risk of re-stenosis remained, but only occurred at the 
proximal or distal edge of the stent graft. If untreated, these edge stenoses may cause acute 
thrombosis due to reduced flow. In Chapter 4 we found that PTA and extension of the endograft 
with another endograft are both feasible treatment modalities for edge stenosis. Nevertheless, 
the recurrence rates of stenosis were high. An extension of the endograft seemed to yield 
somewhat better results, but due to the small number of patients these results have to be 
regarded with care. An important finding was that most edge stenoses developed the first year 
after treatment, which makes intensive routine surveillance essential during this time period. 
However, there is no protocol yet for the best treatment option of edge stenosis. (Chapter 4) An 
acute thrombosis of the stent graft is one of the main complications after endograft placement. 
Therefore, an assessment of the treatment modalities for symptomatic acute thrombosis is 
crucial. In chapter 5 we analyzed thrombolysis and thrombectomy as treatment modalities in 
case of a symptomatic occlusion. The technical success rate of both techniques was high and 
complication rates after these reinterventions were low. Nonetheless, the secondary patency 
rates after restoration were lower compared to initial stent placement. Additionally, in two thirds 
of cases an edge stenosis was the underlying cause, again indicating the need for surveillance. 
A possible shortcoming of covered stents might be the coverage of collateral arteries, which 
would reduce limb salvage rates and even may change the level of amputation or worsen the 
clinical state in case of failure of the graft. However, a fourth of patients had no remaining 
symptoms after the occlusion of the covered stent. The observation that 80% of patients did 
not deteriorate in clinical state after failure suggests that the covering of collaterals may not be 
clinically relevant. Nonetheless, 25% of patients with a failure ended with a below-knee bypass 
and secondary reconstructions in case of failure showed low patency rates (1-year primary 
patency rate of 55%). Still, the amputation rate was low (4%; n=2). (Chapter 6) The covered 
stents were also used in the endovascular treatment of popliteal artery aneurysms (PAA). 
Several studies showed 4-year patency rates of 64-88% which were comparable to the 4-year 
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patency rates of surgical bypass (69-88%).26-31 Analyzing the outcome of the heparin-bonding 
technology in treating PAA showed good 1-year primary, primary assisted, and secondary 
patency rates of 83%, 87% and 88%, respectively. These results are comparable with patency 
rates of surgical treatment. Moreover, endovascular treatment had a low complication rate, a 
short hospital stay and no amputations during follow up in our study. The diameter of which a 
PAA requires treatment is still matter of debate. In our study we treated patients with a PAA 
diameter of >20 mm, while other studies treated PAA with a threshold diameter of >25 mm. 
Therefore, our results may possibly be affected positively, as PAA with small diameters seem to 
be easier to treat. (Chapter 7) There is a lack of knowledge on the long-term (>5 years) results 
of treating PAA with stent grafts. Previous studies have already described the occurrence of 
stent fractures and stent occlusions as complications that may occur during follow up. The 
true incidence of these complications and outcome, however, can only be recognized after 
longer follow-up time. In chapter 8 we analyzed the long-term outcome of PAA treatment. 
Primary patency rates at 1, 5, and 10 years were 84%, 60%, and 51%, primary-assisted patency 
rates of 84%, 65%, and 57%, and secondary patency rates of 89%, 71%, and 60%, respectively. 
Stent fractures occurred in one third of cases, but did not lead to limb loss in any of the cases. 
FUTURE PERSPECTIVES 
 The ultimate goal of occlusive and aneurysmal disease in the femoropopliteal tract is to 
treat these lesions with endovascular therapy, due to its minimal invasive character, but with 
comparable or even better patency rates to an autologous venous conduit. As a consequence, 
future research with long-term follow up of the heparin-bonded stent graft is needed to 
point out if endovascular treatment can reach comparable patency rates. The 1-year results 
of the SuperB trial already showed promising patency rates with endovascular therapy for 
long occlusive lesions which were similar to surgical patency rates.32 Furthermore, little was 
known of the health status of patients undergoing either one of both methods. The SuperB trial 
clarified this matter, as this study showed a faster and sustained improvement in health status 
in the endovascular group.32 However, these results are still with a short-term follow-up.
 Endovascular treatment modalities for occlusive SFA disease keep evolving. Other relatively 
new modalities are drug-coated balloons (DCB) and drug-eluting stents (DES), which are 
already extensively used to treat coronary artery disease.33,34 The use of DCB in femoropopliteal 
arteries was investigated and showed improved short-term patency (primary patency, target 
lesion revascularization and restenosis) compared to PTA.35-37 Nonetheless, DCB are still not 
generally recommended, as data are limited by a short and incomplete follow-up, limited clinical 
data and heterogeneous cohorts.38 Moreover, long-term results and data of clinical effects 
(ankle-brachial index, amputation rate, mortality rate and clinical symptoms) are limited. In 
addition, the effect of DCB is mainly analyzed in de novo lesions. There is limited knowledge on 
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the effect of DCB in in-stent re-stenosis. The recent study of Micari et al. described the effect 
of DCB in femoropopliteal lesions. In this cohort 18% had an in-stent restenotic lesion.39 They 
found that in-stent restenosis was one of the factors that was associated with an increased 
risk for clinically driven target lesion revascularization within 24 months.39 However this was 
a single-arm trial no comparisons were made with other endovascular treatment and with a 
relatively short follow-up. Hopefully future research will analyze the long-term outcome of 
DCB in these re-stenotic lesions and comparing it to other endovascular options. 
 The most frequently used DES in the femoropopliteal artery is the paclitaxel-eluting stent. 
The paclitaxel-eluting stent has shown its superiority compared to sirolimus-eluting stent and 
everolimus-eluting stent.40-43 The randomized controlled trial of Dake et al. showed promising 
5-year results in comparing paclitaxel-eluting stent versus PTA, PTA with additional bare 
metal stenting and bare metal stenting. Five-year primary patency rates showed a significant 
difference between the overall DES group and the overall PTA group with patency rates of 66% 
and 43%, respectively.44 However, little is known of long-term (>5 years) outcome. Additionally, 
there is no randomized controlled trial yet which compares covered stents with paclitaxel-
eluting stents. The BASIL-3 trial is comparing DCB with bare metal stenting, PTA with bare 
metal stenting and primary DES placement. The results of this trial will probably clarify which 
endovascular therapy will have the best patency rate.45
 Another important unaddressed issue to date is the cost-effectiveness. Due to the higher 
re-intervention rate with endovascular therapy compared to surgery, it is compelling to analyze 
the costs. As we already know surgical treatment is correlated with a longer hospital stay and 
a higher complication rate. It is important to analyze and compare the costs of both treatment 
modalities, including re-interventions during follow-up. 
 The more research on this topic, the more we find out about the advantages and 
disadvantages of endovascular therapy. The additional answers to the above mentioned topics 
can help define the role of endovascular therapy in the treatment modality of PAD.
GENERAL CONCLUSION
 Our research has shown that treating chronic long occlusive lesions of the SFA and PAA 
with stent grafts is feasible and safe. Additionally, the heparin-bonding technology shows 
patency rates which approach the patency rates of surgical venous reconstructions. The 
minimal invasive approach and the low complication rate of endovascular therapy make this 
a good treatment option in a carefully selected patient group. Therefore stent grafts might be 
an alternative for or postpone surgery. The results of future studies on quality of life and cost 
effectiveness will further determine the position of stent grafts in the treatment algorithm.  
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NEDERLANDSE SAMENVATTING & DISCUSSIE
 Perifeer vaatlijden (PVL) is een wereldwijd probleem met een prevalentie tussen de 
3-12%.1-3 De prevalentie stijgt vanaf 70-jarige leeftijd zelfs naar 15-20%.4-5 Naar schatting zijn 
er wereldwijd > 200 miljoen mensen met PVL.4 In 80-90% van de patiënten met symptomatisch 
PVL zijn de arteria femoralis en de arteria poplitea aangedaan, in 40-50% de arteriae tibiales 
en arteria peronea, en in 30% de aorta-iliacale arteriën.7 
 De primaire behandeling van PVL bestaat uit het reduceren van het cardiovasculaire risico 
door het aanpassen van de leefstijl en het toepassen van pharmacotherapie. Daarnaast is er, bij 
patiënten met intermitterende claudicatio, een belangrijke rol weggelegd voor gesuperviseerde 
looptraining. Een endovasculaire en/of chirurgische behandeling komt pas ter sprake wanneer 
ondanks gesuperviseerde looptraining de patiënt geïnvalideerd blijft door claudicatio en bij 
patiënten met kritieke ischemie.
 De gouden standaard bij het behandelen van chronische occlusieve laesies van de arteria 
femoralis superficialis (AFS) is, volgens de richtlijnen1, tot noch toe de chirurgische behandeling 
met een autologe vene. De afgelopen jaren is er echter wel een verandering opgetreden in 
de behandelmogelijkheden.8 Een derde van de patiënten met een femoropopliteale laesie 
die een chirurgische bypass behoeft, heeft echter geen geschikte vene en derhalve moeten 
deze laesies met kunststof materiaal zoals polyester (Dacron) en polytetrafluorethyleen 
(PTFE) worden behandeld.9 Drie jaar na chirurgische behandeling met een kunststof bypass 
worden primaire patency waarden (percentage van bypass/stents welke doorgankelijk zijn en 
functioneren) gerapporteerd van 61-64%, hetgeen beduidend lager is dan de gerapporteerde 
patency van een autologe veneuze bypass.10-12 Daarnaast zijn in vergelijking met endovasculaire 
behandelingen chirurgische bypass operaties geassocieerd met een verlengde opnameduur 
en een verhoogd complicatie risico.13-16 Gezien het minimaal invasieve karakter bij een fragiele 
patiëntengroep heeft de endovasculaire behandeling een plek veroverd in de behandeling 
van PVL. In voorgaande hoofdstukken hebben wij de rol van gecoverde PTFE stents in de 
behandeling van laesies van de AFS en van een aneurysma van de arteria popitea (AAP) 
onderzocht en geanalyseerd. 
 Voor korte laesies in de AFS was percutane transluminale angioplastiek (PTA) al gedurende 
een langere tijd een primaire behandeloptie.1 Echter het werd ook duidelijk dat de patency 
afnam naarmate de lengte van de laesie toenam. De patency verbeterde significant door in 
langere laesies PTA te combineren met het plaatsen van een nitinol stent.17,18 De grootste 
beperking van het toepassen van nitinol stents bij lange laesies is het optreden van een in-
stent re-stenose (ISR) door intima neohyperplasie.17 Om het optreden van ISR te verminderen, 
werden er gecoverde stents en geneesmiddel-eluerende stents geïntroduceerd. De meest 
gebruikte gecoverde stent in het femoropopliteale traject was de Hemobahn, later opgevolgd 
door de Viabahn (W.L. Gore & associates, Flagstaff, AZ, USA). Deze gecoverde stent is gemaakt 
van een externe nitinol structuur met een PTFE voering. Het gebruik van gecoverde stents 
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gaf initiëel wisselende resultaten. Dit kwam waarschijnlijk door de verschillen in patiënt,- en 
laesie karakteristieken, verschillen in behandelingsprotocollen en het feit dat de gecoverde 
stents kwalitatief verder verbeterden gedurende de onderzoeksperiode.19 (Hoofdstuk 2) 
 De gerandomiseerde studie van McQuade et al. liet na een follow-up van 4 jaar zien dat 
de patency van gecoverde stents vergelijkbaar was met de patency van een supragenuale 
kunststof bypass in het femoropopliteale traject.20 Vervolgens werd in de VIASTAR trial het 
effect van de gecoverde stent (Viabahn) vergeleken met de niet gecoverde stent (nitinol). Deze 
trial liet zien dat de Viabahn superieur was ten opzichte van de nitinol stent, met name in 
langere laesies na een follow-up van 24 maanden.21 Het ontwerp van de gecoverde stent bleef 
aan ontwikkeling onderhevig en het duurde niet lang totdat er heparinemoleculen werden 
toegevoegd aan de binnenkant van de PTFE voering van de Viabahn. Tevens werd de proximale 
rand opnieuw gevormd ter voorkoming van het naar binnen vouwen van de stent. Daarnaast 
kwamen er langere stents beschikbaar, waardoor minder overlap tussen stents nodig was, 
hetgeen de resultaten positief zou kunnen beïnvloeden. Initiële resultaten van verscheidene 
onderzoeken lieten inderdaad veelbelovende resultaten zien met een 1-jaars primaire patency 
van 67-78%.22-25 In een onderzoek van Lensvelt et al. werd de heparine-gebonden Viabahn 
gebruikt om TASC II C/D femoropopliteale laesies te behandelen. In deze studie werden 
1-jaars primaire en secundaire patencies van respectievelijk 67% en 97% beschreven.22 Na 
3 jaar werden een primaire, primair geassisteerde en secundaire patency van respectievelijk 
59%, 71% en 82% gerapporteerd en waren er, gedurende deze 3 jaar, geen amputaties nodig. 
(Hoofdstuk 3) Het risico van re-stenosering bleef echter bestaan, maar dit trad alleen op aan 
de uiteinden van de stent (edge-stenosen genoemd). Onbehandelde edge-stenosen kunnen 
acute trombose veroorzaken door een verminderde bloedstroom en turbulenties ter plaatse 
van de stenose. 
 In hoofdstuk 4 zagen wij dat PTA en verlenging van de stent beiden mogelijkheden zijn bij 
het behandelen van edge-stenosen, alhoewel er in beide groepen een hoog recidief percentage 
werd gezien. Een verlenging van de stent leek een iets betere patency te geven, echter door de 
kleine groep kon er geen statistisch significant verschil worden aangetoond. Een belangrijke 
additionele bevinding was dat de meeste edge-stenosen zich binnen het eerste jaar na 
behandeling ontwikkelden. Derhalve is een intensieve en regelmatige follow-up noodzakelijk 
in het eerste jaar. Tot op heden is er nog geen protocol voor de beste behandeling van edge-
stenosen. (Hoofdstuk 4) 
 Een acute trombosering van de stent is een van de meest voorkomende complicaties na het 
plaatsen van een stent. Informatie over mogelijke behandelopties bij een symptomatische acute 
trombosering is dan ook cruciaal. In hoofdstuk 5 hebben wij geanalyseerd wat de resultaten 
waren na trombolyse en na trombectomie verricht in verband met een symptomatische 
occlusie. Beide behandelopties lieten een hoog technisch succes percentage zien met een 
laag complicatie risico. De secundaire patency na de re-interventie was lager dan de initiële 
secundaire patency na plaatsing van de stent. In 2/3 van de casus werd er een edge-stenose 
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gevonden als oorzaak van de occlusie, waarbij opnieuw duidelijk werd dat intensieve follow-
up zeer belangrijk is. Gecoverde stents zouden mogelijk nog een nadeel hebben, namelijk het 
afdekken/overstenten van collateralen. Dit zou theoretisch kunnen leiden tot meer amputaties, 
hogere amputatie niveaus en een verslechtering van de kliniek bij het falen van de stent. Uit 
ons onderzoek bleek dat bij een kwart van de patiënten, waarbij een occlusie van de gecoverde 
stent optrad, er geen klinische symptomen waren. Daarnaast werd er bij 80% van de patiënten 
geen verschil in klinische uitkomsten gezien na het falen van de stent ten opzichte van ervoor. 
Dit bevestigt dat het afdekken van collateralen klinisch niet relevant is. Vijfentwintig procent 
van de patiënten eindigde met een infragenuale bypass na het falen van de gecoverde stent. 
Secundaire reconstucties na falen van de stent leidde tot een lagere patency (1-jaar primaire 
patency van 55%), maar leidde ook tot slechts twee amputaties (4%). (Hoofdstuk 6) 
 Gecoverde stents worden ook gebruikt bij de endovasculaire behandeling van aneurysma’s 
van de arteria poplitea (AAP). Verschillende onderzoeken lieten een 4-jaars patency zien 
van 64-88% welke vergelijkbaar was met de 4-jaars patency van een chirurgische bypass 
(69-88%).26-31 De resultaten van de heparine-gebonden technologie bij de behandeling van 
AAP lieten goede 1-jaars primaire, primair geassisteerde en secundaire patencies zien van 
respectievelijk 83%, 87% en 88%. Deze resultaten zijn vergelijkbaar met een chirurgische 
benadering. Daarbij heeft de endovasculaire behandeling een laag complicatie risico, een 
korte ziekenhuisopnameduur en er hoefden geen amputaties te worden uitgevoerd gedurende 
de follow-up van ons onderzoek. In onze studie hebben we patiënten met een AAP diameter 
van >20 mm behandeld, terwijl andere studies AAP behandelden met een diameter van >25 
mm. Derhalve zouden onze resultaten positief beïnvloed kunnen zijn, gezien AAP met kleine 
diameters gemakkelijker te behandelen lijken. (Hoofdstuk 7) Er is weinig bekend over de 
lange termijn (>5 jaar) resultaten bij de behandeling van AAP met stents. Eerder onderzoek 
heeft reeds aangetoond dat er gedurende de follow-up complicaties kunnen optreden zoals 
stentbreuken en stent occlusies. De daadwerkelijke incidentie van deze complicaties kan 
echter alleen worden aangetoond bij een langere follow-up. In hoofdstuk 8 hebben wij de lange 
termijn resultaten van de endovasculaire behandeling van AAP geanalyseerd. Primaire patency 
na 1, 5 en 10 jaar was respectievelijk 84%, 60% en 51%, primaire geassisteerde patency was 
84%, 65% en 57% en secundaire patency was 89%, 71% en 60%. Stentbreuken werden gezien 
in 1/3 van de patienten, maar deze hebben niet geleid tot amputaties. 
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 Het ultieme doel is om occlusieve en aneurysmale laesies in het femoropopliteale 
traject endovasculair te behandelen, gezien het minimaal invasieve karakter, maar wel met 
vergelijkbare of zelfs een betere patency ten opzichte van de operatie met een autologe vene. 
Hiervoor is toekomstig onderzoek met lange termijn follow-up van de heparine gebonden 
stents noodzakelijk. Bij de SuperB trial, waarin endovasculaire behandeling werd vergeleken 
met de open chirurgische behandeling voor lange occlusieve laesies, werd een veelbelovende 
1-jaars patency gevonden welke vergelijkbaar is met de patency na de chirurgische behandeling 
met autologe vene.32 Tot op heden is er weinig onderzoek gedaan naar de kwaliteit van leven 
en het algemeen welbevinden in patiënten met PVL. De SuperB trial heeft dit onderzocht; 
dit onderzoek liet een snellere en stabiele verbetering zien in het algemeen welzijn van de 
endovasculaire groep in de vroege fase na operatie, maar vergelijkbare resultaten na 1 jaar 
follow-up.32 Het wachten is nu op langere follow-up resultaten.
 Endovasculaire behandelopties voor occlusieve laesies van de AFS blijven aan 
ontwikkeling onderhevig. Andere relatief nieuwe opties zijn medicijn-gecoate ballonnen 
(DCB) en medicijn eluerende stents (DES), die reeds extensief worden gebruikt bij coronaire 
slagader aandoeningen.33,34 Het gebruik van DCB in het femoropopliteale traject is onderzocht 
en liet een verbeterde korte termijn patency (primaire patency, target laesie revascularisatie 
en restenosen) zien in vergelijking met PTA.35-37 Desalniettemin wordt DCB vooralsnog niet 
algemeen aanbevolen, gezien data gelimiteerd zijn door een korte en incomplete follow-up en 
heterogene cohorten.38 Daarnaast zijn lange termijn resultaten en data betreffende klinische 
effecten (enkel-arm index, percentage amputaties, mortaliteit en klinische symptomen) 
minimaal beschreven. Bovendien is het effect van DCB voornamelijk geanalyseerd in de novo 
laesies. Er is een beperkte kennis over het effect van DCB in in-stent restenose. In een recent 
onderzoek van Micari et al. werd een in-stent restenose gevonden in 18% van de behandelde 
patienten. In-stent restenose was in deze studie geassocieerd met een verhoogd risico op 
een re-interventie voor symptomatisch restenose/occlusie gedurende twee jaar follow-up. 
Limitaties van dit onderzoek waren het ontbreken van een controle groep en vergelijkingen 
met andere endovasculaire behandelingen, en tot slot de relatief korte follow-up duur. 39 De 
resultaten van DCB op langere termijn van instent-restenosen en de vergelijking met andere 
endovasculaire behandelingen zullen moeten worden afgewacht.
 De meest gebruikte DES in het femoropopliteale traject is de paclitaxel eluerende stent. 
De paclitaxel eluerende stent heeft zijn superioriteit laten zien ten opzichte van de sirolimus 
eluerende stent en de everolimus eluerende stent.40-43 Het gerandomiseerd onderzoek van Dake 
et al. liet veelbelovende 5-jaars resultaten zien bij het vergelijken van de paclitaxel eluerende 
stent met PTA, PTA met een bare metal stent en alleen een bare metal stent. De 5-jaars primaire 
patency was significant beter in de DES groep vergeleken met de PTA groep (respectievelijk 
66% en 43%).44 Meer lange termijn resultaten(> 5 jaar) zijn nodig, evenals gerandomiseerd 
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onderzoek waarin gecoverde stents worden vergeleken met de paclitaxel eluerende stents. 
De BASIL-3 studie vergelijkt DCB met bare metal stents, PTA en bare metal stents en primair 
DES plaatsing. Hopelijk zullen deze resultaten ophelderen welke endovasculaire optie de beste 
patency geeft, en nog belangrijker, wat de patiënt als beste behandeling ervaart.45 Een ander 
essentieel onderwerp is de kosten-effectiviteit. Doordat er bij een endovasculaire behandeling 
vaker een re-interventie nodig is in vergelijking met een chirurgische behandeling, die op zijn 
beurt weer gepaard gaat met een langere ziekenhuisopnameduur en meer complicaties, is het 
belangrijk om de kosten-effectiviteit in kaart te brengen. In de onderlinge vergelijking lijkt het 
van belang niet alleen te kijken naar het aantal re-interventies gedurende follow-up, maar zijn 
ook de ervaringen van de patiënt van belang. 
ALGEMENE CONCLUSIE
 Ons onderzoek heeft laten zien dat het behandelen van chronische lange laesies van de 
AFS of AAP met behulp van stents haalbaar en veilig is. Daarbij laat de heparine gebonden 
techniek een patency zien die de patency benadert van de (huidige) standaard chirurgische 
veneuze reconstructie. Het minimaal invasieve karakter en het lage complicatie risico van 
de endovasculaire behandeling maken dit een goede behandelingsoptie in een zorgvuldig 
geselecteerde patiëntengroep. Hierdoor zouden stents een alternatieve optie kunnen zijn voor 
chirurgie of chirurgie kunnen uitstellen. De resultaten van toekomstig onderzoek zoals het 
algemeen welzijn en de kosten-effectiviteit zullen verder de positie van stents in het behandel 
algoritme bepalen. 
529929-L-bw-Golchehr




1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral 
arterial disease (TASC II). J Vasc Surg 2007;45:5-67.
2. Olin JW, Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and 
management. Mayo Clin Proc 2010;85:678-692.
3. Novo S. Classification, epidemiology, risk factors, and natural history of peripheral arterial disease. 
Diabetes Obes Metab 2002;4:1-6.
4. Fowkes FG, Rudan D, Aboyans V, et al. Comparison of global estimates of prevalence and risk 
factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 
2013;382:1329-1340.
5. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the Unites 
States: results from the national health and nutrition examination survey, 1999-2000. Circulation 
2004;110:738-743.
6. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a 
defined population. Circulation 1985;71:510-515. 
7. Carey WD, Current clinical medicine, The Cleveland Clinic Foundation. Saunders Elsevier; Sector 
2:Chapter 28, Philadelphia 2009.
8. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of 
peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). 
Eur J Vasc Endovasc Surg 2018;55:305-368.
9. Sayers RD, Raptis S, Berce M, et al. Long-term results of femorotibial bypass with vein or 
polytetrafluorethylene. Br J Surg 1998;85:934-938.
10. Twine CP, McLain AD. Graft type for femoro-popliteal bypass surgery. Cochrane Database of Syst Rev 
2010;5:CD001487.
11. Post S, Kraus T, Müller-Reinartz U, et al. Dacron vs. polytetrafluorethylene grafts for femoropopliteal 
bypass: a prospective randomized multicenter trial. Eur J Vasc Endovasc Surg 2001;22:226-231.
12. Klinkert P, van Dijk PJ, Breslau PJ. Polytetrafluorethylene femorotibial bypass grafting: 5-year patency 
and limb salvage. Ann Vasc Surg 2003;17:486-491.
13. Norgren L. Operations, total hospital stay and costs of critical leg ischemia. Acta Orthop Scand 
1997;68:180-181.
14. Burger DH, Kappetein AP, van Bockel JH, et al. A prospective randomized trial comparing vein with 
polytetrafluorethylene in above-knee femoropopliteal bypass grafting. J Vasc Surg 200;32:278-283.
15. Te Slaa A, Dolmans DE, Ho GH, et al. Prospective randomized controlled trial to analyze the effects of 
intermittent pneumatic compression on edema following autologous femoropopliteal bypass surgery. 
World J Surg 2011;35:446-454.
16. Rosenthal D, Arous EJ, Friedman SG, et al. Endovascular-assisted versus conventional in situ 
saphenous vein bypass grafting: cumulative patency, limb salvage, and cost results in a 39-month 
multicenter study. J Vasc Surg 2000;31:60-68.
17. Laird, JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation vs. balloon angioplasty for lesions 
in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year 
follow-up from the RESILIENT randomized trial. J Endovasc Ther 2012;19:1-9.
18. Zeller, T, Saratzis N, Scheinert D, et al. Non-randomized, prospective, multi-centre evaluation of 
the ABSOLUTE .035 peripheral self-expanding stent system for occluded or stenotic superficial 
femoral or proximal popliteal arteries (ASSESS Trial): acute and 30-day results. J Cardiovasc Surg 
2007;48:719-726.
19. Lensvelt MM, Reijnen MM, Wallis de Vries BM, Zeebregts CJ. Treatment strategies for extensive 
chronic SFA occlusions: indications and results. J Cardiovasc Surg (Torino) 2012;53:161-170.
529929-L-bw-Golchehr




20. McQuade K, Gable D, Pearl G, et al. Four-year randomized prospective comparison of percutaneous 
ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment 
of superficial femoral artery occlusive disease. J Vasc Surg 2010;52:584–590.
21. Lammer J, Zeller T, Hausegger KA, et al. Sustained benefit at 2 years for covered stents versus bare-
metal stents in long SFA lesions: The Viastar Trial. Cardiovasc Intervent Radiol 2015;38:25-32.
22. Lensvelt MMA, Fritschy WM, van Oostayen JA, et al. Results of heparin-bonded ePTFE-covered stents 
for chronic occlusive superficial femoral artery disease. J Vasc Surg 2012;56:118-125.
23. Saxon RR, Chervu A, Jones PA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined 
stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn 
Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery 
Obstructive Disease) trial. J Vasc Interv Radiol 2013;24:165-173.
24. Lammer J, Zeller T, Hausegger KA, et al. Heparin-bonded covered stents versus bare-metal stents for 
complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with 
PROPATEN bioactive surface versus bare nitinol stent in the treatment of long lesions in superficial 
femoral artery occlusive disease). J Am Coll Cardiol 2013;62:1320-1327.
25. Zeller T, Peeters P, Bosiers M, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D 
femoropopliteal lesions: the Viabahn-25 cm trial. J Endovasc Ther 2014;21:765-774.
26. Wain RA, Hines G. A contemporary review of popliteal artery aneurysms. Cardiol Rev 2007;15:102-107.
27. Antonello M, Frigatti P, Battocchio P, et al. Endovascular treatment of asymptomatic popliteal 
aneurysm: 8-year concurrent comparison with open repair. J Cardiovasc Surg 2007;48:267-274. 
28. Curi MA, Geraghty PJ, Merino OA, et al. Mid-term outcomes of endovascular popliteal artery aneurysm 
repair. J Vasc Surg 2007;45:505-510.
29. Pulli R, Dorigo W, Castelli P, et al. A multicentric experience with open surgical repair and endovascular 
exclusion of popliteal artery aneurysms. Eur J Vasc Endovasc Surg 2013; 45:357-363.
30. Rajasinghe HA, Tzilinis A, Keller T, et al. Endovascular exclusion of popliteal artery aneurysms with 
expanded polytetrafluoroethylene stent-grafts: early results. Vasc Endovasc Surg 2007;40:460-466.
31. Tielliu IFJ, Verhoeven ELG, Zeebregts CJ, et al. Endovascular treatment of popliteal artery aneurysms: 
is the technique a valid alternative to open surgery? J Cardiovasc Surg 2007;48:275-279.
32. Reijnen MMPJ, Walraven LA, Fritschy WM, et al. One-year results of a multicenter randomized 
controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass. JACC Cardiovasc 
Interv 2017;10:2320-2331.
33. Cui K, Lyu S, Song X, et al. Drug-eluting balloon versus bare-metal stent and drug-eluting stent for 
de novo coronary artery disease: a systematic review and meta-analysis of 14 randomized controlled 
trials. PLos One 2017;12:e0176365.
34. Fröhlich GM, Lansky AJ, Ko DT, et al. Drug eluting balloons for de novo coronary lesions- a systematic 
review and meta-analysis. BMC Med 2013;11:123.
35. Tendara M, Aboyans V, Bartelink ML, et al. Guidelines on the diagnosis and treatment of peripheral 
artery disease: document covering atherosclerotic disease of extracranial carotid and vertebral, 
mesenteric, renal, upper and lower extremity arteries: the Task Force on the diagnosis and treatment 
of peripheral artery diseases of the European society of Cardiology (ESC). Eur Heart J 2011;32:2851-
2906.
36. Katsanos K, Tepe G, Tsetis D, Fanelli F. Standards of practice for superficial femoral and popliteal 
artery angioplasty and stenting. Cardiovasc Intervent Radiol 2014;37:592-603.
37. Klein AJ, Pinto DS, Gray BH, et al. SCAI expert consensus statement for femoro-popliteal arterial 
intervention appropriate use. Catheter Cardiovasc Interv 2014;84:529-538.
38. Conte MS, Pomposelli FB. Society for vascular surgery practice guidelines for atherosclerotic 
occlusive disease of the lower extremities management of asymptomatic disease and claudication. J 
Vasc Surg 2015;61:1S.
529929-L-bw-Golchehr
Processed on: 1-4-2019 PDF page: 148
39. Micari A, Brodmann M, Keirse K, et al. Drug-coated balloon treatment of femoropopliteal lesions for 
patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT global 
study. JACC Cardiovasc Interv 2018;11:945-953.
40. Müller-Hülsbeck S, Keirse K, Zeller T, Schroë H, Diaz-Cartelle J. Twelve-month results from the 
MAJESTIC trial of the Eluvia paclitaxel eluting-stent for treatment of obstructive femoropopliteal 
disease. J Endovasc Ther 2016;23:701-707.
41. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of 
atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J 
Endovasc Ther 2006;13:701-710.
42. Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting 
stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011;54:394-401.
43. Dake MD, Ansel, GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty 
and bare metal stents in femoropoploteal disease: twelve-month zilver PTX randomized study results. 
Circ Cardiovasc Interv 2011;4:495-504.
44. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the 
femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation 2016;133:1472-
1483.
45. Hunt BD, Popplewell MA, Davies H, et al. Balloon versus Stenting in severe ischaemia of the Leg-3 
(BASIL-3): study protocol for a randomized controlled trial. Trials 2017;18:224.
529929-L-bw-Golchehr
Processed on: 1-4-2019 PDF page: 149
529929-L-bw-Golchehr
Processed on: 1-4-2019 PDF page: 150
529929-L-bw-Golchehr
Processed on: 1-4-2019 PDF page: 151
Acknowledgements / Dankwoord
529929-L-bw-Golchehr
Processed on: 1-4-2019 PDF page: 152
152
529929-L-bw-Golchehr




 In de laatste fase van mijn Geneeskunde opleiding werd ik aangestoken door het 
wetenschappelijk enthousiasme van Mare Lensvelt en Michel Reijnen. Na een gesprek met 
Michel was ik helemaal om en begon ik aan het avontuur wat promoveren heet. Ik weet nog 
dat ik dacht:’’Hoe moeilijk kan het zijn, ik kan dit prima naast mijn werk als assistent Chirurgie 
doen’’. Nu terugkijkend op het avontuur, welke ik met plezier heb beleefd, komt er een nummer 
van een Nederlandse zanger in mijn hoofd ‘’Bloed, zweet en tranen’’. Vol trots en een beetje 
ongeloof dat het moment nu eindelijk daar is, ligt hier mijn proefschrift. Dit hele proces was 
zonder steun en hulp van velen onmogelijk geweest, daarom wil ik iedereen bedanken die een 
bijdrage heeft geleverd aan dit proefschrift. 
 Beste Michel, jouw enorm enthousiasme voor wetenschappelijk onderzoek en het 
vertrouwen in dit proefschrift is de continue drijfveer geweest in het hele proces. Door je snelle 
reacties (zelfs in het weekend) voelde ik me niet de enige die in de avonden en weekenden 
achter de laptop zat. Zonder jou was dit proefschrift niet tot stand gekomen. Bedankt voor al je 
inzet en steun!
 Geachte prof.dr. Zeebregts, Beste Clark, door jouw wetenschappelijk en deskundig inzicht 
konden we ‘’de puntjes op de i zetten’’ bij de artikelen. Jouw kijk op de wetenschap heeft mij 
het onderste uit de kan laten halen. De krachtige samenwerking met Michel heeft voor een 
goede vaart gezorgd in dit proces. Ook jouw snelle reacties ben ik zeer dankbaar voor. Bedankt 
dat je mijn promotor wilt zijn.
 Beste Suzanne, zonder jou had ik niet mijn statische analyses kunnen uitvoeren. Jouw 
uitleg over het statistisch programma (SPSS) is de basis geweest voor mijn proefschrift. Elke 
keer als ik ergens tegen aanliep met de analyses kon ik altijd bij je terecht. De data en de 
verscheidene formules duizelden in mijn hoofd, na jouw uitleg kon ik er weer volle moed 
tegenaan! Zowel in dit proces, als in privésferen heb ik je steun ervaren. Dank daarvoor!
 Geachte dr. Tielliu, dank voor je aandeel en inzet bij dit proefschrift. Jouw interesse en 
expertise in de poplitea aneurysma’s hebben een extra dimensie gegeven in dit proces. 
 Beste dr. Fritschy, dr. Kruse en dr. van Walraven, dank voor het delen van jullie expertise 
en jullie bijdrage aan dit proefschrift. 
 Geachte leden van de leescommissie, prof. dr. H.J.M. Verhagen, prof. dr. M.W. de Haan en 
prof. dr. A.J. Smit, dank u voor het lezen en beoordelen van mijn boekje.
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 Lieve Marilou en Steffi, mijn paranymfen, ik had niemand anders aan mijn zijde willen 
hebben op deze dag. Ik ben blij dat ik jullie heb leren kennen en met jullie heb mogen 
samenwerken in het Jeroen Bosch Ziekenhuis. We hebben veel mooie herinneringen aan 
die tijd en hoop dat er nog veel mooie herinneringen bijkomen. Bedankt voor jullie hulp en 
bemoedigende woorden.
 Graag wil ik alle mede-auteurs bedanken voor hun bijdrage aan de artikelen. Lieve Mare, 
zonder jou was ik niet in dit proces gerold. Dank voor je vertrouwen, steun en inzet. Beste 
Denise, dank voor je bijdrage aan dit proefschrift. 
 Beste Lian Roovers, zonder jou waren mijn statistische grafieken niet zo mooi geworden, 
dank voor je geduld en bijdrage. 
 Het chirurgisch team van Rijnstate, hier heb ik mijn eerste voetstappen gezet als arts-
assistent Chirurgie. Dank voor jullie begeleiding, onderwijs, geduld, steun en waardering. Ik 
heb hier ontzettend veel geleerd en kijk er met een warm gevoel naar terug.
 Beste oud collega’s van het Radboudumc bedankt voor jullie samenwerking.
 Lieve collega’s van het Jeroen Bosch Ziekenhuis, bedankt voor jullie vertrouwen en de fijne 
samenwerking. 
 Lieve vrienden bedankt voor jullie steun. Ik wil in het bijzonder Charissa, Fatima, Inge, 
Jean, Marc en Satish bedanken, dank voor jullie geduld, de bemoedigende woorden, de steun 
in goede en slechte tijden. Ik kon niet altijd overal bij zijn, doordat ik mijn vrije uren in dit 
proefschrift moest steken en een turbulent jaar achter de rug heb, maar vanaf nu krijgen jullie 
weer mijn volledige aandacht. Ik mag me gelukkig prijzen met zulke mooie mensen als jullie 
om me heen. Laten we er een mooi feestje van maken!
 Lieve Saba, mijn kleine zussie, opgroeien in Nederland ging ons niet altijd even gemakkelijk 
af, de weg hierheen had voor ons allebei een aantal heuveltjes. Je hebt het toch voor elkaar 
gekregen om een paar maanden mij voor te zijn met promoveren. Woorden schieten mij te kort 
om te beschrijven hoe trots ik op je ben. Net als jij, moest ik ook veel tijd aan het proefschrift 
spenderen. Hopelijk kunnen we vanaf nu weer meer quaility time met elkaar hebben hier of in 
Thailand. Love u. 
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 Papa, mama, waar moet ik beginnen om jullie te bedanken. Zonder jullie heldhaftig besluit 
had ik vandaag niet hier gestaan. Jullie hebben mij geleerd wat doorzetten en strijden is. Op 
momenten dat ik het niet meer zag zitten, hoefde ik alleen naar jullie te kijken om te weten dat 
het wel goed zou komen. Jullie moed en vastberadenheid, is iets wat ik mijn hele leven bij mij 
zal dragen. Ik ben trots dat ik jullie dochter ben! Ik hou van jullie.
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